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ABSTRACT
The neuropeptide substance P, recently re-named neurokinin-1 and 
abbreviated to NK-1, is a member of a family of neuropeptides called 
the tachykinins. Those neuropeptides are distributed throughout 
both the mammalian central and peripheral nervous systems and 
have likely roles in a myriad of cellular functions ranging from 
nociception to development. Neurokinin-1 has been localised to 
several interesting regions of the brain, regions that show 
phenotypic changes in line with the progression of clinical 
neurodegenerative diseases such as Huntingdons disease for 
example. NK-1 is encoded by the preprotachykinin-A (PPT-A) gene. 
The neurokinin-1 receptor (NK-1R) gene encodes the G-protein- 
coupled receptor for NK-1. In order to investigate the proposed 
involvement of the PPT-A and NK-1R genes in diseases of the 
nervous system and other cellular activities, it is important to 
firstly understand the normal function and regulation of those genes 
at the molecular level.
This project sets out to examine the normal function and regulation 
of the PPT-A and NK-1R genes by molecularly cloning the murine 
PPT-A and NK-1R genes and provisionally characterising those 
genes. Gene targeting vectors for both genes will then be described. 
Vectors were designed for use in homologous recombination 
experiments, which is the first step required in order to generate 
transgenic mice bearing specifically altered forms of those genes.
This objective was pursued by firstly cloning the murine NK-1 
precursor (PPT-A) gene from a genomic bacteriophage library. A 423 
bp probe was generated by polymerase chain reaction (PCR) from 
mouse genomic DNA template and was subcloned and sequenced. 
Optimal hybridisation conditions were then determined and the probe 
used to isolate lambda bacteriophage clones from a library. 
S im ilarly, positively-hybridising clones of the NK-1R (receptor) 
gene were isolated from another bacteriophage library using an 865 
bp rat NK-1 R cDNA-derived probe.
Secondly, the PPT-A bacteriophage clones were analysed by 
restriction mapping, PCR and by hybridisation to exon-specific 
probes. The exons of the murine PPT-A gene were then subcloned, 
restriction mapped and positioned relative to each other on linear 
restriction maps. Some mouse PPT-A sequence was obtained and 
aligned with other species to determine the extent of identity and 
homology. A similar approach was used for the NK-1R bacteriophage 
clones.
Thirdly, gene targeting vectors for use in homologous recombination 
experiments in mouse embryonic stem cells were then constructed 
for each of the genes. Multiple cloning and subcloning steps were 
required to do this. Several endonuclease recognition sequences 
were altered by ligation of DNA linker sequences. A n e o m y c in  
(G418) resistance gene with its own promoter was introduced into 
PPT-A exon 3, or in the the other vector, the neom ycin  resistance 
gene was introduced in place of a deleted 2.4 kb genomic sequence 
containing PPT-A exons 3 and 4. For the NK-1R vector, exons 3 and 4 
were deleted and replaced by the neo  resistance gene. In each 
vector, a thymidine kinase (TK) counter-selection gene from herpes  
simplex I virus (HSV1) was also inserted.
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CHAPTER 1
INTRODUCTION
The objective of this chapter will be to provide an overview of the 
background information and literature which both prompted and 
acted as the platform on which the experimental investigations 
detailed in this thesis were built. Information which was both 
pertinent and available when this research project was firs t 
designed will be described below, as will the influential research 
findings which were published while the project was ongoing and 
which subsequently impacted on the progress of the research.
The overview sets the scene by briefly introducing the modes of 
communication in the mammalian nervous system and then focuses 
on one important mode in particular, namely the neuropeptides as a 
signalling system. To be more specific, the tachykinin family of 
neuropeptides are of specific interest. The discovery and the 
history to date of the tachykinin neuropeptide neurokinin-1 (NK-1, 
formerly substance P) is then detailed, as is the equivalent 
chronology of the G-protein linked, membrane-bound, NK-1 receptor 
(formerly substance P receptor). The basis for the study of this 
neuropeptide, and its corresponding receptor, will then be described 
with respect to the clinical relevence and proposed therapeutic 
value of such research. Areas where further research would be 
useful and the principle objective of the research detailed in this 
text is also discussed. The field of modern homologous gene 
targeting technology, and in particular the approach adopted for the 
research presented below, will also be explored.
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1.1. COMMUNICATION IN THE MAMMALIAN NERVOUS SYSTEM
The brain is without doubt the most complex and least understood
mammalian organ. At the point of maturity it weighs approximately
1.4 Kg and is composed of 180 billion cells, of which 50 billion are
directly engaged in information processing. In addition to the scale,
the complexity of this organ is difficult to comprehend. Each of*
those 50 billion cells is estimated to recieve up to 15,000 physical 
connections from other cells. Communication between those cells is 
therefore fundamental for the multicellular organism to function. 
Such communication is central to the coordination of many cellular 
functions including cell metabolism, cell growth and differentiation. 
In mammalian nervous systems, specific responses are illicited by 
highly specialised messenger molecules. The neuro-physiologist 
Otto Loewi in 1921 was the first scientist to present evidence to 
support the concept that biochemical substances are central to 
communication between nerves, muscles and glands. This evidence 
ultimately provided the foundation for the later identification of one 
precise mode of intercellular communication. By stimulating the 
vagus nerve to a frogs heart, he noted that the rate of the heart 
declined. If the slowing heart was simultaneously rinsed in a 
solution which was collected and later poured over another frogs 
heart, a decline in the rate of heartbeat of the second heart could be 
induced. A substance, which he named 'V a g u s s to ff ' (vagus 
substance) and which was later identified as acetylcholine, had been 
released from the firs t heart into solution and had been 
subsequently responsible for the slowing of the second heart. 
Conversely, by stimulating the heart to increase its rate of beating, 
Loewi managed to identify the molecule epinephrine which up- 
regulates the mammalian heartbeat. He therefore proposed that 
neurons communicate with each other and with other tissues by the 
release of biochemical neurotransmiters.
A neurotransmitter is defined as a chemical which is found in the 
terminal of a neuron, is released from the terminal when the neuron 
fires, and when incubated in the presence of innervated tissue, is 
capable of inducing the same response in the tissue as the response 
generated by neural stimulation. Additionally, there must be a
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mechanism in the area of the synaptic cleft to inactivate the
transm itter either chem ically or by way of uptake of the
neurotransmitter. There are many subtypes of neuortransmitter.
Several amino acids act in this way, including gamma-aminobutyric
acid (GABA) to which there are a family of receptors, several
antagonists and a number of known agonists such as baclofen
(detailed in section 1.7.3). The 'classical' (or canonical) chemical%
neurotransmitters include acetylcholine which can act as a ligand 
for both muscarinic and nicotinic receptors. The nicotinic receptors 
are known to form transmembrane ion channels, whereas the 
muscarinic receptors act through G-proteins (GTP-binding proteins) 
to activate a variety of second messenger systems (Nathanson et al, 
1987). Several biogenic amines, including dopamine and serotonin, 
have been studied and found to act as neurotransmitters. One known 
agonist to serotonin receptors is the psycho-active narcotic LSD. An 
antagonist to the receptor for the amino acid transmitter molecule 
glycine is strychnine.
A number of peptides are known to be neuroactive and are 
collectively known as the neuropeptide family of transmitters. The 
neuropeptides are diverse and include neurokinin-1 which is the 
focus of the research presented in this text. Tachykinins in general 
and NK-1 specifically are discussed in depth below.
1.2 NEUROPEPTIDES
1.2.1 The History of Neuropeptides
Neuropeptides are biologically active peptides which are produced by 
neurons and which can illic it responses proximally or distally 
within the mammalian nervous system and other tissues. Of the 
many cell types that comprise the nervous system, peptidergic 
neurons are the nerve cells which are specialized to produce and 
secrete neuropeptides. The list of known neuropeptides is ever 
increasing and currently stands at between 100 and 1000 taking
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account of processed variants of the known peptides (Davies et al, 
1994). Neuropeptides which mediate long-range communication 
between neurons are traditionally referred to as 'hormones'. Those 
which mediate short-range communication and occur in membrane- 
bound vesicles are termed 'transmitters' (Burbach et al, 1992). A 
broad range of neuropeptides exist in the brain partly as a 
consequence of molecular processing such as alternative splicing of 
primary gene transcripts and differential precursor processing. The 
known neuropeptides are sub-divided into groupings in line with 
their common sites of either release or action. For example, there 
are the brain-gut peptides which can induce specific responses in 
the gastro-intestinal tract, amongst other tissues, and include 
glucagon, substance P, neurotensin, leucine enkephalin and 
vasoactive in testina l peptide (VIP). A lso there are the 
hypothalam ic-releasing hormones such as thyrotropin-releasing 
hormone (TRH) and somatostatin. Another group comprising the 
pituitary peptides such as ^-endorphin and adrenocorticotropin, are 
secreted by the pituitary gland. Several other neuropeptides have 
been identified but as yet do not lie within any of the existing sub­
categories. The other neuropeptides include angiotensin II, 
bradykinin, vasopressin and oxytocin (Kandel et al, 1981). 
Neuropeptide Y is one neuropeptide which is researched 'intensively'. 
This 36 amino acid neuropeptide is found in high levels in the 
central and peripheral nervous systems. There is growing evidence 
indicating that this neuropeptide acts as a neurotransmitter and 
neuromodulator in several regions of the brain (Morris, 1992).
1.2.2 The Roles of Neuropeptides
1.2.2.1 Neuropeptides and Nociception
It has been proposed that NK-1 has a role in nociception 
(transduction o f pain). An understanding of the molecular basis of 
the activation of peripheral nociceptive sensory neurons is 
necessary to allow pharmacological intervention in the treatment of 
pain. One research approach to this is the generation of hybrid cell 
lines. Wood et al (1990) generated hybrid cell lines by fusing
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neonatal rat dorsal root ganglia neurons with mouse neuroblastoma
N18Tg2 cells. The resulting hybrids exhibited sensory neuron-like
properties which are not displayed by the parental neuroblastoma
cells. One such property is the synthesis of NK-1. These novel cell
lines provide one means to study the mechanisms of nociceptor
activation and the regulation of expression of sensory neuron-
specific markers such as the neuropeptide NK-1. This model may■%
subsequently permit a clearer understanding of NK-1 synthesis and 
its role in nociception.
1.2.2.2 Neuropeptides and Behaviour
Neuropeptides are known to play a vital role in both the control and 
expression of behaviour in many organisms (Tublitz et al, 1991). For 
example, in insects, moulting is initiated by ecloisin hormone 
(Reynolds et al, 1983), and in lobsters defensive postures are 
triggered by proctolin (Siwicki et al, 1987). In rats, drinking is 
activated by angiotensin I I  (Fitzsimmons et al, 1978), maternal 
behaviour is enhanced by oxytocin (Fahrbach et al, 1986), and feeding 
is inhibited by cholecystokinin (Forman et al, 1977). Neuropeptides 
are believed to influence a range of other more complex, long-term 
behavioural changes such as learning, arousal, memory, emotional 
state and schizophrenia (Gilles et al, 1979; McKelvy et al, 1986). 
The lack of knowledge regarding the exact nature of those influences 
has prompted an upsurge of research in the field of neuropeptides. 
The molecular approach to neuropeptide research (section 1.7.4) 
should help to identify those influences.
1.2.2.3 Modulation of the Immune System
The regulation of the response of the immune system has 
traditionally been thought to be controlled by interactions between 
immunocompetent cells. Such cells were believed to express 
surface determinants, secrete regulatory molecules and be capable 
of recognising the signals emanating from other cells of the immune 
system. An alternative system has subsequently been observed. The 
nervous system, which had previously been considered to have no 
involvement in immunocompetence, may have a direct influence on
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immunological responses (Payan et al, 1984). An early example of 
this was presented by Webber ef a / (1970) who demonstrated that 
stimulation of the post-ganglionic sympathetic nerves attached to 
bone marrow elevated the level of leucocyte production. 
Neuropeptides were implicated in the regulation of the local immune 
response as determined by tissue inflammation. Neuropeptides were 
shown to be transported to the distal nerve endings of unmyelinated 
dorsal root C-fibres and released upon stimulation of the axons. As 
an example of the involvement of neuropeptides as a modulator of 
the immune system, the neuropeptide NK-1, when incubated in vitro 
with human T-lymphocytes, stimulates DNA and protein synthesis as 
determ ined by 3 H-thym idm e and 3 H-leucine incorporation, 
respectively (Payan, 1983). Furthermore, a particular subset of 
blood T-lymphocytes have been shown to carry specific receptors 
for NK-1 (Payan et al, 1983). This was determined using a 
fluorescent conjugate of NK-1 in addition to radiolabelled NK-1. 
Somatostatin is another neuropeptide associated with modulation of 
the immune system. Both NK-1 and som atostatin e lic it 
neurocytotoxic histamine release from rat peritoneal mast cells in  
vitro which is as rapid and complete as that evoked by conventional, 
IgE-dependent stimulation (Foreman et al, 1983). Both of these 
neuropeptides have also been associated with 'neurogenic 
inflammation'. This is elicited by substances which are released 
from the peripheral terminals of sensory nerve fibres (Gamse et al, 
1980). The electrical stimulation of these peripheral primary 
afferent neurons activates their neuropeptide-rich terminals. Their 
release, in turn, results in a local increase in vasodilation and 
vascular permeability to large molecules and leukocytes. Taking 
account of the observations presented above, Payan e f a / ( 1 9 8 4 )  
proposed a model linking the sensory neuropeptides and the effector 
pathway of the immune system. He hypothesised that a noxious 
stimuli of sufficient intensity could cause retrograde impulses in 
neuropeptide-containing C-fibres and this would cause the release 
of NK-1 and somatostatin from peripheral terminals as an axon 
reflex. NK-1 would result in vasodilation and the increased 
permeability of the local microcirculation as well as activation of 
mast cells to release histamine and leukotactic peptides which 
trigger established response cascades within the immune system.
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Recent experimental evidence (Smith et al, 1994) has confirmed the
inter-relationships between the central nervous, the neuroendocrine
and the immune system, where there is extensive overlapping usage
of neurotransmitters, hormones and receptors by these systems.
Chambers et al (1993) has reviewed at length the role of both
neuropeptides and other neurotransmitters in the modulation of
immune function. Chambers summarises the published findings with*
respect to the several neuropeptides which have been shown to act 
on immune function by way of inhibiting or enhancing B-cell and/or 
T-cell function; where NK-1 has been shown to enhance T-cell 
function. The occurrence of interleukin receptors on neural cells 
demonstrates the bidirectionality of* the nervous system-immune 
system relationship. The evidence suggests that the immune and 
nervous systems can operate in conjunction in the best interest of 
the host. However, the exact nature of this relationship has yet to 
be defined.
1.2.2.4 Neuropeptides and Development
There are a large number of published findings which support the 
invo lvem ent of neuropeptides in mammalian developm ent. 
Neurokinin-1 is an example of such a neuropeptide and is discussed 
in depth in section 1.4. As an example, McGregor et al (1995) 
reported the transient expression of the NK-1 gene in the developing 
rat endocrine pancreas and noted that this can be regulated in the 
RINm5F cell line model system. Expresssion of NK-1 precursor 
therefore varies during development.
1.2.3 Activation and Inactivation of Neuropeptides
The production of biologically active peptides and proteins in cells 
and tissues requires not only biosynthesis but also post- 
translational modification. These modifications include proteolysis 
(the hydrolysis of peptide bonds), glycosylation, phosphorylation and 
methylation. Proteolysis is the most general of all covalent 
m od ifica tions occuring in vivo (Wold et al, 1981). 'Limited 
proteolysis' is the cleavage of selected peptide bonds, as opposed to
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the non-selective degradation of a whole peptide (Linderstrom-Lang 
et al, 1949). Limited proteolysis has particular relevence to 
neuropeptides as these peptides are often activated by such 
cleavage. These proteolytic events are programmed so as to occur in 
specific cellular compartments where the appropriate enzymes are 
both present and active. The rough endoplasmic reticulum (RER) is 
the site of synthesis for the full neuropeptide gene product. This is 
the largest form of the peptide and is referred to as the pre-pro­
protein (For example, pre-pro-tachykinin). The "pre" refers to a 15- 
30 amino acid 'signal sequence' which is rich in hydrophobic residues 
and is located at the N-terminus of the newly synthesized peptide. 
As the peptide emerges from the RER the 'pre' sequence is cleaved 
leaving a pro-protein. . The pro-protein is often packaged into 
secretory granules in the golgi aparatus of the cell (Blobel and 
Dobberstein, 1975). The first proteolytic cleavage of the pro­
protein can occur either in the golgi aparatus or when the pro­
protein has been packaged into secretory granules. Biosynthesis and 
axonal transport studies of the neuropeptide vasopressin in the rat 
hypothalam o-neurophysia l system have indicated that p ro ­
vasopressin is processed in the secretory granules during axonal 
transport (Grainer et al, 1977). It is likely that NK-1 is processed 
in the same way. Modern molecular cloning technology has permitted 
the identification and determination of the primary structures and 
amino acid sequences of neuropeptide pro-proteins. This, in turn, 
has allowed the identification of amino acid motifs which are 
common to groups o f pro-proteins and which are believed to act as 
the recpgnition sequences which are crucial to the proteolytic 
processing steps (Nakanishi et al, 1979). The majority of known 
pro-proteins have pairs of basic amino acids flanking the cleavage 
site, for example, the lysine and arginine amino acid pairing for pro­
vasopressin (Land et al, 1982). The common amino acid sequences of 
the tachykinin family of neuropeptides are detailed in Section 1.5. 
Before the intact pro-protein is cleaved, other post-translational 
modifications such as glycosylation and the formation of disulphide 
bridges often takes place. Conversely, prior to cleavage, processes 
such as C-terminal amidation and N-terminal acetylation are 
believed to occur (Czicki et al, 1977, Phelps et al, 1980, England e t 
al, 1980). Several methods for the identification of neuropeptide
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processing products, including radioimmunoassay, have been 
presented by Harmar et al (1986).
Some neuropeptide pro-proteins can generate more than one 
biologically active peptide. Pro-opiocortin can be converted into 
endorphin and three other active peptides (Eipper et a l 1980). 
Similarly, pro-enkephalin contains six 'Met-enkephalin' sequences 
and one 'Leu-enkephalin' (Gubler et al, 1982). The most pertinent 
example of this 'common precursor1 or 'multivalent' production of 
several active peptides from one original pre-pro-protein is NK-1. 
This, and several other neuropeptides including substance K, are 
derived from the single PPT-A gene (see Section 1.3.4). 
Intermediates in proteolytic processing of tachykinins precursors 
have been detected by Kream et al (1985) and the possibility cannot 
be excluded that one or more of these intermediates is an active 
peptide in its own right. Other mechanisms can also account for the 
generation of multiple peptides in this way such as control of 
transcriptional processing. Those mechanisms are discussed below.
N europeptide pro-prote ins typ ica lly  undergo two types of 
proteolytic activity in order to generate an active peptide. Firstly, 
an enzyme is required to recognise the paired amino acid basic 
residues (as detailed above), and secondly, a carboxypeptidase-B- 
like enzyme is required to remove the basic residues from the C- 
term inus of the peptide. Further post-translational modification 
can occur after cleavage, commonly C or N-terminal modifications 
such as the sulphation of tyrosine in cholecystokinin (CCK) (Anastasi 
etal, 1968).
An early and pertinent example of the cleavage of neuropeptides by 
tissue-specific enzymes is presented by Blumberg et al (1980). This 
publication documents the cleavage of the proline-glycine bond in 
bovine NK-1 (11 amino acids in total: H -A rg -P ro -L ys-P ro -G ln -G ln - 
P he-Phe-G ly-Leu-M et-N H 2) into the N-terminal tetrapeptide H -A rg -
Pro-Lys-Pro-O H  and the heptapeptide H -G ly-G ln -P he-P he-G ly-Leu - 
M e t-N H 2 . The heptapeptide has been shown to be as active as
uncleaved NK-1 itself in a number of bioassays. The tetrapeptide 
has been found to stimulate the formation of cAMP and neurite
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extension in neuroblastoma cells as well as to enhance the 
phagocytotic activity of macrophage. The intrinsically distinct 
activities of these cleavage products suggested that NK-1 has at 
least a dual role and at that early stage hinted at the 
multifunctionality of NK-1 which was to be clarified by further 
research.
Peptide neurotransmitters are believed to be inactivated by enzymes 
in the synaptic cleft, e.g., hydrolysis by a peptidase. Alternative 
proposed methods of peptide transmitter removal include the uptake 
of the peptide by neighbouring cells and the internalisation of the 
whole ligand-receptor complex.
1.3 THE TACHYKININ NEUROPEPTIDE FAMILY
1.3.1 Discovery and History
In 1931, two pioneering pharmacologists, Gaddum and von Euler, 
discovered a hypotensive and spasmogenic activity in acid ethanol 
extracts of equine intestine which they found to be different from 
the neurotransm itter acetyl choline. It was during early 
experiments to map the distribution of acetyl choline that this new 
activity was first noted. Not only was it found to be capable of 
causing the contraction of the rabbit jejunum in the absence of 
atropine, but this research indicated that it was proteinaceous in 
nature (von Euler and Gaddum, 1931). This new activity was named 
substance P (P for preparation). This neuropeptide was subsequently 
re-named neurokinin-1 (NK-1, see Section 1.3.2). In 1949, Erspamer, 
whose career would later increasingly focus on neuropeptide 
research, identified an activity with hypotensive and spasmogenic 
properties similar to those previously associated with NK-1. He 
noted this while studying the posterior salivary glands of the 
mediterranean octopus Elidone moschata. This activity, christened 
eledo is in , was identified as a polypeptide. Significantly, eledoisin 
was found in octopus salivary gland at a higher concentration than
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that of NK-1 in mammalian brain tissue. 1450 kg of live octopus 
was required as starting material in order to purify enough of the 
peptide to permit sequence analysis. In 1962, eledoisin was the 
first tachykinin peptide to be sequenced (Erspamer et al, 1962). 
Fellow amphibian peptides physa laem in  and phyllom edusin  were 
subsequently identified, purified and sequenced by the same group 
(Erspamer et al, 1964, Anastasi et al, 1970). These active peptides 
demonstrated a characteristic fast onset of action on tissues of the 
gut (compared to the slower acting b ra d y k in in s )  and were 
consequently named the tachykinins (TK). There is a high degree of 
functiona l d ive rs ity  w ith in  the tachyk in in  peptide fam ily. 
Regulation of both peptide synthesis and peptide-receptor 
interaction has contributed to this functional diversity (Nakanishi e t 
al, 1987). Study of the peptides has also highlighted a common 
carboxy-terminal amino acid sequence; Phe-X-Gly-Leu-Met-NH2 . 
This common sequence is characteristic of the tachykinin family of 
neuropeptides where X is either a hydrophobic or aromatic amino 
acid residue (Erspamer et al, 1981). In the tachykinin neuropeptide 
neurokinin-1 , the residue X is phenylalanine, whereas in substance K, 
residue X is valine (Kimura et al, 1983; Maggio et al, 1983; Nawa et 
al, 1983).
The biological properties of the tachykinins were studied using 
synthetic peptide analogues (Section 1.7.3.2). The conserved amino 
acid sequence Phe-X-Gly-Leu-Met-NH2 was found to be critical. 
Prior to its amino acid sequence being conclusively determined (by 
Chang et al in 1971), Erspamer predicted that the sequence of the 
mammalian TK neurokinin-1 would include this conserved amino acid 
motif which was common to the non-mammalian peptides (Erspamer 
et al, 1971). The subsequent discovery of other mammalian and non- 
mammalian TKs has indicated that members of this peptide family 
probably exist in all phyla from coelenterates to vertebrates.
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Figure 1.1 : Amino Acid Sequences of the Tachykinin Peptides.
Mammalian Tachykinin Peptide Sequences
Substance P 
(neurokinin-1) 
Substance K 
(neurokinin-A) 
Neuromedin K 
(neurokinin-B) 
Neuropeptide-K
Neuropeptide- y 
Neurokinin-A(3-10)
Arg-Pro-Lys-Pro-Glh-PHE-Phe-GLY-LEU-MET-NH 2
His-Lys-Thr-Asp-Ser-PHE-Val-GLY-LEU-MET-NH 2
Asp-Met-His-Asp-Phe-PHE-Val-GLY-LEU-MET-NH 2
Asp-Ala-Asp-Ser-Serlle-Glu-Lys-Gln-Val- 
-Ala-Leu-Leu-Lys-Ala-Leu-Tyr-Gly-His- 
-Gly-Gln-lle-Ser-His-Lys-Arg-His-Lys- 
-Thr-Asp-Ser-PHE-Val-GLY-LEU-MET-NH 2 
Asp-Ala-Gly-His-Gly-Gln-lle-Ser-His-Lys-Arg-His- 
-Lys-Th r-Asp-Ser- P H E-Val-GLY-LEU-M ET-N H 2 
Th r-Asp-Ser-P H E-V al-G LY-LE U-M ET-N H2
Non-Mammalian Tachykinin Peptide Sequences
Scyliorhinin I
Physalaemin
Lys-Physalaemin
Uperolein
Hylambatin
Entero-Hylambatin
Phyllomedusin 
Scyliorhinin II
Glu-Pro-Kassinin 
Kassinin ' 
Entero-Kassinin
Eledoisin
Canonical tachykinin C
Ala-Lys-Phe-Asp-Lys-PHE-Tyr-GLY-LEU-MET-NH 2 
pGlu-Ala-Asp-Pro-Asn-PHE-Tyr-GLY-LEU-MET-NH2 
pGlu-Ala-Asp-Pro-Lys-PH E-Tyr-G LY-LE U-M ET-N H2 
pGlu-Pro-Asp-Pro-Asn-Lys-PHE-Tyr-GLY-LEU-MET-NH 2
Asp-Pro-Pro-Asp-Pro-Asp-Arg-
-PHE-Tyr-GLY-Met-MET-NH2
Asp-Pro-Pro-Asp-Pro-Asp-Arg-PHE-Tyr-GLY-Met-MET-
NH2
pGlu-Asn-Pro-Asn-Arg-PHE-lle-GLY-LEU-MET-NH 2 
Ser-Pro-Ser-Asn-Ser-Lys-Cys-Pro-Asp-Gly-Pro-Asp-
Cys=PH E-Val-GLY-LEU-MET-NH 2 
Asp-Glu-Pro-Lys-Pro-Asp-Gln-PHE-Val-GLY-LEU-MET-NH 2 
Asp-Val-Pro-Lys-Pro-Asp-Gln-PHE-Val-GLY-LEU-MET-NH 2 
H-Asp-Glu-Pro-Asn-Pro-Asp-Gln-PHE-lle-GLY-LEU-MET-
NH2
pGlu-Pro-Ser-Lys-Asp-Ala-PHE-lle-GLY-LEU-MET-NH 2 
■terminal sequence - . .  PHE-X-GLY-LEU-MET-NH „2
F igure  1.1: Source references: For substance P (NK-1), see Chang et al, (1971), 
for substance K and neuromedin K, see Kimura et al, (1983), for scylorhinin, see 
Conlon et al, (1986), for phylaemin, see Erspamer et al, (1964), for uperolein, see 
Anastasia et al, (1975), for hylambatin, see Yasuhara et al, (1981), for 
phyllomedusin, see Anastasi et al, (1970), and for eledoisin, see Erspamer et al, 
(1962), for neuropeptide-K, neuropeptide-y and neurokinin-A[3-10], see Helke et al, 
(1990).
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1.3.2 Nomenclature
There have been several attempts to reach agreement on the use of a 
single name for each of the tachykinin peptides. Several identical 
peptides have been cited in publications under more than one name. 
For example neuromedin K is also referred to as neurokinin B. The 
International Tachykinin Nomenclature Committee, chaired by R. 
Michael Snider of Pfizer Inc., presented recommendations regarding 
tachykinin nomenclature (Henry et al, 1989). Unfortunately, the 
recommendations have not been adopted unanimously. The gene at 
the heart of the research presented in this text, PPT-A, encodes 
several neuropeptides including neurokinin-1 (NK-1) which was 
originally referred to as substance P. The preprotachykinin-A (PPT- 
A) gene has been referred to as the 'SP' or 'substance P gene' in the 
past.
The tachykinins exhibit different pharmacological properties and on 
this basis this, were divided into two sub-groups (Lee et al, 1982). 
One group, composed of substance P (NK-1 ) and physalaemin, was 
named the SP-P sub-group, whereas the other, comprising kassinin 
and eledoisin, was designated the SP-E group. Physalaemin and 
kassin in were used as the key d iscrim inatory compounds, 
respectively. This crude system of distinguishing the tachykinins 
served a purpose at the time but has subsequently been found to be 
over-simplistic. It has been superceded and is no longer used. 
Substance P is now referred to as neurokinin-1 (NK-1).
1.3.3 Biosynthesis
As discussed above, neuropeptides are synthesized as precursor 
proteins in the cell body of neurons. They are transported by an 
anterograde action to the nerve te rm ina ls  where they are 
enzymatically cleaved into their active form, stored in specific 
vesicles (different vesicles from when they are stored as cd- 
transmitters) and released when the neuron is stimulated. This 
con tras ts  w ith the c lassica l neuro transm itte rs  which are 
synthesized in the nerve terminals from where they are released
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directly. The mammalian tachykinins, be in j neurokinin-1, substance 
K and neuromedin K are encoded by two genes, namely, the 
preprotachykinin-A (PPT-A) gene and preprotachykinin-B (PPT-B) 
gene.
1.3.4 The Preprotachykinin-A (PPT-A) Gene
* *
The preprotachykinin-A (or PPT-A) gene, encodes several mammalian 
tachykinin neuropeptides. Neurokinin-1 , neurokinin A, neuropeptide 
K, and neuropeptide y are each encoded from this gene by way of 
tissue-specific, a lternative post-transcriptional (alternative RNA 
splicing) and post-translational pathways (Carter et al, 1990). Each 
of the PPT-A gene-encoded peptides are biologically active (Regoli 
et al, 1989). Of these, NK-1 and substance K are the most 
extensively characterised. Alternative splicing of the primary PPT- 
A RNA transcripts generates three mRNAs which, in turn, generate 
several distinct precursor proteins. McDonald et al (1989) presented 
results which demonstrated that multiple tachykinins are produced 
and secreted as a consequence of post-translational processing of 
the three preprotachykinin-A precursor proteins, a -, p -, and y- 
preprotachykinin. The transcripts encoded by the NK-1 gene are 
named a-, p - and y-preprotachykinin mRNA. The a transcript encodes 
neurok in in -1 (SP) only, whereas the p-transcrip t encodes 
neurokin in-1 , neurokinin-A (formerly SK), neuropeptide K and 
neurokin in A(3-10), which is a post-translational variant of 
neurokinin A. The y-transcript encodes neurokinin-1, neurokinin-A, 
neuropeptide-y, and neurokinin A(3-10) (Helke et al, 1990, 
Kawaguchi et al, 1986). In rat and human .PPT-A‘ expressing tissue, 
the p- and y-transcrip ts  together constitute 99% of the .total 
transcripts derived from the gene. The a -transcrip t is therefore 
relatively rare. Tissue-specific generation of the bovine a and p- 
transcripts was demonstrated originally by Nawa e fa /(1984 ). The 
neurokinin-1 peptide is encoded by exon 3 of the PPT-A gene, 
whereas neurokinin-A is encoded by exon 6  (Nawa et al, 1984). 
D ifferentia l post-transla tional processing of the neurokinin-A 
portions of the p- and y-PPT-A mRNAs results in the generation of 
different forms of neurokinin-A; neuropeptide K, which is derived
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from exons 3 to 6  of the (Mranscript, and neuropeptide -7  which is 
derived from exons 3, 4 and 5 of the 7 -PPT-A mRNA. Aqueous 
hybridisation and S 1 nuclease protection assay techniques were used 
to examine both the RNA transcripts and the neuropeptides which are 
encoded by the PPT-A gene (Krause et al, 1989).
Figure 1.2: Transcription and Transcript Splicing of the Rat PPT-A Gene
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Figure 1.2: A schematic representation of the transcription and transcript splicing 
of the rat PPT-A gene primary transcript. Furthermore, the translation and post­
translational processing of the a - ,  p- and y-PPT precursor proteins is also 
represented (Helke et al, 1990). The rat NK-1 gene is depicted at the top and the 
exons are numbered 1 through to 7. Transcription of the gene and splicing of the 
primary transcript generates the a-, (3- and y-PPT mRNAs which are translated with 
concomitant signal peptide cleavage. The number above each PPT precursor 
represents the number of amino acids in each peptide. The abbreviations used are: H, 
HinDlW; G, Bgl II; P, Pst I; B, BamH I; PPT, preprotachykinin. Schematic taken from 
Helke etal, 1990.
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As described in the neuropeptide section above, neuropeptides are 
often activa ted. by cleavage of a precursor protein. The primary 
structure of two forms of bovine braiin neurokinin -1 precursor 
protein were identified by Nawa et al (1,983). The bovine PPT-A 
gene is 8.4 kb in length and comprises 7 exons and 6 introns 
(Nakanishi et al, 1986).
cDNAs encoding the preprotachykinin-A and preprotachykinin-B 
protein precursors respectively, were isolated from a mouse brain 
cDNA library by Kako e fa /(1993). The cDNAs isolated represented 
the p- and y-PPT-A transcripts. The mouse neurokinin-1 precursor 
protein was shown to consist of 130 amino acids, which were highly 
conserved with their rat, human and bovine equivalents, with 99%, 
93% and 92% amino acid identity respectively. The neurokinin-1 and 
neurokinin-A sequences were found to be identical between these 
species. The mouse preprotachykinin-B precursor protein was shown 
to comprise 116 amino acids and have 93% and 78% amino acid 
sequence identity with equivalent rat and bovine sequences 
respectively. Similarly, the sequence of neurokinin B was also 
identical for those species.
The nucleotide sequence of the cDNA which encodes the human. 
neurokinin-1 precursor protein, p-preprotachykinin, was determined 
by Harmar et 3s/ (1986). The p-PPT polypeptide is 129 amino acids in 
length and encompasses regions which encode neurokinin-1 and 
neurokinin A. The same research group was later to identify a  
fourth NK-1 gene mRNA variant. In addition to a mRNA containing all 
7 exons of the gene (p-PPT) and two other alternatively spliced 
forms lacking exon 4 (y-PPT) or exon 6  (a-PPT), a fourth variant was 
isolated which lacked both exons 4 and 6 . A PCR based approach was 
employed to amplify cDNAs which were then sequenced. This novel 
transcript was named S-PPT and is likely to encode a novel 
precursor polypeptide (Harmar et a l, 1990).
1.3.5 Regulation of the PPT-A Gene
The rat PPT-A gene has been shown to be regulated by a number of 
stimuli including growth factors (Kessler et al, 1981), conditioned
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media (Nawa e ta /,  1990), cocaine (Hurd et al, 1992), inflammation 
(Noguchi et al, 1992), and factors present in innervated target 
tissue (Barakat-Walter et al, 1991). Expression of the PPT-A gene 
and the level of tachykinin biosynthesis appears to be under 
homeostatic control. This is clearly the case in both the peripheral
and central nervous systems where expression can be induced or
repressed by modulation as a result of extracellular signals (Walker 
et al, 1991). Tachykinin expression in the anterior pituitary gland 
has been shown to be under hormonal control (Jonassen etal, 1987).
Mulderry et al (1993) used deletion analysis to study the rat PPT-A 
promoter and the regulation of expression. Adult rat sensory 
neurons in culture were transfected by microinjection of plasmids 
containing genomic DNA sequences linked to a lacZ (B-galactosidase) 
reporter gene. Deletion analysis results indicated that a 5-flanking 
sequence, 865 bp upstream of the rat PPT-A gene transcription 
in itia tion  site was responsible for directing high levels of 
expression of the reporter gene.
Mulderry et a l (1993) also found that the majority of the sequences 
which are important to the regulation of this gene in rat dorsal root 
ganglia (DRG) neurons are located between 47 and 865 nucleotides 
upsteam of the start of the gene. DNAase 1 footprinting analysis
studies of the rat PPT-A gene promoter were conducted by
Mendelson et a l (1995a). This technique fac ilita tes  the 
identfication of regulatory sequences by digesting DNA with DNAase. 
I to leave only the DNA sequences to which a regulatory peptide is 
directly bound. Such sequences are protected from the nuclease and 
therefore remain intact. Two footprints were generated which 
permitted the identification of E-box consensus sequences (CANNTG) 
which are recognised by dimeric protein complexes. Such complexes 
are composed of members of the basic helix-loop-helix (bHLH) and 
basic helix-loop-helix leucine zipper (bHLH-zip) families of proteins 
(Murre et al, 1989). One was found to span nucleotides -67 to -47 
while the other spanned -177 to -155. The function of these 
complexes have not been defined. The functional E-box motif in the 
proximal rat PPT-A promoter spans nucleotides -67 to -47. This 
was later mutated by insertion of a 10 bp DNA sequence. Using
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cultured PC12 cells, this element was shown to be likely to function 
as an important c/s-regulatory domain in this promoter (Paterson e t  
al, 1995). Purine-rich motifs, which may serve as binding sites for 
AP-1, Sp1 or other zinc finger-containing proteins, were also 
identified upstream of the rat PPT-A gene. Several other footprints 
were identified and could potentially be regulatory sequences for 
the rat PPT-A gene. The elements identified are likely to be 
involved in both tissue-specific and stimulus-dependent regulation 
of the gene (Mendelson etal, 1995a; Paterson etal, 1995).
The rat PPT-A gene was isolated frpm a genomic library by Carter e t  
al (1990). One major and two minor transcription initiation sites 
were identified upstream of the rat PPT-A gene. Comparison of the 
rat and the bovine PPT-A gene sequences demonstrated highly 
conserved regions throughout the entire coding region and within the 
5' flanking region.
The cell lines RINm5F and R IN rl046-38 currently offer one means of 
investigating which factors and mechanisms are involved in the 
regulation of the NK-1 gene in vitro. Using RINm5F cells, McGregor 
et al (1995) reported the transient expression of the PPT-^A gene in 
the developing rat endocrine pancreas. This approach could be 
extended to the mouse PPT-A gene.
1.3.6 Preprotachvkinin-B (PPT-B) Gene
Neurokinin-B, which was previously known as : neuromedin K, is 
encoded by the fifth exon of the preprotachykinin-B (PPT-B) gene and 
has been isolated from porcine spinal cord. In order to do this, a 
bioassay which determined the tachykinin-like effect of a sample on 
guinea-pig ileum smooth muscle contraction was employed (Kangawa 
e ta l, 1984). Later, a cDNA encoding the 116 amino acid precursor of 
neurokinin-B was isolated from a rat cerebral cortex cDNA library 
(Bonner et al, 1987).
The diversity of the mammalian tachykinin system may have evolved 
as a result of mechanisms such as gene duplication and differential
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expression of duplicated genes. An insight into this was gained as a 
consequence of cloning the bovine preprotachykinin-B (PPT-B) gene. 
Molecular cloning and sequence analysis techniques were utilised to 
identify cDNA and genomic DNA clones of the mammalian 
neuropeptide, neuromedin K (Kotani et al, 1986). Neuromedin K is a 
126 amino acid peptide with a sequence which includes a signal 
peptide sequence and is encoded by the PPT-B gene. This gene 
encodes two mRNAs which differ in the 5' untranslated region. The 
gene organisation of the PPT-B gene was found to closely resemble, 
in terms of the mRNA transcripts, that of the PPT-A gene, which 
encodes the precursor for substance P, substance K and other 
neuropetides (see above). The genetic resemblence suggests that the 
two preprotachykinin genes may be derived from a common ancestor 
gene. Using in situ hybridisation techniques, Nakanishis' research 
team have demonstrated that the expression patterns of the mRNAs 
of the PPT-A and PPT-B genes are different (Kotani etal, 1986).
1.3.7 Regulation of the Preprotachvkinin Genes
Synthesis of the precursor proteins from the preprotachykinin genes 
can be regulated in several ways including transcriptional 
activation, splicing of primary transcripts, translational efficiency 
and post-translational processing. Transcription can be activated by 
the binding of tra n s -acting factors to cis regulatory sequences in 
the promoter or enhancer regions of the gene, and therefore allowing 
RNA polymerase II to transcribe the gene. Alternative splicing of
primary transcripts can vary the synthesis of pro-peptides, often in
a development-dependent or tissue-specific manner. For example, 
bovine a-PPT-A mRNAs are found in high relative concentrations in 
the bovine brain tissue whereas the p-PPT-A mRNAs are abundant in 
bovine intestinal and thyroid tissues (Nawa et al, 1983). Similarly, 
species-specific splicing has been observed in rat and human tissues 
and the relative levels of the a, p and y-PPT-A mRNA transcripts 
determined. In rat, the 7 transcript is the most abundant, whereas in
human tissues, the p-transcript is prevalent (Helke et al, 1990). For
example, in the rat striatum, PPT-A mRNA from post-natal day 2 to 
day 5, levels do marginally fluctuate, (Haverstick etal, 1989).
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1.3.8 Roles of Tachykinins
Tachykinins are distributed throughout the peripheral and central 
nervous systems. Within the CNS, it has been suggested that 
tachykinins are involved in dopaminergic activation and dopamine 
release in addition to sleep control, Alzheimer's disease and 
neuroprotection. With respect to the PNS, tachykinins are thought to 
be involved in skin hypersensetivity and modulation of the immune 
response. Mammalian tachykinins have been associated with sensory 
and motor function as well as immunologic, inflammatory, 
ca rd io vascu la r, resp ira to ry  and gas tro in tes tina l functions. 
Additionally, they may be trophic and mitogenic factors.
The extent of tachykinin research is vast and several hundred 
related papers are published every year. Most of that research is 
inevitably focussed on substance P (NK-1) which was the first 
neuropeptide to be identified, and is arguably much the best studied 
(Maggio et al, 1988). The tachykinin neuropeptides are widely 
distributed and are active in the central and peripheral nervous 
systems and evoke numerous responses in numerous tissues. They 
are known to evoke responses, in neurons and act as secretagagues 
(promoting secretion of other substances). They are also potent 
vasocontractors and can induce the contraction of smooth muscle 
e ither d irectly  (or ind irectly  v ia  the release of c lassica l 
neurotransmitters). Of particular interest to. the neurobiologist is 
the apparent involvem ent of tachykinins in the . nigro-striatal 
pathway and primary sensory afferent transmission. The role of 
tachykinins as mediators between the nervous and immune systems 
has also generated much research interest (Section 1.2.2.3).
1.3.8.1 Asthma
In 1992, a study by Ichinose using a tachykinin receptor antagonist 
called FK-224, demonstrated that such antagonists may have a use 
in the treatment of asthma. This was demonstrated by the reversal 
of broncho-constriction which had been induced by the inhalation of 
bradykinin in asthmatic patients (Ichinose, 1992).
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1 .3 :8 .2  Inflam mation and Arthritis
Rheumatoid arthritis can be initiated by an auto-immune reaction 
(Guard et al, 1991). The sensory and sympathetic nervous system is 
im portant in the maintainance and progression of rheumatoid 
arthiritis. Support for this is provided by the observation that 
sensory nociceptive fibres (which activate sympathetic fibres via 
spinal connections) demonstrate neurokinin -1 immunoreactivity. 
Tachykinin antagonists may provide useful local treatment for 
rheum atoid arthritis. Tachykinin peptides may have some 
involvement with neurogenic inflammation (Guard e ta l,  1991) and 
may therefore be involved in the processes of arthritis.
1.3.8.3 Development
Previous studies have demonstrated that immature cortical neurons 
can express neuroactive substances which are not found in the adult 
cortex; neurokinin-1 is one such substance (Zhang et at, 1994). 
Immunocytochemistry and in situ hybrid isation (histochemistry) 
have been used to investigate the distribution of neurokinin-1 and 
neuromedin K in various cortical areas of the rat cerebrum during 
development (Zhang ef a/, 1994).* Studies were performed at several 
prenatal and postnatal stages in order to identify a population of 
transitory neurons equivalent to those that appear to play a role 
during the development of the cerebral cortex in mice. The number 
of neurokinin-1 mRNA-positive neurons and neurokinin-1 -immuno- 
reactive cells was found to decrease from postnatal day 10  and .15 
onward, respectively. The identification of transient populations of 
tachykinin-expressing neurons has provided further evidence of the 
role of tachykinins in mammalian neurobiological development.
The floor plate is a ventral mid-line structure which is crucial to 
the organisation of the developing vertebrate CNS and may also be 
involved in regulation of neuronal d iffe rentia tion by guiding 
developing axons. Neurokinin-1 is one of the first transmitters to 
be expressed in the developing spinal cord. The distribution of the 
neurokinin-1 receptor in the vertebrate spinal cord was examined by 
in situ hybridisation and immunocytochemistry (Heath e ta l, 1995). 
Neurokinin-1 and other peptide modulators may contribute to the
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fine tuning of developmental processes in the embryonic CNS. 
Elsewhere, (see section 1.4.3) results have indicated that the PPT-A 
gene for example, which encodes several tachykinins, is actively 
expressed in the pancreas during development, but not in the adult 
pancreas (McGregor eta l, 1995).
1.3.8.4 Neurotransmission
The proposed role of the tachykinins in neurotransmission is 
supported by the evidence indicating a role for these peptides in 
nociception (Section 1.2.2.1). Furthermore, the tachykinin , neuro­
peptides are present in nerve terminals packaged in vesicles which 
are encased by membranes which can fuse with the membranes of 
other cells. Evidence for the role of tachykinins in the regulation of 
neurotransmission is presented by Maggio e fa /(1 98 8 ). The role of 
tachykinins in the perception of pain presented by Helke et al (1990) 
also supports this.
1 .3.8.5 Sleep Regulation
The locus coeruleus region of the mamalian brain plays an integral 
role in the control of sleep and alertness (Kolb ef a/; 1989). 
Tachykinins, including neurokinin-1 , have been shown to be potent 
activators of locus coeruleus neurons and it has been proposed that 
they are likely to be involved in sleep/alertness control. NK-1 also 
activates other neuronal cell types and therefore the precise 
involvement of this neuropeptide with sleep has yet to be clarified. 
Further research is required.
' 1 .3.8.6 Immunoreaulation
The CNS is believed to regulate the immune system, but to an 
unknown extent (see section 1.2.2.3). Tachykinins are thought to be . 
s ignificant mediators of this. Neurokinin -1 and neurokinin-A 
stimulate T-cell proliferation and tachykinin receptors have been 
localised on lymphocytes and other cells of the . immune system. 
Tachykinins may also mediate local inflammation as they have been
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shown to stimulate histamine secretion from mast cells (Ljundahl 
et al, 1978) and polymorphonuclear leucocytes (Bar-Shavit et al, 
1980), in addition to mediating local vasodilation in response to 
injury.
1.4 SUBSTANCE P
1.4.1 The Discovery and History of Substance P (NK-1)
As detailed in the tachykinin section above, while investigating the 
tissue distribution of acetylcholine, Von Euler and Gaddum (1931) 
discovered a spasmogenic and hypotensive activity in acid ethanol 
extracts of equine intestine which they named substance P and 
which has formed the bedrock of neuropeptide research. Early 
experiments indicated that this activity was proteinaceous in nature 
rather than a classical, acetyl cho line-like neurotransm itter 
(Gaddum and Schild, 1934). Of . the tachykinin, brain-gut peptides, 
substance P has the. longest scientific history and was the first 
active compound extracted from neural tissue which was found to be 
proteinaceous. Substance P has since been re-named neurokinin-1. 
As detailed above, neurokinin-1 and neurokinin A are the major 
peptides expressed by the PPT-A gene and they are produced 
predominantly by neuronal cells of the central and peripheral 
nervous systems (Krause et alt 1989).
For th irty years after the discovery of neurokinin-1, research 
focused on the pharmacological activities, the chemical properties 
and the tissue distribution of this tachykinin (Pernow ef a/,1983). 
However, with the benefit of hindsight, the variable purity of 
neurokinin-1 isolates used during that period calls into question the- 
accuracy of the results presented and published at that time. 
Findings made prior to the complete, purification and amino, acid 
sequencing of neurokinin-1 (Chang et al, 1971) included the 
assertion that neurokinin-1 was identical in brain and gut, unevenly 
distributed in the nervous system, and active in the gastrointestinal
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tracts of many species. These observations have been subsequently 
validated. Of the several known peptidergic neurotransmitters/ 
neuromodulators, neurokinin-1 is one of the best-characterised 
(Nakanishi et al, 1986). .
1.4.2 Distribution of Neurokinin-1
" " _ m i . ^
1 .4.2.1 Central Nervous System
As a consequence of the common carboxy terminal amino acid 
sequence, antisera raised against one particular tachykinin peptide 
and used in immunocytochemical studies, may cross-react with one 
or more o f the other tachykinins (Milner et al, 1988). This, in 
addition to the relatively recent discovery of the peptides NPy and 
NKA(3-10) expressed from the same PPT-A gene, has cast a doubt 
over . the specificity of early radioimmunoassay and immuno­
cytochemical studies. The distinct regional and cellular distribution 
of each neuropeptide has yet to be ascertained accurately- However, 
to date, the highest concentration of neurokinin-1 in any region of 
the brain, is found in the substantia nigra where it is concentrated 
in nerve endings of' afferent neurons in. the striatum, and is 
subsequently released (Duffy et al, 1975). This also supports the 
role of neurokiniri-1 as a neurotransmitter.
Neurokinin-1 can be isolated from the brains of alf vertebrates 
ranging from fish to mammals, including man. The concentration of 
neurok in in -1 appears to be' lower in species with highly 
differentiated brains; in increasing order, man, cat, rabbit, guinea- 
pig, rat, duck, pigeon, and chicken (Grabner ef al, 1959). Generally 
neurokinin -1 concentration is higher in grey matter than white 
matter. The highest brain concentrations have been found in the 
substantia nigra, hypothalamus, globus palladus, caudate nucleus, 
putamen and the central grey matter (Pernow ef al, 1983). In the 
spinal cord, the dorsal half contains more neurokinin-1 . than the 
ventral. In the peripheral nervous system, levels are low relative to. 
the central nervous system yet are highest in the spinal ganglia and 
sympathetic trunk of the peripheral system (Pernow et al, 1953).
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Neurokinin-1 has also been localised to the gastrointestinaltract o f 
several species (Euler et al, 1977). The distribution of neurokinin-1 
has been determined traditionally using radioimmunoassay and 
im m unocytochem ical techniques (Section 1.7.3). However 
distribution has been determined most accurately using the in situ  
hybridisation technique, where, in the rat central nervous system 
for example, distinct patterns of cells producing PPT-A' mRNA have 
been mapped (Warden et al, 1984). Such cells are prominent in 
la m in a e  i  and n  of the spinal cord and in the thoracic 
intermediolateral cell column. Similarly, the sensory neurons of the 
dorsal root ganglia and the medullary raphe neurons which project to 
the spinal cord, contain relatively high levels of PPT-A mRNA 
(Warden etal, 1984) (see figure 1.3).
A subpopulation of primary afferent neurons have been shown to be 
positively immunoreactive for neurokinin-1. In addition to several 
other neuropeptides including vasoactive intestinal polypeptide 
(VIP) and calcitonin gene related polypeptide (CGRP), neurokinin-1 
has been localised to late differentiating (LD) neural crest cells in 
culture (Matsumoto et al, 1994). Conversely, a population of early 
differentiating (ED) neural crest cells was found to lack th is 
neurokinin-1 immunoreactivity.
The organisation of the extrapyramidal motor system includes the 
reciprocal neuronal connections between the corpus striatum 
(caudate-putamen) and the substantia nigra. Distinct defects in the 
extrapyramidal system have been shown to result in Huntingdon's 
and Parkinson's disease. Microdissected brain tissue has been 
examined and high concentrations of neurokinin-1 have been 
demonstrated in both the caudate nucleus and the zona reticulata of. 
the substantia nigra (Brownstein e ta l,  1976, Davies e ta l,  1976). 
The immmunocytochemical experiments of Ljungdahl e fa /(1 9 7 8 ) 
showed that the neurokinin-1 immunoreactive neuronal cell bodies 
in the caudate-putamen are the source of the neurokinin-1  - 
immunoreactive nerve terminals in the substantia nigra and the. 
globus pallidus. This suggests that neurokinin-1 may have some role 
to play in Huntington's and/or Parkinson's disease because those; 
regions are known to demonstrate altered morphology in patients
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with the clinical symptoms of those diseases. Ii has also been noted 
that neurokinin-1-im m unoreactive neurons in the substantia nigra 
appear to regulate the nigral dopaminergic neurons which project 
into the striatum. Similarly, expression of the PPT-A gene in the 
stria tum  is regulated by those n igrostria ta l dopaminergic cells 
(Bannon etal, 1987).
* '
Figure 1.3 :Distribution of Tachykinin (TK1 immuno-Reactivitv in the Rat.
Thoracic Spinal Cord Tachykinin-ir
N K-3NK-1NKB mRNASP/NKA (PPT) mRNA
Figure 1.3: Representation of a) laminar divisions of the thoracic spinal cord in rat 
(left side) and the distribution and relative intensity of tachykinin (TK) immuno- 
reactivity in the rat. TK immunoreactivity was assessed using a monoclonal antibody 
to neurokinin-1 which cross-reacts extensively with NK-A (and NK-A related 
peptides) and NK-B. b) Distribution and relative density of cell bodies containing PPT 
mRNA (left side) or NK-B precursor mRNA (Warden et al, 1988). c) Distribution and 
relative density of NK-1 binding sites (left side, labelled with [125I]BH-SP) and of NK- 
3 binding sites (labelled with [125l]BH-eledoisin, Mantyh et al, 1989). IML, 
intermediolateral cell column; LSp, lateral spinal nucleus; NK-A, neurokinin-A; SP, 
substance P; PPT, preprotachykinin; NK-B, neurokinin-B; (Helke etal, 1990).
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Figu re 1.4_ : Distribution of NK-1 in Rat and Human Tissues
Rat Human
Kanazawa, |> 7 f BiuwtuScla. 1976 Douclei. 1911' <Mc. 1971 Enuon, 1980 OoopcO?*
( a - 4 ) <a - 20) (n -€ » (a -  10-20J (n -3 -1 3 ) ( i t -6 .1 0 )
Telencephalon
S oM lO M M oqrw rtu l t ± X *
Visual cortex 23 ±  4
O lfactory bulb 62 ±1 1 2 0 ± 6 41 ± 6
O lfactory tubercle 300±  14
Hippocampus 27 ± 4 340 ±4 5 104 ±29
A ny(d«U 382 ± 8 6 340 ±60 25 ±12 2 6 ± 3
Nucleus caudatus 247 ± 2 8 370 ±60 138 ±14 113 ±1 2
Putamen ‘ 330 ±60 112±29 8 1 ± U
Globus paflidus 332 ± 4 5 1800 ±330 877 ±253 618 ±15
Septum 405 ±4 4 116±14 89 ±23
Lateral septal nucleus 360 ± 2 0
Interna l capsule 137 ±2 1
Retina 86 ± 1 4
O ptic nerve *65 ± 1 4 O 6 ± 0 ^
Pienoephalon
Hypothalamus (medial) 626 ± 6 4 208 ± 3 7 122 ± 22
Hypothalamus (lateral} 135 ± 20
Hubenula 377 ±101
2 0 7 ± 8 8 3 ±  14
P itu ita ry  stalk sad median 134 ±21
Posterior p itu itary 489 ± 2 4
A n te rio r p itu ita ry 7 1 ± 2 2 0 ± 5
Thalam ic nucleus 215 ± 6 8 3S ±S
CSobuspalGdus 332 ±4S 1800 ±330 877 ±253 518 ±151
Latera l pealcdate body 82 ± 1 2 90 ± 1 3 37±10
M u enccph iha
SobstantUnlcpa 1725 ±106 2560±195
Zooaoompecta 298±44 4720 ±480 1264 ±239
Zoos reticularis 1138 ±136 4290 ±490 1S3S±170 922 ±156
ZooaUtereEs 238±39
Periaqueductalcentnlcrqr €14 ± 3 7 130 ±21
Itttftfpodm ouliM  nodcttt 699 ± 6 3 690±129 994±149 . 83 ±2 5
Ra»d nucleus 68 ± 1 2 76 ± 1 9
IntterieriorcoO icufi 94 ± 1 8 234 ± 1 9
Ptone
Lucus coeruleus 33 2±6 0 199 ±3 2
M odel parshrschiales 646±124
K o to r nucleus V 14S±29
D orsal raphe nudeos 222±25
GetebeQum
C ortex 1 0 ± 4 2 ± 1 12 ± 1 2 0 ± 6 l± 0 ll
M odel 2 9 ± 6 i± a i
Mudeuscunestus 32 0±3 2
M adras taactus spinalis V 383 ±125
Modeus tvacCus soCtaru 436±93
M o to r nudeus X n 217 ± 2 6
Areapostrema 167 ± 3 6 114 ±4 7
Kudeus reticularis pcaatooeQuIaris 95 ± 1 1
In fe rio r otive 127 ± 1 5 8 ± 2
Modeus raphe magnus 229±23 71 ± 1 5
M edulla y m li«
Docaal horn 1070 ±160*
Dorsal column 129 ± 2 9
V entral horn 134 ± 3 3
ELqpJie 1.4: Regional distribution of neurokinin-1 in the tissues of the rat and human 
nervous systems (taken from Pernow review, 1983). All values have been converted 
to pmol/g -of wet tissue. Values are given as "mean+/- SEM". Authors of original 
publications are given in the column headings. Determined by radioimmuno assay.
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■1 .4.2,2 The Peripheral Nervous System
Neurokinin-1 is localised to the peripheral as well as the central
nervous system and two neuronal networks in particular. Both the
primary sensory neurons and the neurons intrinsic to the
gastrointestinal tract contain neurokinin-1 -immunoreactive cells.
The central role of neurokinin-1 in the contraction of the smooth*
muscle of the gastrointestinal tract via the peripheral nervous 
system is well documented (Bartho et al, 1985) and is summarised 
below. Neurokinin-1 is also localised to numerous cell bodies 
including the trigeminal and the spinal ganglia (Cuello etal, 1978).
1.4.2.3 Peripheral tissues
Neurokinin-1-containing fibres have been localised to most 
peripheral tissues and organs ranging from the human skin 
(Dalsgaard et a l 1983) to the taste buds of the cat (Lunberg et a l  
1979). Neurokinin-1-containing nerve cells and fibres are also 
present in all parts o f the peripheral visual system, and in nerves 
which govern motility in the gastrointestinal tract (Pemow, 1983).
1.4.3 Apparent Functional Roles of Neurokinin-1
The excitatory capability of neurokinin-1 has been determined and 
this may well be the primary role of this peptide in the adult 
mammal. Further to von Euler and Gaddums' observations (1933), 
Konishi et al (1974) showed that hypothalamic neurokinin-1 caused 
excitatory pulses in spinal motor neurones of newborn rats. As 
further evidence of its capabilities as a neurotransmitter, Matsuto 
et al (1984) also demonstrated that neurokinin-1 is capable of 
depolarising spinal motorneurons. In the central nervous system, 
neurokinin-1 and neurokinin A function as activating molecules in 
synaptic transmission (neuromodulators), whereas in the peripheral 
nervous system they act as neuro-effectors in the paracrine 
regulation of a variety of neuronal cells (Maggio e ta l  1988). There 
are similarities in the distribution of neurokinin-1 and neurotensin 
in the anterior pituitary gland where these peptides may act as
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paracrine regulators (Aronin et a/, 1986). These peptides appear to 
function as paracrine neuro-effectors of peripheral tissues such as 
gastrointestinal smooth muscle (Bartho e ta l,  1985). Neurokinln-1 
acts on postganglionic cholinergic neurons in the gut to cause 
acetylcholine release which in turn causes smooth muscle 
contraction. Neurokinin-1 depolarizes neurons and in this respect is 
200-900 times more potent than L-glutamate (Bartho,.e t al, 1985). 
Several non-neuronal cell types (such as gastrointestinal muscle 
cells) also contain these peptides (Ericsson et al, 1990). The
function underlying the occurence of these peptides in several
tissues, and the physiological importance of their presence in those 
tissues, remains to be resolved. As an example, tachykirtin- 
immunoreactive neuronal cells are connected to the islets of 
Langerhans (Sharkey et al, 1984) and the anterior pituitary gland (Ju 
et al, 1989) yet the function of such connections is not clear. In the
mature spinal cord neurokinin-1 is released from primary afferent
term inals in the dorsal horn and has been implicated in the 
transm ission of nociceptive sensory information (Willis et al, 
1991). Evidence has also been presented indicating that neurokinin- 
1 has a role in pain. At the cellular level, neurokinin-1 has been 
localised to the cell bodies of sensory ganglia -and the spinal 
trigem inal nucleus system (Cuello et alt 1978) ahd therefore 
provides a distributional support for the involvement of neurokinin- 
1 in nociception. From a neuro-physiological standpoint, evidence 
includes the observation that neurokinin-1 applied iontophoretically 
to single units located in the dorsal horn of the spinal cord 
selectively excites those cells (Henry et al, 1977). There is also a 
large volume of pharmacological evidence. This includes the use of 
capsaicin which inhibits the axonal flow of neurokinin-1 when 
applied locally (Gamse et al, 1982).
Neurokinin -1 also acts in the cortex where it has a powerful 
stimulatory effect on cortical Betz neurons (Phyllis et al, 1974). 
Early studies proposed a relationship between acetyl choline and 
peptides such as neurokinin-l where neurokinin-1 was thought to 
have a presynaptic, acetylcholine-releasing action (Phyllis et al, 
1974). This has subsequently been corroborated. In the 
hypothalamus, a calcium-dependent, potassium-induced release of
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neurokinin-1 has been demonstrated. This may have some role in the 
firing of hypothalamic neurons (Ogata et al, 1981). Release of 
neurokinin-1 both in vivo and in vitro in the striato-nigral pathway 
has been demonstrated, as has the excitatory and inhibitory effects 
of neurokin in -1 at this locus. The effects of administering 
neurokinin-1 to laboratory animals for example are multiple. The 
complexity of these actions may stem from the relationship between 
the tachykinin peptides and the classical neurotransmitters. For 
example, iontophoretic administration of neurokinin-1 to single 
neurons in the substantia nigra induces a prolonged increase in 
neuroactivity (Davies et al, 1976), and bilateral injections of 
neurok in in -1 into the rat substantia nigra increases basal 
locomotive activity (Kelley et al, 1978).
Results suggests that there is a significant relationship between 
the dopam inergic nigro-striatal and neurokinin -1 s tria to-n igra l 
pathways and that there may be a role for neurokinin-1 as a 
dopamine modulator. This is indicated by results which show that 
neurokinin-1 afferents enhance the firing rate of dopamine neurons 
(Hanson et al, 1981). GABA, which is also found at high levels in the 
» substantia nigra has been attributed a transmitter role in inhibitory 
stria to -n ig ra l neurons although a c lear anatomical d istinction 
between GABA and neurokinin-1 pathways in this area has been 
demonstrated (Brownstein et al, 1976). The proposed functional 
significance of neurokinin -1 in the substantia nigra is further 
supported by the low levels of neurokinin-1 observed in this area of 
the brain of patients with Huntingdon's chorea. This disease is 
typified by a marked atrophy in the basal ganglia (Gale et al, 1978). 
The role of neurokinin-1 in this remains unclear.
Application of neurokinin-1 to the dorsal surface of the rabbit 
medulla elicits a considerable enhancement in. respiratory rate and 
am plitude (Yamamoto et al, 1981). This suggests that the 
stim ulatory effect of neurokinin-1 on ventilation is exerted on 
structures located in the lower brain stem. Neurokinin-1 also has a 
wide distribution and an important role in vasodilation of the 
circulatory system as well as a role in airway hyper-reactivity 
(Lundberg, 1983). It is also a potent stimulator of salivation in
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several animals but not in others. The sialagogic properties of 
neurokinin-1 are well documented (Pernow, T983). NK-1 also has a 
role in kidney function and water homeostasis (Mills et al, 1974).
Neurokinin-1 and other neuropeptides have been found to frequently 
coexist where high concentrations of both molecules have been 
localised to the same c& tl . This has occured in both central and 
peripheral neurons. The precise reasoning for this co-existence, 
based on the assumption that there is a mutual relationship, is not 
clear. The work carried out by Lundberg et al (1982) based on a 
population of neurons containing acetylcholine and vasoactive 
in te s tina l pep tide  im m unoreactiv ities , suggests that one 
phsysiological function of the neuropeptides such as neurokinin-1 
may be to potentia te  the effect of co-existing classical 
neurotransmitters.
Further evidence suggesting the involvement of neurokinin-1 in the 
development of the central nervous system is presented by De Felipe 
et al (1995). The chemotropism of developing axons is well 
established. The results of De Felipes1 research indicate a role for 
neurokinin-1 in regulating the release of chemo-attractants from 
the cells of the embryonic rat floor plate and subsequently the 
layout of the developing neuronal pathways.
1.4.4 Biosynthesis and Degradation
The biosynthesis of neuropeptides and the activation of those 
peptides is detailed in Sections 1.3.3 and 1.4.4. Using 3 5S - 
methionine and 3 H-proline in incorporation studies, the biosynthesis 
of neurokinin-1 in dorsal root ganglia has been researched (Harmar 
et al, 1981). This peptide is synthesized ribosomally and is 
transported to nerve terminals by an anterograde movement. In the 
sciatic nerve for example, transport has been determined to be about 
1mm per hour. Faster-moving neurokinin-1 travels in a peripheral 
direction along axons at about 120mm per day (Harmar et al, 1981). 
Demecoline, which inhibits the axonal transport of vesicles 
(including those containing neurotransmitters), causes accumulation
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of neurokinin-1 in the ganglion. Neurokinin-1 is synthesized in the 
cell bodies of the dorsal root ganglia from where it migrates along 
axons to the dorsal horn of the spinal cord and the substantia 
gelatinosa of the medulla. It is also transported peripherally to the 
sensory neurons and the nerve terminals situated in peripheral 
tissues (Takahashi e ta l, 1975). Neurokinin-1 is released from nerve 
terminals upon electrical stimulation and when evoked ,by potassium 
(Otsuka etal, 1976).
Many tissues and organs have the capacity to degrade neurokinin-1 
(Berger et al, 1979) and the location of this activity may be 
indicative of the sites where the neurokinin-1 ligand is released. 
The capacity to degrade neurokinin-1 correlates strongly with the 
levels of neurokinin-1 present in that tissue, for example in the 
gastrointestinal tract (Lee et al, 1982). The inactivation of 
neuropeptides such as NK-1 is detailed further in section 1 .2.3.
1.4.5 Localisation of Neurokinin-1
Neurokinin-1 has been measured by radioimmunoassay using raised 
antiserum and monoclonal neurokinin-1 antibodies: Highly specific
antibodies to certain portions of the neurokinin-1 peptide have been 
generated. For example, an antiserum directed specifically to the N- 
terminal part, of the molecule was shown to have only 0 .1% and 
0.01% cross-reactiv ity to the SP2 ’ 1 1 and SP3 ~11 peptides, 
respectively, which lack the N-terminal. sequence common to all 
tachykinins (Lee et al, 1980). Immunocytochemical techniques have 
also been successful used in the study of the cellular distribution of 
neurok in in -1 . Indirect im m unofluorecence techniques using 
conjugated, species-specific antibodies have been used to study 
neurokinin-1 levels in formalin-fixed tissue sections. The in situ 
hybridisation approach is the method currently favoured for 
determining the location of neurokinin-1. Warden et al (1988) used 
48-base synthetic oligodeoxynucleotide probes radioactively labeled 
with 35S to examine the cell labelling pattern for neurokinin-1 and 
neurokinin-B mRNA in the rat CNS. This study demonstrated the
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sensitivity and specificity of in situ hybrid isation histochemistry 
for mapping peptidergic neurons.
Pharmacological studies of the NK-1 receptor has been facilitated 
by the development of chemical antagonists. Antagonists such as 
baclofen (Saito et al, 1975) and other neurokinin-1 analogues have 
been used in an attempt to further understand the physiological role 
of the neurokinin -1 receptor. These chemicals are used in 
conjunction with the assays described above (Section 1 .7.3).
1.5 THE TACHYKININ RECEPTOR FAMILY
Com m unication between cells is critica l for a m ultice llu lar 
organism to function. The bovine, rat and human substance K 
receptors have been cloned and characterised, as have the rat 
neurokinin-1 and neuromedin K receptors [Masu et al, (1987), Sasai 
et al, (1989), Gerard e t at, (1990), Yokota et al, (1989), Hershey e t  
al, (1990)]. Many signal molecules use transmembrane signaling 
systems to illic it a response in a target ce ll.. Such a system 
requires at least two components; the extracellular part which binds 
the ligand (namely, the receptor) and secondly, the intracellular part 
which continues the transduction cascade (namely, the internal 
effector molecule). Receptors. have subsequently been classified as 
either ligand-gated ion channels (such as the nicotinic acetylcholine 
receptor), receptors w ith an in trinsic in trace llu la r enzymatic 
domain (such as the insulin receptor), and receptors that couple to a 
guanine nucleotide-binding regulatory protein (G-protein) which in 
turn activates an effector molecule like an enzyme (for example the 
3-adrenoceptor, Burbach et al, 1992). The neuropeptide receptors, 
including the tachykinin receptors fall into the latter, G-protein 
coupled membrane receptor category. G-protein coupled receptors 
are detailed in section 1.5.4.
The effects illicited by the tachykinin neuropeptides are mediated 
by those membrane receptors. Pharmacological, biochemical and 
molecular cloning studies have demonstrated that there are three
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distinct mammalian tachykinin receptors, NK1, NK2 and NK3. They 
are members of the G-protein-coupled receptor super-family,. each 
of which possess seven putative transmembrane domains (Lefkowitz 
et al, 1989). The nomenclature NK1, NK-2 and NK-3 for the three 
tachykinin receptors replaced the previous system whereby those 
receptors were known as SP-P, SP-E and SP-N respectively (Iverson, 
1990). An early report indicating three distinct ;types of TK 
receptor in rat peripheral tissues was presented by Maggi et a l 
(1987). (t*C ..
The tachykinin receptors are present at low concentrations as 
cellu lar components and are tightly embedded in the plasma 
membrane. The neurokinin-1 receptor was solubilised from bovine 
brain using detergents (Nakata et al, 1988). The high-affinity 
binding of neurokinin-1 to solubilised protein was inhibited by GTP, 
suggesting a G-protein related receptor coupling (Too et al, 1988).
Study of the mammalian receptors was undertaken by Harada et a l
(1987) using receptor mRNA injection into Xenopus oocytes. The
expressed receptor was examined electrophysiologically using 
ligand binding. These studies indicated that there are at least two 
distinct mRNAs encoding the neurokinin-1 and substance K receptors 
(Harada et al, 1987). Based on these experiments and others, the 
signal transduction mechanism for activation of the tachykinin 
receptors was proposed (Harada et al, 1987, Nakanishi et al, 1990); 
The tachykinin receptor expressed in an oocyte acts through a G- 
protein to cause production of IP3  (inositol triphosohate) which in.
turn elevates cytoplasmic calcium ion levels. This calcium then
activates a calcium-dependent chloride channel in the plasma 
membrane.
1.5.1 Primary Receptor Structure
The rat neurokinin-1, substance K and neuromedin K receptors 
consist of 407, 390 and 452 amino acids respectively. These 
receptors have seven hydrophobic segments, each consisting of about 
20-25 uncharged amino acid residues, and share a significant 
sequence similarity with G-protein coupled receptors (Dixon 1988,
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O'Dowd et al, 1989, Bonner et al, 1989). The amino terminal and 
carboxy terminal regions of the three receptors also show a pattern 
similar to the G-protein coupled receptors. Each of the receptors 
possess potential N-glycosylation sites at the amino terminal and 
multiple threonine and serine residues as possible phosphorylation 
sites at the carboxy terminal. Subsequently, all three tachykinin 
receptors are members of the G-protein family of G-Rr,otein-coupled 
receptors and possess seven transmem brane domains w ith 
extrace llu la r amino termini and cytoplasm ic carboxy term ini 
(Nakanishi, 1989) (see figure 1.5). The core sequences covering the 
seven putative transmembrane domains are highly conserved (54- 
6 6 %) among the three tachykinin n&eptors (Shigemoto et al, 1990). 
Furthermore, the p2 -adrenergic receptor contains two cysteine 
residues in the first and second extracellular loops which are 
believed to form a disulphide linkage between the loops (Dixon et al, 
1987). Another cysteine residue, which is located immediately 
adjacent to transmembrane segment V II,  has been shown to be 
palmitoylated. It can therefore act as the membrane-embedded 
anchor for this receptor. The three cysteine residues are conserved 
in the three tachykinin receptors.
1.5.2 Receptor Specificity .
The combination of the cross-reactivity of the receptors with other 
TKs and the low abundance of the receptors in cell membranes has 
hindered their analysis using classical tools such as antisera, 
antagonists and radioligands (Maggio et al, 1988). The isolation of 
receptor gene cDNA clones has allowed them to be studied 
individually. From receptor ligand-binding studies, the Ki values of 
the receptors has been determined (see figure 1.5). The neurokinin- 
A and neuromedin K receptors are, in terms of ligand/agonist 
specificity, more closely related to each other than to the NK-1R. 
This contrasts with the higher overall homology between the 
neurokinin-1 and neuromedin K receptors at the amino acid level. 
Marked species-specific differences in NK-1R pharmacology have 
been noted. For example, the antagonist CP96345 has been shown to 
be two orders of magnitude less potent on NK-1 receptors in rat and
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mouse than in human (Snider et al, 1991). The converse is observed 
for the antagonist RP67580 (Garrett et al, 1991). Furthermore, the 
three TK receptors show desensitisation in response to repeated 
application of agonists, but to different degrees (Shigemoto et al, 
1990). The pharmacological approach to the study of neuropeptides 
and their receptors is discussed in greater depth later in this text.
Figure 1.5 : The Ki Dissociation Values for Three Rat TK Receptors
• . 1. For the Rat NK-.1 Receptor
Ki for neurokinin-1 was 1.5 x IO -10 M. 
Ki for neurokinin-A was I .T x IO ^ M .
Ki for neuromedin K was 5.3 x 10-8 M.
. 2. For the Rat NK-2 Receptor
Kj for neurokinin-A was 3.0 x 10’19 M. 
Ki for neuromedin K was 5.6x10:9 M.
Ki for neurokinin-1 was 1.0x10"7 M.
3. For the Rat NK-3 Receptor,
Ki for neuromedin K was 4.2 x10"1° M. 
Ki for neurokinin-A was 2 .9x10“8 M.
Ki for neurokinin-1 was 1.9x10*7 M.
Figure 1.5: The Ki dissociation values as determined for the the three rat tachykinin 
receptors with respect to three of the potential tachykinin ligands; neurokinin-1, 
neurokinin-A and neuromedin K (taken from Shigamoto et al, 1990). The relative 
potencies of the ligands is indicated by the Ki values given. .
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Figure 1.6 : Transmembrane Topology of the Tachykinin Receptors
EXTRACELLULAR
E1  x ^ E 2  E 3
N -T E R M IN A L
2 cP „3 d £ MEMBRANETM =
C -T E R M IN A L INTRACELLULAR
F igure  1.6: Generalised transmembrane topology of the tachykinin receptors as 
prototypes of G-protein-coupled receptors. The model spans the regions of the NK-1, 
NK-2 and NK-3 receptors of the rat from the first to the last identical amino acid in 
the three receptors. Consequently, most of the N- and C-terminal regions are not 
shown (taken from Shigamoto et al, 1990). Amino acids in black are identical in all 
three receptors, th e  nomenclature of the transmembrane domains (TM 1-7), 
intracellular (11-3) and extracellular loops (E1-E3) is indicated (Burbach etal, 1992).
Figure 1.7 : Linear Map of the Five Rat NK-1 Receptor Gene Exons
Tl STOP
JL36. 18* 244 310Oqo4*>qo-ciTCH
TM1 TM2TM3 
1
TM4
2
TM5
3
TM6TM7
4
F igure  1.7: Linear map of the five exons of the rat NK-1 receptor and the 
corresponding trransmembrane segments encoded by those exons (taken from Watson 
et al, 1994; G-protein linked receptor handbook).
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Figure 1.8  : Structural Model of the Human NK-1 Receptor
F ig u re  1.8: Helical-wheel representation of the structural model of the human NK-1 
receptor. An anti-clockwise orientation of the helical wheels is shown in an outside- 
inwards view of the receptor. The putative binding site for the non-peptide antagonist 
CP96, 345, as determined by mutational analysis, is indicated in white on black 
sysmbols (taken from Elling ef a/, 1995). • '
1a
1.5.
Using the corresponding cDNA as a hybridisation probe, the tissue 
distribution of the three tachykinin receptor mRNAs in rat was 
determ ined (Tsuchida et al, 1990). . The NK-1R (neurokinin-1 
receptor) mRNA was found to be distributed widely in both the 
central nervous system (CNS) and in peripheral tissues. In the CNS, 
it is expressed at high levels in the hypothalamus, the striatum, the 
spinal cord and the olfactory bulb. Of the peripheral tissues, it is 
highly expressed in the submandibular gland, the urinary bladder and 
the small and large intestines. The NK-3 receptor (NK-3R) mRNA is 
also expressed in both the CNS and in peripheral tissues, but is 
expressed at its highest levels in the cerebellum  and the 
hypothalamus. The NK-2 receptor (NK-2R) mRNA however, appears to 
be expressed principally in peripheral tissues such as the stomach,
iijKvvivT fb/v\,U j 
hfissue Distribution
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the urinary bladder and the adrenal glands. The tissue distribution 
of the tachykinin receptor mRNAs is therefore different in CNS and 
peripheral tissues (Tsuchida et al, 1990). Quantitative receptor 
autoradiography using radiolabelled tachykinins was used to localise 
and characterise tachykinin binding sites in rat CNS and peripheral 
tissues (Mantyh et al, 1989). Furthermore, the distribution of the 
mRNA for the precursor tachykinin peptides (neyrokinin-A for 
example, Maggio et al, 1984) does not mirror the mRNA distribution 
of the corresponding tachykinin receptor (neurokinin-A for example, 
Sasai et al, 1989). The NK-1 receptor was also shown to be
expressed in a subset of floor plate cells in the embryonic rat spinal 
cord which suggests a potential role for substance P in spinal cord 
development (Heath et al, 1995). The rat substantia nigra contains 
the highest concentration of neurokinin-1 in the brain but has no or 
few NK-1 receptors. This is an example of the non-correlation
between the density of neurokinin-1 binding and neurokinin-1
innervation (Mantyh et al, 1984, Sivam et al, 1992). Whitty et a l
(1995) quantitated, localised and investigated the regulation of the 
NK-1, NK-2 and NK-3 receptors in the rat substantia nigra. Relative 
levels of receptor were found to be NK-3 >  NK^1 » >  NK-2, The 
evidence presented by Whitty et al(1995) indicates that neurokinin- 
1 released from striatonigral nerve terminals may act on nigral 
cells through NK-1 receptors, whereas NK-A (which is a co­
transmitter of neurokinin-1) may act preferentially on the same 
dopaminergic neurons through NK-2 receptors.
Stoessl et al, (1994) generated 6-hydroxydopamine lesions in the rat 
brain in order to study the localisation of striatal and nigral 
tachykinin receptors. The results indictate that both NK-1 and NK-3 
receptors within the striatum are predominantly post-synaptic with 
respect to dopamine neurons, whereas nigral NK-3 receptors are 
located on dopaminergic neurons in this region of the brain.
Using multiple sequence alignment, a high degree of homology at the 
amino acid level, ranging up to 90%, was found within families of G- 
protein linked receptors such as the tachykinin receptors. However, 
homology between  families was found to be as low as 20% (Attwood 
etal, 1991).
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1.5.4 G-Protein-Coupled Receptors
G-proteins are guanosine nucleotide-binding regulatory proteins 
which are often coupled to membrane receptors. G-proteins/function 
as intermediates in the transmembrane signal transduction pathway. 
They mediate the actions of many extracellular messengers and 
s tim u li ranging from photons and small molecules (ie. 
catecholamines) to large molecules such as glycopeptide hormones 
(Burbach et at, 1992). They are found in many organisms from man 
to viruses. In figure 1.9 there is a list of 16 (courtesy of Burbach, 
1992) different G-protein coupled receptors for neuropeptides or 
small peptide hormones. This signal transduction system comprises 
three components; the receptor, the G-protein and the effector 
molecule. The role of G-proteins in transmembrane signaling, was 
firs t indicated by an absolute guanosine triphosphate (GTP) 
requirement for the hormonal activation of adenyl cyclase (Rodbell 
et a/, 1971). There are many such receptors including those for a 
number of protein, biogenic amines, polypeptide hormones and 
several neurotransmitters. The rhodopsin receptor and the p- 
adrenergic receptors (for agonists such as epinephrine) are the best 
characterised members of the G-protein coupled family of receptors. 
G-proteins are heteromers and comprise an a, p and a y-subunit (in 
order of descending molecular weight). The a-subunits differ from 
one member of this family to another whereas the p - andy-subunits
are common to some of the receptors. The G-proteins function
cyclically: the system is activated when GTP binds to the a-subunit 
of the G-protein. Hydrolysis of that GTP to GDP and Pi either 
in itia tes or is responsible for deactivation of the system.
Dissociation of GDP appears to be rate limiting (Gilman et al, 1987). 
This system cycles each time the receptor is stimulated. All G- 
protein coupled receptors show a high amino acid homology 
particularly between the seven transmembrane segments which span 
the cell membrane as has been shown for the rhodopsin receptor 
(Hargrave et al, 1982). The transmembrane domains are believed to 
be formed by a-helices of hydrophobic amino acids (Kyte et al, 
1982). Cysteine amino acid residues are often palmitoylated and 
provide membrane anchors for the receptors. Serine residues are 
proposed to be targets for phosphorylation by protein kinases.
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Ligand binding is believed to take place in a pocket formed by the 
seven transmembrane domains together with the extracellular loops 
(Tota et al, 1990), A three dimensional model of the G-protein 
coupled receptors was proposed by Findlay and Eliopoulos,(1990).
Many neurotransmitter receptors have been identified, the majority
of which belong to this G-protein coupled receptor superfamily. It
*
has become evident that there are now more than two distinct 
classes within the G-protein coupled peptide receptors. One is 
typified by the NK-2 receptor which is closely related to receptors 
for the biogenic amines and thyroid stimulating hormones. The 
common feature of this class is the strictly conserved amino acid 
sequences and motifs. Another class, the 'secretin-like1 G-protein 
coupled receptors have no significant sequence homologies with the 
neurokinin-like receptors yet have their own common amino acid 
motifs (Burbach et al, 1992).
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Figure 1.9 : Cloned Neuropeptide Receotors and Cloning StrateavJJsed.
Receptor Species Cloning Strategy Reference
Angiotensin A1 Man Homology screening Furuta et al, 1992
Angiotensin A1 Man COS expression Murphy et al, 1991
Angiotensin A1 Rat Homology screening Iwai e ta l, 1991
Bradykinin B2 Rat Oocyte expression McEashern et al, 1991
Calcitonin Pig COS expression Lin et al, 1991
Endothgelin (ETa) Man Protein purification Nakamuta etal, 1991
Endothgelin (ETa) Man Homology screening Sakamoto etal, 1991
Endothgelin (ETa) Man Homology screening Ogawa eta l, 1991
Endothgelin (ETa) Rat COS expression Sakurai et al, 1990
Endothgelin (ETa) Cow Protein purification Saito et al, 1991
Neuromedin B Man Homology screening Corjay et al, 1991
Neuromedin B Rat Homology screening Wada et al, 1991
Neuromedin K Rat Oocyte expression Shigemoto et al, 1990
Neuromedin K Man PCR Buell et al, 1992
Neuromedin K Man Homology screening Takahashi et al, 1992
Neuropeptide Y Bovine PCR Rimland et al, 1991
Neuropeptide Y Fruit fly PCR Li et al, 192
Neurotensin Rat Oocyte expression Tanaka ef a/, 1990
Substance K Man Homology screening Gerard et al, 1990
Substance K Rat Homology screening Sasai et al, 1989
Substance K Cow Oocyte expression Masu ef al, 1987
Substance P (NK-1) Man PCR T a k e d a e fal, 1991
Substance P (NK-1) Man HomolOgy screening Takahashi et al, 1992
Substance P (NK-1) Rat PCR Hershey et al, 1990
Substance P (NK-1) Rat Oocyte expression Yokota et al, 1989
Tachykinin (type 1) Fruit fly Oocyte expression Li et ah 1992
Tachykinin (type 2) Fruit fly PCR Monnier et al, 1992
F igure  1.9: A list of cloned and identified neuropeptide receptors. The author who 
published each receptor and the cloning strategy used to clone each receptor is also 
given (taken from Burbach et al, 1992).
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1.5.5 The Neurokinin-1 (NK-1) Receptor
The NK-1 receptor (NK-1R), which was previously referred to as the 
substance P receptor (SPR), is discussed in depth in (section 1.6).
1.5.6 The NK-2 Receptor: Substance K Receptor * '
The distribution of this receptor is limited to the peripheral tissues 
such as the smooth muscle of the gastrointestinal, respiratory and 
urogenital systems and there is little evidence of its expression in 
the central nervous system.. Neurokinin-2 receptors exhibit an 
affinity for neurokinin-A that is 10 and 1000 times higher than for 
neurokinin-B and neurokinin-1,; respectively (Whitty et al, 1995, see 
Section 1.5.2). The human NK-2 receptor gene has been localised to 
chromosome 10 and encodes a 398 amino acid protein with a 
molecular weight of 44,425 Daltons. This receptor is palmitoylated 
at cysteine residues Cys324 and Cys325, is glycosylated at 
asparagine residues 11 and 1.9 and has a disulphide bond between 
Cys106 and Cys325 residues.
Neurokinin-A (substance K) is the most potent mammalian 
tachykinin ligand to the NK-2 receptor and can induce receptor 
activation at low nanomolar concentrations (Watson et at, 1994). 
More than one sub-type of the rat NK-2 receptor have been 
demonstrated using [ i 25l]H is-neurokin in-A  (Brown et a/, 1992). 
This is probably a consequence of this receptor being activated by 
more than one ligand (see Figure 1.5). Neurokinin-A is found at high 
concentrations in the substantia nigra. When microiontophoresed on 
to single neuronal units of the. rat substantia nigra, NK-2 excites 
approximately 50% of both dopaminergic and non-dopaminergic 
neuron (Innis e ta l, 1985). This degree of response corroborates the 
reported high concentration of NK-2 receptors in the substantia 
nigra.
The identification of genomic DNA clones for the murine substance K 
receptor was reported by Sundelin et al (1992). The coding sequence 
of this gene was found to be more than 13 Kb including the five
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distinct exons. As reported for the mouse neurokinin-1 receptor 
(Sundelin et al, 1992, above) the genomic clone DNA was used to 
isolate corresponding cDNA clones using the polymerase chain 
reaction method. The deduced amino acid sequence was found to be 
94% identical to the rat and 85% identical to the human sequence.
A cDNA clone for the bovine substance K receptor was isolated by 
combining molecular cloning technology and an electro-physiological 
assay in Xenopus oocytes (Masu et al, 1987). The DNA and amino acid 
sequence analysis of this clone demonstrated that the substance K 
receptor is a 384 amino acid polypeptide. It contains seven 
hydrophobic domains which are believed to be membrane-spanning 
domains indicating that the bovine substance K receptor is also a G- 
protein linked receptor (Masu et al, 1987).
A cDNA of the rat substance K receptor has been isolated, also by 
molecular cloning (Sasai et al, 1989). From the 2,979 bp cloned rat 
substance K receptor cDNA sequence, the sequence of a 390 amino 
acid polypeptide was deduced. It was found to comprise seven* 
hydrophobic motifs and was shown to share a significant similarity 
with other G-protein linked receptors (O'Dowd et al, 1989). This 
sim ilarity is particularly strong in the transmembrane segments HI 
and VII. RNA blot hybridisation studies demonstrated that the rat 
substance K receptor is encoded by two mRNA transcripts which 
differ at the 5' end of the 5'-untranslated sequence. Substance K 
receptor transcripts were shown to occur in the gastrointestinal 
tract as is characteristic of the tachykinin (brain-gut) peptides.
X iao -J iang  et al (1991) screened a Drosophila rtielahogaster 
embryonic cDNA library at low stringency using bovine NK-2 
receptor-derived probes. cDNA clones encoding a Drosophila 
receptor for tachykinin-like peptides were identified. The cDNAs 
were expressed in X enopus  oocytes and analysed using Northern, 
polymerase chain reaction and in situ hybridisation techniques. Peak 
expression of this receptor gene was noted at the later stages of 
embryogenesis and coincided with periods of significant neuronal 
development in Drosophila fruitflies.
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1.5.7 The NK-3 Receptor
The neuropeptide NK-3 acts preferentially oh the NK-3 receptor (NK-
3R). NK-3 receptors have been identified ln guinea pig cerebral
cortex and in brain slices of rat and mouse (Guard et al, 1990, Dietl
et al, 1991, Bergstrom et al, 1987). The human NK-3 receptor was
cloned, characterised at the molecular level and its distribution
%
determined by Buell e fa /(1 99 2 ). This research group chose to do 
this by screening a human genomic bacteriophage library in order to 
isolate and subclone the exons encoding the translated portion of the 
NK-3 transcript. The cloned sequence allowed the design of human 
NK-3 specific PCR primers and subsequently the amplification of 
NK-3 cDNA. Further study demonstrated that this receptor is 
expressed in many areas of the human brain and selectively in some 
peripheral tissues. The human NK-3 receptor encodes a 465 amino 
acid protein with a molecular weight of 52,201 Daltons. This 
receptor is palmitoylated at cysteine residue 374, is glycosylated at 
asparagine residues 23, 50 and 73, and a disulphide bond exists 
between residues Cys158 and Cys233. Neurokinin-3 receptors are 
the least characterised of the lachykinin receptors.
cDNA clones for th e . rat neuromedin K (neurokin-B) receptor were 
isolated from a brain cDNA library by Shigemoto et al (1990). mRNA 
transcribed from this cDNA was injected into Xenopus laevis oocytes 
w herevpon the. expressed recepto r was studied e lectro - 
physiologically. The rank order of ligand affinity for the receptor 
was neuromedin K (NKB) >  substance K (NKA) >  neurokinin-1 (NK1). 
This rat receptor was found to be a 452 amino acid peptide which is 
another G-protein-coupled receptor (Shigemoto et al, 1990).
1.6 THE NEUROKININ-1 YNK-1R) RECEPTOR
Recent technological progress in the fields of molecular biology and 
molecular pharamacology indicates that there are multiple receptors 
and receptor subtypes for neurotransmitters and neuropeptides. To 
recapitulate, three tachykinin receptors have been identified,
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namely the neurokinin-1 (NK-1), NK-2 and NK-3 receptors, and are 
described above. The three receptor gene cDNAs were cloned from 
mammalian tissue in 1987 (Masu et al, 1987, Nakanishi et al, 1987). 
These receptors are pharmacologically distinct (Watson et al, 1987), 
but when they are added at a high enough concentration, each of the 
endogenous mammalian tachykinin neuropeptides can elicit a 
response from each of the three receptors. This is most likely to be 
a consequence of the common carboxy terminal amino acid sequence 
which is characteristic of the tachykinin peptides. The mammalian 
NK-1 receptor has been localised to both peripheral and brain 
tissues. Of the mammalian tachykinins which are potential ligands 
for this receptor, neurokinin-1 has the highest affinity with a Kd = 
0.5-1.0. The rat NK-1 receptor cDNA has been cloned (Yokota et al, 
1989). In the same year, Nakaniski and his research team in Kyoto, 
Japan, cloned the full rat neurokinin-1 (NK-1R) receptor gene. They 
found that the rat neurokinin-1, substance K and neuromedin K 
receptors displayed a high degree of homology in their amino acid 
sequences (Masu et al, 1989). Overall percentage identity was found 
to be between 47 and 58%. From the cDNA, the amino acid sequence 
was determined to total 407. Seven putative transmembrane 
domains have been identified and a high sequence similarity to other 
G protein-coupled receptors was shown to exist (Yokota et al, 1989).
Binding of the ligand to the NK-1 receptor activates it and 
consequently results in the hydrolysis of inositol phospholipid as 
demonstrated in several tissues such as the rat brain (Mantyh et al,
1984). The activation of the NK-1 receptor is typical of the G- 
protein coupled receptors (detailed in section 1.5.4. Appell et al 
(1992) used three classes of NK-1 receptor antagonist to 
demonstrate the species-specific difference in the human, guinea- 
pig, and rat receptors; heterosteroids, cyanines and modified
peptides. Key amino acid changes or altered lipid environments are
the most likely explanation for the differences noted. Regulation of
NK-1 receptor synthesis most likely occurs at the transcriptional
level. Expression of the the PPT-A and NK-1R genes occur at the 
same developmental stage (see in situ results, chapter 6) but not at 
the same location.
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1,6.1 Distribution of the NK-1 Receptor
The NK-1 receptor is expressed by neurons and glial cells in the 
mammalian CNS and in smooth muscle cells, endothelial cells, 
fibroblasts, and many circulating immune and inflammatory cells. In 
the spinal cord, the number of NK-1 binding sites is highest in dorsal 
horn laminae I and II, the intermediolateral cell column and in 
lamina X (Charlton et al, 1985). Ventral horn regions demonstrate 
moderate levels of NK-1R. In the dorsal horn, NK-1-binding sites are 
located postsynaptic to sensory nerve terminals. However, in the 
intermediolateral cell column, the NK-1-binding sites are located on 
the autonomic and somatic motor neurons (Helke et al, 1986). There 
is a low density of NK-1 binding sites in the substantia nigra (SN) in 
contrast to the high relative density in the caudate-putamen (Buck 
et al, 1986). The low density in the SN contrasts with the number of 
neurokinin-1 -immunoreactive terminals in this region. However, 
NK-1 receptor density varies under certain conditions. For example, 
the normal rabbit optic nerve lacks NK-1 receptors. However, 99 
days after transection, this nerve contains the highest density of 
NK-1 receptors found in the whole rabbit forebrain. As the optic 
nerve is in effect a glial scar at this stage, glial cells in vivo appear 
to pre ferentia lly  and transiently express high levels of NK-1 
receptor (Mantyh et al,. 1989). In rat, relatively high levels of NK- 
1R mRNA were found in the urinary bladder and the sublingual 
salivary gland, moderate levels in the submandibular salivary gland, 
hippocampus, midbrain, and olfactory ‘bulb, and lower levels in the 
remainder of the CNS and the alimentary canal (Hershey et al, 1991),
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Figure 1.10: Distribution of Rat mRNA Encoding the NK-1 Receptor,
RNA source pa mRNA/25ua total RNA
(mean +/-1 standard error) 
___________  Central Nervous System_____________
Whole brain 130 +/- 10
Olfactory bulb 230 +/- 10
Cortex 135 +/- 10
S tria tu m 265+/- 10
Hypothalamus 190 +/- 10
Hippocampus 260 +/- 10
Midbrain 240 +/- 10
Cerebellum 20 +/- 10
Medulla-pons 210 +/- 10
Spinal cord 120 +/- 10
Retina 115 +/- 10
Other Tissues
Sublingual gland 355+/- 10
Submandibular gland 270 +/- 10
Parotid gland . 50 +/- 10.
Stomach 25 +/- 5
Duodenum 75 +/-. 5
Jejunum 110 +/- 5
Ileum 165 +/- 5
Colon 80 +/- 5
Liver Not detectable
Spleen Not detectable
Urinary bladder 400 +/-20
T estis Not detectable
Lacrimal gland 20 +1-5
Trigeminal ganglion Not detectable
Thyroid Not detectable
Anterior pitu itary. Not detectable
Muscle Not detectable
F ig u re  1.10: Tissue distribution of mRNA encoding the rat NK-1 receptor. 
Quantification made use of a mRNA standard (taken from Hershey etal, 1991).
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Endoglycosidase F was used to biochemically determine and
characterise that there are two forms of NK-1R in the rat
submaxillary gland which differ in the length of their respective
carboxy termini (Kage e ta l, 1992). Fong et al (1992) have reported
the existence of a shorter form of the human NK-1R which is
generated by alternative splicing and has a truncated carboxy
term inal which lacks seven amino acids. Neurokipin-1 has an
*
a ffin ity  for this form of the receptor which is reduced 
approximately 10-fold.
1.6.2 Organisation of the NK-1R Gene
1.6.2.1 The Human NK-1 R Gene
The molecular cloning of the human neurokinin-1 receptor (NK-1R) 
gene was published in 1992 (Takahashi et al, 1992). The gene 
comprises 5 exons spanning more than 60 kb and is a 407 amino acid 
G-protein coupled receptor. Clones were isolated from a human 
genomic bacteriophage library using sequences derived from the rat 
SPR cDNA (plasmid prTKR2, Shigemoto et al, 1990).. Segments of the 
same plasmid were used as a hybridisation probe used to identify 
the mouse genomic NK-1R clones described in this thesis. The 
human genomic DNA clones which were identified did not overlap 
with one another indicating that the gene spans, more than 60 kb. 
Exons 1 to 5 of the human NKrIR gene are 977, .196, 151, 197 and 
approximately 3300 bp respectively. The exons are interspersed by 
introns of >22 kb, >26 kb, >7 kb and approximately 2.2 kb.. RNA blot 
hybridisation analysis was used to examine the 51 sequence of this 
gene and a TATA box was found to be located 24:27 bp upstream of 
the putative transcription initiation site. The TATA box is involved 
in the polymerase nucleotide selection which initiates transcription 
at a specific site. Furthermore, several promoter, enhancer and 
regulatory DNA elements were also identified in the 5'-flanking 
region including a cyclic AMP responsive element (TGATGTCT) and an 
AP-1 sequence.
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The human NK-1 R gene is located on chromosome 2. This 407 amino 
acid receptor has a molecular weight of 46,248 Daltons. Post- 
translational modifications of this receptor include glycosylation 
sites on two amino acids; Asn14 and Asn18. Furthermore, a 
disulphide bond is believed to form between the cysteine residues at 
positions 105 and 180 and palmitoylation of the receptor occurs at 
cysteine residues 322 and 333 thus providing membrane-inserted 
anchoring side-chains for this receptor (Takeda et al, 1991). The 
gene organisation and primary structure of the human NK-1 receptor 
(and the neuromedin K receptor) has been presented by Takahashi et 
a l (1991). They demonstrate that it is a G-protein coupled receptor 
encoded from 5 exons extending over 60 kb. RNA blot hybridisation 
and primer-extension analyses were used in Takahashi's study of the 
human NK-1 receptor gene.
1.6.2.2 The Rat NK-1R Gene
Firstly, the cDNA for the rat NK-1R gene was cloned by Hershey et a i
(1990). Genomic clones for the rat NK-1R gene were then cloned and 
the expression pattern of the gene analysed, again by Hershey et a l
(1991). Again the gene was shown to be G-protein coupled and to 
comprise 5 exons extending over 45 kb> Exon 1 was found to encode 
the entire 5' untranslated region and the coding region through to the 
end of the third transmembrane domain. Exon 2 contains the second 
intracellu lar region, the fourth transmembrane domain and the 
second in trace llu la r region. Exon 3 encodes the fifth  
transmembrane domain and the third intracellular region. Exon 4 
contains the sixth transmembrane domain, the third intracellular 
region and the seventh transmembrane domain. Exon 5 encodes the 
cytoplasmic carboxyl region and the entire 3' untranslated region. 
The exons are 965, 195, 151, 197 and 2010 bp in length respectively. 
The transcription initiation site was also determined using solution 
hybridisation-nuclease protection experiments.
t  .6.2.3 The Murine NK-1 R Gene
Mouse genomic DNA clones of the NK-1R gene were isolated from a 
murine cosmid library in 1992 (Sundelin et al, 1992) using
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heterologous probes composed of short sequences derived from the 
rat NK-1 R gene cDNA (Hershey, 1990). The gene was found to be 
more than 30 kb in length. The same research group then isolated 
the. corresponding cDNA for the mouse neurokinin-1 receptor gene 
using polymerase chain reaction methodology. The isolated cDNAs 
were transcribed in vitro and microinjected and expressed in 
X enopus  oocytes. Ligand binding studies of the newly expressed 
receptor confirmed its pharmacological identity. The amino acid 
sequence of the mouse neurokinin-1 receptor gene was determined 
to be 99% identical to the rat sequence.
1.6.3 S tructure  and Proposed B inding Sites o f the NK-
1 Receptor
Masu et ai (1987) was the first to report the primary structure of a 
tachykinin receptor. This receptor was the neurokinin-1 receptor 
(Masu et aU 1987). The precise site where the ligand binds to the G- 
protein component of the NK-1 receptor has not yet been identified 
conclusively; however there has been considerable mutational 
analysis of the NK-1 receptor (Fong et at, 1993, Gether et al, 1994) 
and NK-2 (Gether e ta l,  1993) receptors from which binding sites 
have been proposed. It has been indicated that the non-peptide 
antagonists act through residues located between the 7 
transmembrane domains, whereas natural peptide agonists: bind 
mainly to residues scattered in the exterior part of the receptor 
(Fong e ta l,  1992, Rosenkilde et al, 1994). Mutational analysis 
published by Elling et al (1995) demonstrated the conversion of a 
NK-1 receptor binding site for the antagonist CP36,345 to a metal­
ion binding site by the systematic introduction of histidyl residues 
(see figure 1.8).
1.7 APPROACHES TO STUDYING NEUROPEPTIDE FUNCTION
The brain of an individual will differ from the brain of another in the 
same way as their faces will vary, yet there are structures of the
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[brain that are common to all individuals. Indeed, those structures 
appear to be common to all mammals. The anatomist Lorente de No, 
after examining a mouse brain with a microscope, commented that 
iits fine structure was little different from that of the human brain, 
except in proportion. Since many features of the brain are common 
and many animal and human behaviours are similar, it is possible to 
ilearn about the human brain by studying the brains ot 'Other animals 
and vice versa.
There are several approaches to studying brain function. The 
com p ara tive  approach is used to obtain clues to brain function by 
correlating structure and behaviour. The key finding is derived from 
this approach which allows mammals to be distinguished from other 
animals by the thickness of the outer layer of brain tissue; the 
neocortex. This structure is particularly large in humans. The 
developmental, or ontogenetic  approach describes the changes in 
brain structure during the development of an individual. In this way, 
newly developing s tru c tu re s . can be correlated to emerging 
behaviours and the younger brain can be used as a model of the adult . 
brain. The cy to a rch itecton ic  approach is based on describing the 
architecture of cells; their size, shape, structure, distribution and 
connections. This utilises the property whereby certain dyes have 
an affinity to specific parts of the nerve cell. The advent of the 
electron microscope accelerated research of this nature. Another 
approach is the traditional pharm acolog ica l approach which utilises, 
the binding specificities of receptors for ligands. In this way an 
insight can be gained into the role and function of the receptors by 
the use of agonists and antagonists to that receptor (This approach 
is discussed in Section 1.7.3). The most recent approach to the 
study of brain function is the m olecular and biochem ical approach 
where an understanding of the biochemical organisation of the brain 
is pursued. It is clear that certain clusters o f nerve cells 
synthesise, contain and can sectrete biochemical substances that 
are central to intercellular communication. The normal activity o f 
those cells can be related to behaviour and conversely, the 
abnormalities in the functioning of cells at particular loci can be 
related to abnormal behaviour. Modern molecular biology has 
provided the latest set of tools that allow the neuroscientist to
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adopt this biochemical approach. Molecular gene cloning, 
manipulation of nucleic acids and the means to introduce specific, 
targeted genetic mutations have fuelled the ongoing surge in 
molecular and biochemical neurobiological research.
1.7.1 Strategies for Cloning Neuropeptide Precursor
and Receptor Genes
There are two general approaches to cloning neuropeptide receptors. 
The first is ligand based, where the starting point is a ligand from 
which the DNAs can be identified. The second approach is DNA based 
where the DNA is the starting point. The ligand-based approach 
includes the classical receptor purification method where a bound 
ligand identifies a receptor which is purified and its amino acid 
sequence determined. From this, oligodeoxynucleotides can then be 
designed as hybridisation probes for screening genomic or cDNA 
libraries in order to isolate clones. The human endothelin ETb 
receptor has been cloned in this way (Nakamuta et al, 1991). 
Another ligand-based approach includes the functional expression of 
cDNAs, where mRNA transcribed in vitro from a cDNA library are 
expressed in Xenopus oocytes. Detection of an expressed receptor is 
based on the electrophysiological response of the oocyte to the 
peptide ligand as measured by voltage clamp. The bovine neurokinin- 
A receptor was cloned in this way (Masu et al, 1987) and this 
approach was used in an early study of tachykinin receptors NK-1 
and NK-2 (Harada et al, 1987). Another ligand-based method 
involves the use of mammaliah COS cells rather than Zenopus 
oocytes. Receptors are functionally expressed in COS-1 or COS-7 
cells after transfection of cDNA libraries. COS cells provide high 
levels of expression (Gluzman et al, 1981). This allows 
identification of a particular cDNA in an expressed library.
The DNA-based approaches to cloning neuropeptide precursor and 
receptor genes includes the use of a cDNA derived from one species 
to identify clones from a library derived from a different species. 
This approach was used in the research detailed in this thesis to 
clone the mouse NK-1 presursor and receptor genes. A segment of 
the rat NK-1 receptor cDNA was used as a heterologous hybridisation
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probe to screen mouse genomic DNA libraries in order to identify 
DNA clones. This approach was used successfully and is detailed in 
depth in this text. This approach can also facilitate the 
identification of new, as opposed to known, receptors based on 
nucleotide homology. Another DNA-based, molecular approach uses 
degenerate oligodeoxynucleotide PCR (DOP-PCR) methodology, where 
degenerate primers to highly conserved regions .such as the 
membrane spanning domains of G-proteins have been used to amplify 
related sequences from cDNAs (Frohman et al, 1988). Similarly, 
oligodeoxynucleotides derived in this way from conserved regions 
can be radioactively labeled and used as probes to screen genomic 
DNA or cDNA libraries.
1.7.2 Neuroantibodies and Immunocytochemistry
An alternative and complementary approach to the study of 
functional and developmental processes in the mouse central 
nervous system, which involves neuroantibodies, has been presented 
by Picciolo et al (1991). This is based on the local expression of 
specific monoclonal antibodies by cells of the central nervous 
system. This paper describes research which uses the anti­
neurokinin-1 rat monoclonal antibody NC1/34HL. It was expressed 
in specific neuronal cell subpopulations. This antibody specifically 
recognises and binds the carboxy term inal of neurokin in-11 
preventing it from binding to its receptor. This direct interference 
with the neuro-cellular communication pathway (by sequestering the 
neurokinin-1 ligand) is analogous to the gene targeted deletion of 
neurokinin-1 expression. In both cases, the normal action of the 
neuropreptide is likely to be altered. Results obtained in this way 
will complement, along with the classical pharmacological results, 
the molecular gene targeting approach to the study of the functional 
role of neurokinin-1. This approach is likely to be applied to other 
tachykinin neuropeptides in the future.
Antibodies have also been used to localise neuropeptide receptors in 
cell lines and tissues. The NK-1 receptor has been studied in two 
ways, each based on this antibody technique (Vigna et at, 1994)..
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Firstly, antisera were raised against the 15 amino acids that 
comprise the intracellular ca rboxyr terminus of the NK-1 receptor. 
The second approach involved the generation of antibodies raised 
against a chimeric NK-1 receptor. The chimeric receptor construct 
was genetically engineered (by polymerase chain reaction) to tag a 
hydrophilic 'flag' peptide (DYKDDDDK) onto the extracellular amino 
terminus of the NK-1 receptor which was expressed'in rat kidney 
epithelial cells (Vigna etal, 1994).
1.7.3 The Pharmacological Approach
The traditional pharmacological approach to studying active ligands 
and their corresponding receptors involved the use of agonists and 
antagonists as tools. Pharmacological research in the field of 
neurobiology is extensive, as testified by the annual literature on 
the subject. It also serves to complement and corroborate the 
results determined using the molecular approach (or vice versa). The 
molecular approach is detailed elsewhere in this text. The 
pharmacological approach generates results which implicate certain 
peptides with certain biological processes.
1.7.3.1 Agonists and Antagonists
These molecules can be biochemical^ molecules or proteinaceous 
ligands such as the neuropeptides. Radidlabelled ligands 
(’radio ligands1) were used in itia lly  in the study of tachykinin 
receptor binding, the first report being that of Nakata ef a /(1 97 8 ) 
using tritiated neurokinin-1 (3H-NK-1). The potencies of various 
agonists have been determined, in both pharmacological studies and 
in radioligand binding assays. The archetypal NK-1 assay is to 
determine the degree of contraction induced in the longitudinal 
muscle of the guinea-pig ileum in the presence of atropine. Both 
natural and synthetic tachykinin agonists and antagonists have'been 
used in this type of research. Selective peptide antagonists for the 
NK-1 and NK-2 receptors have been developed. For example, to 
elucidate the role of tachykinin receptor subtypes in sensory 
nervous system processing, selective agonists to the NK-1 and NK-3 ‘
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receptors were administered intrathecally. The time taken for 
conscious rats to respond to noxious radiant heat stimuli was 
measured. As the applied dose of the agonist, namely 
[Pro9,Met(C>2) 11]NK-1 in this case, increased, the reaction time 
decreased proportionally (Laneuville et al, 1988). Further 
nociceptive responses including compulsive biting, scratching and
licking of the hindlimbs were also induced by a NK-1 selective
*
agonist (Papir-Kricheli et al, 1987). These experiments mimic the 
nociceptive effects of tachykinins when released from primary 
sensory nerve terminals of the dorsal horn and demonstrate the 
pharmacological approach and the study of pharmacologically- 
induced behavioural changes. A hexapeptide agonist named septide 
[pGlu6, Pro9]substance P(SP)6-n has been shown to be as potent as 
neurokinin-1 in eliciting smooth muscle contraction in several in  
vitro preparations (Pradier et al, 1994).
Pharmaceutical companies such as GlaxoWellcome have developed 
and published details of novel tachykinin antagonists (McKnight e t  
a l, 1991, Ward, 1990). Studies using one antagonist indicate the 
existence of NK-2a and NK-2b receptor subtypes (Maggi et al, 1992). 
More recently, potent and highly selective non-peptide antagonists 
have been • identified for the NK-1 receptor (Garrett ef a/, 1991; : 
Cascieri et al, 1992). Research has suggested, with the benefit of 
the non-peptide antagonists, that pharmacologically the NK-1 and 
NK-2 receptors may be capable of further sub-classification in the 
future. Neurokinin-1 antagonists include baclofen which is known 
to effectively antagonise the depolarising action of neurokinin-1 on 
spinal motqneurons (Saito et al, 1975). Baclofen is known to block 
the excitatory activity of neurokinin-1 but is not a specific 
neurokinin-1 antagonist.
There has been a surge in pharmacological study of the 
neuropeptides, and in particular the tachykinin receptors in the 
1990s. This interest stems from the development of an array of 
se le c tive , h igh a ffin ity , non -pep tide  an tagon is ts  which 
pharmacolgists can use. The activity and distribution of the binding 
sites in the central nervous system for a non-peptide neurokinin-1 
antagonist (CP-66,345) has been documented by McLean et al (1991). 
The cDNAs for the NK-1, NK-2 and NK-3 receptors have been cloned
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and functionally characterised. Subsequently, chimeric and point- 
mutated receptors have been used to further elucidate the receptor 
structure-function relationship with regard to binding domains for 
peptide agonists and non-peptide antagonists, and agonist- 
stimulated second messenger responses (Nakanishi etal, 1993).
Antagonists are of greater importance, pharmacologically speaking, 
than agonists principally because antagonists bind to the recognition 
site of the receptor but lack intrinsic biological activity, whereas 
agonists bind and activate receptors. Antagonists can be used to 
distinguish between receptors. The peptidergic TK antagonists were 
developed by modification of the amino acid sequence.
1.7.3.2 Peptide and Non-Peptide Analogues
Another approach to peptide ligand research uses peptide analogues. 
The principle of peptide analogues is to modify a peptide in order to 
reduce the agonistic activity and to subsequently generate an 
effective inhibitor molecule. The rationale for the design of a 
series o f . cyclic peptide analogues to the tachykinin receptors is 
described by McKnight e fa /(1991). Several NK-1 analogues have 
been synthesized. Modification of the pharmacologically critical 
carboxy terminal amino acid sequence of the NK-1 peptide can 
generate a peptide with weak, or even no agonistic effect. For 
example, [D -A rg i, D-Pro2, D-Trp7»9, Leu11]NK-1 which is a 
particularly potent antagonists (Russell et al, 1983). The various 
neurokinin-1 antagonists have been pharmacologically tested on 
several tissues (see Pernow review, 1983).
1.7.4 The Molecular Approach to the Study of Neuropeptide
Function
Genetics has traditionally been seen as the most effective way to 
study the molecular intricacies of complex biological systems. The 
basic tenet that genotype correlates directly to phenotype has been 
examined from both the phenotypic and genotypic perspectives using 
standard genetics and more recently, reverse genetics, respectively.
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1.7.4 .1  Reverse G enetics
The traditional approach to genetical analysis has been phenotype 
focussed, from where the corresponding genotype is pursued. This 
standard genetic analysis approach starts by observing discrete 
variations in well-defined aspects of phenotype before classifying 
mutations into functional units (genes) using complementation 
tests. Genes are then located on a genetic map using 
recombinational mapping. The genetic map can be related to the 
physical location of the gene in the DNA molecule using the 
distribution function of local recombination rates. Therefore, when 
the gene in question is identified, a direct link between alterations 
in the gene and its product and an effect on the biology of the 
organism can be determined. Organisms such as C aenorhabd itis  
elegans  and Drosophila m elanogaster which have relatively small 
genomes and in a practical sense are easy to use, have been the 
favoured models for doing this. The rate-limiting component of this 
approach is the physical isolation of the DNA corresponding to a 
genetic locus.
In contrast, an a lternative approach which guarantees the 
establishment of a correlation between altered genotype and altered 
phenotype is known as 'reverse genetics' (see figure 1.11). This 
approach starts with a cloned DNA sequence which is used to 
generate animals (such as mice) with mutated forms of a particular 
gene.
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Figure 1.11 : Reverse Genetics and Standard Genetics
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F ig u re  1.11: Reverse mouse genetics and its relationship to standard mouse
genetics. Two different approaches- to determining' the phenotype/genotype 
relationship (taken from Davies etal, 1994).
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1.7.4.2 Gene Targeting
The number of genes cloned in the last decade has increased rapidly, 
yet the function of many of those genes remains unknown. The 
recent development of gene targeting technology has provided the 
means to scrutinise genes and to study gene function in the living 
animal (review: Hooper etal, 1993).
Reverse genetics utilises gene targeting techniques in order to 
generate specific changes in genotype such as a loss-of-function 
mutations (which are referred to as gene 'knock-outs'). In essence, a 
gene targeting experiment involves the transfection of cells 
(embryonic stem cells in this insbance) in tissue culture with a 
linearised, cloned sequence of isogenic genomic DNA which has been 
specifically modified (such as by the insertion of a marker gene into 
the exonic sequence of the cloned gene). The generation of mutant 
mice lacking the PPT-A or NK-1R gene is the objective. Gene 
targeting is used to 'knock out' one allele of the gene in ES cells. In 
the event of successfully generating targeted ES cell lines, those 
lines would be used to create chimaeric mice which, if germ line 
transmissible, would produce homozygous mutant mice for the PPT- 
A or NK-1R genes. Homologous recombination is required for the 
successful introduction of the modified sequence into the recipient, 
target genom ic loci. This experimental approach was used 
successfully for the first time in mouse cells in 1985 (Lin et al,
1985) and in human cells in the same year (Smithies et al, 1985). 
This technique has been applied to embryonic stem (ES) cells 
resulting in the production of mutant mouse cell lines in tissue 
culture. ES cells are derived from the inner cell mass of 3.5 day 
post-coitum mouse embryos (at the blastocyst stage) and can be 
cultured in vitro while retaining totipotency. Targeted ES cell lines 
are injected into C57BI/6 blastocysts for example and are re­
introduced into the uterus of a pseudo-pregnant m ouse ' foster- 
mother, where they develop, forming a proportion of the tissues o f 
the resulting chimaeric mouse. Any induced mutation should 
therefore enter the germ-line of the chimaera and the germ-line of 
any offspring transgenic mice o f that chimaera. Therefore* a
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strategy tor the introduction of mutations in any mouse gene which 
has been cloned, does exist.
The frequency o f the homologous recombination events between the 
target genomic DNA locus and the targeting fragment ('targeting 
vector1) will vary from gene to gene. There is also a degree of 
background and non-specific recombination. The use o f isogenic DNA 
helps to reduce this, as does the length of the targeting fragment 
used; a length of 6 kb in total with at least 1 Kb either side of the 
modified sequence, is recommended for a typical replacement vector 
(Davies et al, 1994). Screening recombinants for successful 
integration is performed using polymerase chain reaction (PCR) or 
Southern blotting. Several non-homologous integration events can 
occur including end extension repaired fragments (Aratani et al, 
1992). For this scenario, the incoming fragment is extended by 
copying chromosomal sequences which are not included in the 
targeting vector. To circumvent the PCR analysis anomalies which 
can also arise at the screening stage as a result of this, Southern 
blotting is the definitive screen for targeted recombinants. In a 
targeting experim ent, typ ified  by Mansour et al (1988), a . 
replacement vector and a positive-negative selection protocol 
resulted in a homologous to heterologous recombination event ratio 
of between 1:10 and 1:100 for most genes (as determined by G418 
resistance).
There are two established gene targeting vector strategies; the ' 
replacement vector and the insertion vectors strategies (Thomas e t  
al, 1987). The insertional strategy encompasses the integrative and 
the promoter-trap vectors (Davies et al, 1994) (see Figure 1.12). 
The replacement vector strategy is the most widely used approach 
and is the one which has been adopted in this study to target the 
cloned murine PPT-A and NK-1R genes described in this text. A 
replacement vector consists of a sequence o f DNA homology 
interrupted within its exonic sequence by a selectable marker, such 
as a neomycin cassette which would typically comprise a promoter 
and polyadenylation sequences thus creating a functional neomycin 
phosphotransferase gene 'cassette'. In addition to being mutagenic 
in its own right, this cassette confers positive selection for the
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genomic integration of the vector into ES cell chromosomal DNA 
(using G418 selection). For this, typically a minimum of 6 kb of 
genomic DNA is interrupted by the introduction of the selectable! 
marker gene and the vector is linearized outside the region of 
homology. In order to minimise the high number of background
recombinations which can arise from replacement recombination
strategies, a counter-selectable marker gene is included and is 
typically positioned outside the region of homology. In most cases, 
the thymidinine kinase (TK) gene from the herpes simplex I virus 
(HSV1) is used for this purpose. This particular counter-selection 
marker is included in the mouse PPT-A and NK-1R gene targeting 
vectors detailed in this text. The replacement vector strategy is 
believed to work by homologously integrating the vector DNA by way 
of two reciprocal crossover events occuring between the two arms 
of homologous . genomic sequence in the vector and the equivalent 
sequences in the endogenous gene. The exact mechanism has not 
been defined, but Ellis et al, (1989) proposed another possible 
mechanism where a single strand exchange within one of the regions 
of homology would occur. This would be followed by branch 
•migration and resolution, within the second arm of homology to 
complete integration up to the point where homology ends; this is 
typically where the TK counter-selection gene is located. Therefore, 
successful integration by this mechanism w ill result in the
exclusion of the TK gene in the ES cell chromosomal DNA. However,
in the case of random, non-homologous recombination events, the TK 
gene will be integrated and will thus permit the researcher to 
distinguish between precise and random recombination events. This 
selection is posssible using a toxic nucleotide analogue such as 
gancyclovir or FIAU (1-[2-deoxy-2-fluro-p-D -arabinofuranosyl]-5- 
iodouracil). These biochemicals act as substrates for the thymidine 
kinase gene in the vector but not in the cellular DNA. The system 
whereby selection fo r  integration and a g a in s t non-homologous 
integration is possible simultaneously is known as the positive- 
negative selection strategy (PNS) and the enrichment for targeted 
clones was reported to be up to 2000-fold for this technique 
(Mansour et al, 1988), although this figure is realistically nearer 20. 
In the case of the integrational vector strategy, various forms of 
engineered neomycin cassette can be used such as enhancer-less
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cassettes, (Jasin et al, 1988), a neomycin cassette lacking a poly- 
adenylation signal, (Donehowe et al, 1992), or a promoter-less 
neomycin cassette (Jeannotte et al, 1991). This type of vector 
requires the chromosomal integration site to provide the sequences 
necessary in order to generate a functional neomycin gene/cassette. 
Stated another way, as a measure of successful recombination, the 
expression of the selectable marker (and/or a visible 'm arker gene) 
is dependent upon integration into a transcribed gene (Skarnes et al, 
1992). In effect, the marker gene is fused upstream of a splice 
acceptor site so that mRNA splicing leads to the production of a 
fusion protein. Therefore, in embryonic stem cells, gene-trap 
vectors of this kind generate mutations which can be examined in 
resultant transgenic mouse lines. For a promoter-less construct, 
approximately 1% of random integrants provide promoter sequences 
for neomycin activation. Therefore, this approach results in an 
enrichment for homologous integrations of approximately 100-fold.
The insertional vector strategy involves the placement of a 
selectable marker gene outside the region of genomic DNA homology 
in & given vector and for that vector to be linearized within the 
region of homology prior to ES cell transfection (Hasty et al, 1991). 
This generates a recombinational hotspot which results in an 
integration frequency 5-12 fold higher than that of the replacement 
vector strategy and results in the complete insertion of the vector 
into the target locus, thus creating a duplication of the region of 
homology at the integration site. This is resolved during later cell 
multiplication. An in-frame fusion is typically made of the neo 
coding region to the exon of the gene to be targeted. This form of 
mutational disruption of a gene will typically generate a null allele. 
As a resu lt of this strategy, few random, non-homologous 
recombinations occur (also see Section 7. 4). Insertional vectors 
can be used to introduce specific subtle mutations into the target 
gene as demonstrated by the ‘Hit and Run' and 'In-Out' vectors (Hasty 
et al, 1991, and Valancius et al, 1991, respectively). Insertional 
vectors use a two step recombinational approach to do this. The 
first step involves selecting those cells which have integrated the 
vector as determined by neomycin gene expression. The second step 
involves applying negative selection against the thymidine kinase
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selectable marker. This can result in excision of the vector along
with one copy of the duplicated sequence so that the desired
mutation is retained within the genetic locus (This involves
intrachromosomal recombination), f  prGmoierless c a r\ a ls o
be used WuBa ?)
In contrast to the relatively crude loss-of-function mutations, gene
targeting can also be used to introduce subtle, specify mutations as 
detailed above. This allows the study of the in vivo structure­
function relationships of a particular protein or in vivo analysis of 
functional elements of promoters. Specific, single base alterations 
can be used to study the importance of particular sequences within a 
gene. The vectors described in this text are designed to generate 
whole gene knock-outs, while providing the foundation for the design 
of subtle mutations in the future.
There are several ways of introducing altered DNA sequences into 
the germ-line of a cell line in addition to plasmid or cosmid 
targeting vectors. Yeast artificial chromosome (YAC) clones, for
example, have been used successfully to produce transgenic mice, 
both by DNA injection into fertilised eggs (Schedl et al, 1993) and 
transformation of ES cells (Strauss e ta l, 1993).
\-ndm fr^ort/ mserbooai vectors do ncH- have a K i^he /
ejV''c>erOj thaAreptace^AeAt- vet-to/5 A^e. 
eb a \  /  m Z )  .
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Figure 1.12 : G en e Targeting using Mouse Embryonic Stem Ceils
R everse  G e n e t ic s  o f  t h e  M o use  C N S
GENOMIC CLONE ISOGENIC TO ES CELL DNA
r
REPLACEMENT INTEGRATIVE
r m r m l
PROMOTER-TRAP
*
TRANSFORM ES CELLS (SELECT RESISTANT CELLS 
AND COUNTERSELECT)
TARGETED ES CELL LINES
I
MtCROINJECTlON OR AGGREGATION 
1
CHIMAERIC MICE 
GERMUNE TRANSMISSION
TRANSGENIC MICE (HETEROZYGOTES) 
1
MUTANT HOMOZYGOTES
I
PHENOTYPE
Figure  1.12: Gene targeting approaches using the mouse embryonic stem cell 
system. The principles and procedures of the replacement, integrative and promoter- 
trap approaches are detailed. NEO; neomycin phosphotransferase gene conferring 
G418 resistance, TK; herpes simplex virus thymidine kinase gene conferring 
sensitivity to gancyclovir or FIAU. Exons are shaded, introns are not shaded. The 
asterisk indicates that in promoter-traps the neo gene is fused in-frame with an exon 
of the gene to be targeted and lacks a promoter and translation start signal, whereas 
in replacement fragments it is out of frame and has normal regulatory and translation 
elements (Davies et al, 1994, Hooper et al, 1993).
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1.7.4.3 Gene Targeting and Clinical Neuroscience
In the field of mammalian and human neuroscience, the predominant
analytical approach remains the pharmacological one (as detailed
above). The potential of either standard or reverse genetical
analysis as a means of examining neural gene function has been on
the whole neglected but has gained increased attention, over the last
%
few years.
When using standard genetics to study the central nervous system, 
one problematic area is the identification of a mutation at the 
phenotypic level. Several behavioural tests exist such as the 
elevated T-maze which is used to indicate the degree of anxiety. 
Subsequently, many of the observed mutations of the mouse are 
behavioural (Sidman et al, 1979). When successful, the molecular 
approach, however, will always generate a phenotypic marker. This 
can be reinforced in some instances by the occurence of some kind of 
behavioural manifestation. The molecular approach can therefore 
provide an excellent tool in the pursuit of an understanding of the 
role of specific molecules, and the genes encoding those molecules, 
in neurological conditions including neurodegenerative diseases.
1 .8  THE AIMS OF THIS RESEARCH
The aims of the research presented in this thesis are as follows:
1) To use the published rat and bovine PPT-A and NK-1R receptor 
gene sequences to design suitable heterologous DNA probes in order 
to facilitate the identification of bacteriophage clones of those 
genes from a murine genomic DNA library.
2) To identify and isolate clones for both the murine PPT-A 
(substance P) precursor gene and the murine NK-1 receptor (NK-1R) 
gene from that library.
Chapter 1 Introduction
3) From the identified bacteriophage clones, selected plasmid 
subclones would be generated. The sequence, and the genomic 
organisation of the genes contained within that sequence, would 
subsequently be characterised by restriction enzyme mapping, DNA 
sequencing and exon hybridisation manninn
4 )  The plasmid subclones could also be used as the foundation for 
the design and generation of gene targeting vectors for both genes 
for use in homologous recombination experiments. Those vectors 
would be subsequently used in embryonic stem (ES) cell tissue 
culture transfection experiments in order to generate transgenic 
mice with altered, preferably halted, PPT-A or NK-1R gene 
expression.
Those targeting experiments would be undertaken as a means of 
defining the functional role of both genes and the peptides they 
encode in normal neural function. This in turn would provide a basis 
fo r the elucidation of the proposed role of the tachykinin 
neuropeptide signalling systems in neuronal disorders and in 
particular neurodegenerative disease.
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MATERIALS AND METHODS
INTRODUCTION
This chapter contains the general methods and procedures used in 
the experiments which were the basis of this research. They are 
detailed below and are sub-divided into four sections: (1) 
m icrobiological techniques and standard media, (2) bacterial 
strains, bacteriophage, plasmids and vectors, (3) manipulation of 
bacteriophage and (4) isolation and manipulation of nucleic acids.
MICROBIOLOGICAL TECHNIQUES 
AND STANDARD MEDIA
2.1 E. COL! GROWTH CONDITIONS
E. coli strains were grown as liquid cultures in L-broth inoculated 
with a single colony in the presence of the appropriate antibiotic at 
50 ng per ml. E. coli strain LE392 was grown without antibiotic 
present. The volume of L-broth inoculated depended on the quantity 
of plasmid required. Routinely, 3 ml and 100 ml cultures were used 
for sm all (m ini) and medium (midi) plasm id preparations 
respectively. In order to maximise aeration of the culture, the 
volume of the flask used was typically five times that of the 
culture. Cultures were incubated at 37°C in an orbital shaker at 250 
rpm overnight or for shorter periods depending on the intended use 
of the cultures. E. coli strains were also propagated on petri dish 
plates containing 25 ml L-agar and the appropriate antibiotic, and 
were incubated at 37°C overnight.
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2.2 STANDARD MEDIA FOR THE PROPAGATION OF E.COLf
L-Broth (LB): 10 g tryptone, 5 g NaCI, 5 g yeast extract, 20 mg 
thymine, made up to 1 litre with distilled water and the pH adjusted 
to 7.0 with 0.1 M NaOH.
L-Aaar (LAI: As for L-broth without glucose and with agar added to 
15 g per litre.
2xYT Medium: 10 g yeast extract, 16 g bactotryptone, 5 g NaCI, made 
up to 1 litre with distilled water.
S.O.C. Transformation Recovery Medium: 2 g bactotryptone, 0.5 g 
yeast extract, 1 ml 1M NaCI, 0.25 ml 1M KCI, added to 97 ml of 
distilled water and autoclaved; supplemented with 1 ml 2M glucose 
and 1 ml of 1M MgCl2 /1M MgSC>4 . Filter sterilized.
NZCYM Broth: 5 g NaCI, 5 g bacto-yeast extract, 10 g NZ amine, 1 g 
casamino acids, 2 g MgSC>4.7H20, added to 950 ml distilled water, 
shaken until dissolved then the pH adjusted to 7.0 with 5M NaOH. 
Sterilised by autoclaving.
NZCYM Aaar (top and bottoml: As for NZCYM broth except with agar 
added to 15 g per litre for bottom agar and to 7 g per litre for top 
agar.
Terrific Broth: 12 g bactotryptone, 24 g bacto-yeast extract, 4 ml 
glycerol dissolved in 900 ml distilled water. Autoclaved for 15 min. 
at 15 p.s.i. When cooled to <60°C, add 100 ml of sterile 0.17M 
KH2P04, 0.72M KHPO4 solution.
2.3 STERILISATION
Glassware and growth media were sterilised by autoclaving at 
120°C, 15 p.s.i. for 15 min. Buffers and supplements were heated to
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105°C, 15 p.s.i. for 10 min. Heat-labile solutions were sterilised by
filtration through Nalgene 0.22 jmm pore membranes.
2.4 INTRODUCTION OF DNA INTO E. COLI
*
Plasmids were introduced into E. coli XL1-Blue, TG1, TG2, or nova 
blue strains by genetic transformation using either rubidium 
chloride transformation or electroporation. The transformation 
efficiencies varied according to both the strain and the method used. 
Typically, efficiencies were in the range of 106- 10 7 colonies jig~1 
plasmid DNA.
2.4.1 Rubidium Chloride Transformations
A 2.5 ml overnight culture of recipient E. coli was grown in 2xYT 
media. The culture was diluted 1:100 into L-broth (100 ml 
typically) and incubated at 37°C, 250 rpm for 2 hrs, until ODeoo was 
0.4, Cells were harvested by centrifugation at 5000xg for 5 min at 
4°C, then resuspended in 1 ml ice-cold TFB (see solutions) and 
placed on ice for 15 min. 37 pJ of DMF (100% dimethyl formamide) 
was then added. After 5 min on ice, 37 j i l  of d ilute B- 
mercaptoethanol solution (27 [i\ in 500 jil dH20) was added and a 
further 10 min incubation on ice followed. Finally, another 37 jil of 
DMF was added and, after 5 min on ice, the cells were considered 
competent and ready for use in transformations.
200 \l\ aliquots of competent cells were added to a maximum of 10 
jjJ of plasmid DNA solution (1-1 OOng) or ligation mix in a 1.5 ml 
microfuge tube. The mix was placed on ice for 45 min then heat- 
shocked at 42°C for 3 min (or 40 sec for nova blue cells). 200 \l\ of 
SOC media was immediately added and the culture was incubated at 
37°C, 250 rpm for 1 hr. One tenth of the culture was plated on L- 
agar plates containing ampicillin antibiotic and incubated at 37°C 
overnight.
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2.4.2 Transformations by Electroporation
A 2.5 ml overnight culture of recipient E. coli culture was grown in 
2xYT media. The culture was diluted 1:100 in fresh L-broth and 
incubated for 3 hrs at 37°C until OD600 was 0.6 at which point the 
culture was chilled on ice for 15 min. The cells were harvested by 
centrifugation at 4000xg for 15 min at 4°C. Cells were resuspended 
in 1 litre of ice-cold water and centrifuged as above. Cells were 
then resuspended in 0.5 litres of ice-cold water and re-centrifuged. 
Finally cells were resuspended in 3 ml of 10% glycerol to a 
concentration of 3x1010 cells per ml. The electro-competent cells 
can be aliquoted and stored at -70°C for up to 6 months or used 
im m ed ia te ly . For transfo rm ation  of com petent ce lls  by 
electroporation a Bio-Rad Gene Pulser™ was used. The apparatus 
was set at a capacitance of 25 pF and a voltage of 2.5 kV. The 'Pulse 
Controller Unit' was set at 200 Q. To 40 pi of competent cells, 1 pi 
of plasmid DNA or 5 pi of ligation mix was added and incubated on 
ice for 15 min. The mix was then transferred to a 0.2 cm 
electroporation cuvette (pre-chilled). One pulse was then applied 
generating 12.5 kV/cm with a time constant ideally of 4/5 msec. 
Immediately after transformation, 1 ml of SOC media was added and 
the mix was incubated at 37°C, 250 rpm for 1 hr. 50 pi is . then 
plated on antibiotic-containing L-agar plates and incubated at 37°C 
overnight.
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2.5 ANTIBIOTICS. INDICATORS AND INDUCERS
Figure 2.1 : Antibiotics, indicators and inducers used .
Supplement Concentration Stock concentration
Ampicillin
IPTG
Tetracyclin
X-Gal
50yngmM 
20mM 
10 jjgml-1 
80 jygml-1
10Omgml-1 in distilled water. 
20mgml"1 in distilled water. 
lOmgmM in dilute HCI (1:1000). 
40mgml"1 in DMF.
Figure 2.1: Antibiotics, indicators and inducers used in the research described in 
this thesis.
The in d ica to r X-Gal (5 -b ro m o -4 -ch lo ro -3 -in d o ly l-B -g a la c to - 
sidCcle), and the inducer IPTG (Iso p ro p y l-p -D -th io g a la c to -
pyranoside) stocks were stored at -20°C, and were used in
conjunction with several plasm id cloning vectors (such as
pBluescript from Stratagene) to identify E. coli strains carrying 
recombinant vectors containing DNA sequence inserted into the
multiple cloning sites of that vector. Recombinants containing 
inserts appear white, whereas those lacking inserts appear blue. 
This selection is based on the principle of gene disruption by the 
inserted DNA fragment which subsequently permits the synthesis of 
bacterial colonies which lack the blue colour. Visual screening of 
plates can therefore permit identification of recombinants. The 
antibiotics listed above were stored at -20°C.
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BACTERIAL STRAINS, BACTERIOPHAGE, 
PLASMIDS AND VECTORS
2.6 BACTERIAL STRAINS
All bacterial strains are derivatives of E. coli K-12.
Figure 2.2 : Bacterial Strains Used.
Stra in Genotype Ref./Source
XL1-Blue supE44 hsdR17 recA endA 
gyrA46 lac recA1 thi-1
Bullock et al, 1987
LE392 supE44 supF58 hsdR514 
galT22 metB1 galK22 lacY1 
trpR55
Sambrook et al, 
1988
TG2 supEthiA(lac-proAB)hsdA5
A (srl-recA )306 ::T n10(te tr)
Sambrook et al, 
1988
DH5a F>80d lacZ AM 15 recA1 endA1 Promega Corp. 
gyrA96 thi-1 hsdR 17 (fVmi< +)
supE44 relA1 deoR A(lacZYA- 
argF)U169
TG1 supE thi A(lac-proAB) hsdA5 
F'[traD36proAB+lacLlacZ 
AM 15]
Stratagene Inc.
Nova Blue A(mcrBC-mrr)(rB -m e ') 
A(gpt-proA)62 leu supE44 
ara14 galK2l acY1 mtl-1 
rpsl_20(Strr ) xly-5 
recA13[F+::Tn1000(Tcs)]
Novagen Ltd.
Figure 2.2: Bacterial strains used in the research presented in this text.
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2.7 BACTERIOPHAGE LAMBDA VECTORS
Three different mouse genomic bacteriophage lambda libraries were 
screened for either positively-hybridising PPT-A or SPR gene clones. 
The vector was different for each library.
Figure 2.3 : Bacteriophage Vectors and Clones Used.
Library Vector Probe Clones Isolated Library Ref./Source
Glaxo XF\X PPT-A A.PPT1-A.PPT5 Courtesy Glaxo pic.
Cambridge ?i2001 PPT-A ^PPT6-)tPPT10 Smith, pers. comm.
Toronto XDASH SPR A.SPR1-&SPR16 Rossant, pers comm
Figure 2.3 : A list of the bacteriophage vectors used to generate the libraries, the
sources of those libraries and a list of the clones isolated.
2.8 PLASMID VECTORS AND SUBCLONES
Figure 2.4: Plasmid Vectors and Subclones Generated.
Plasmid Description Ref./Source
pBluescriptll
pBluescriptll
pGEM® 5Zf+
pDK101
3kb pUC19-derived phagemid 
3kb pUC19-derived phagemid
cloning and sequencing vector: pKS+
and pSK- versions used.
Short etal, 1988 
Short et al, 1988
3kb cloning and sequencing vector Promega Corp. 
with multiple features including 
blue/white selection.
pGEM 5Zf+ derived cloning vector 
designed for PCR product cloning.
Kovalic etal, 
1991.
(continued)
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(continued)
Plasmid Description Ref./Source
pSP9
pSP7
pSP10.6
pKS+.Bst
pSP7.2
pSP7.2 II 
pSP7.2 III
pSP7.2 IV
pSP900 
pSP900 II 
pSP900 III
9kb Nco I-A/co I fragment of X PPT9 Chapter 4 
in pGEM5.
7kb Nco \-Nco I fragment of X 
in pGEM5.
10.6kb Sst I-Sst I fragment of 
XPPT9 in pKS+
pKS+ vector with Bst Ell site 
introduced in Kpn I site by linker 
insertion.
7.2kb Bst El\-Bst Ell fragment of 
pSP10.6 in pKS+.Bst.
PPT9 Chapter 4
Chapter 5
Chapter 5
Chapter 5
As pSP7.2 minus 0.9kb Mlu I-Mlu I Chapter 5
fragment.
pSP7.2 II with 2.7kb Mlu \-Mlu I Chapter 5
fragment of pSP900V containing neo 
gene in PPT-A exon 3.
As pSP7.2 III with 2.7kb Mlu I-Mlu I Chapter 5
fragment of pSP900V in opposite
orientation
0.9kb Mlu I-Mlu I fragment of pSP9 Chapter 5
cloned in pSPORT.
0.9kb Mlu I-Mlu I fragment of pSP9 Chapter 5
cloned in plBI24.
As pSP900 II with polylinker Chapter 5
Pst I site lost by Sal I-Xho I 
digestion and re-ligation.
(continued)
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(continued)
Plasmid Description Ref./Source
pSP900 IV 
pSP900V
pSP900 VI 
pSPR5
pSPR8
pSPR8.5
pPPTNeo
pPPTNeoi i  
pi BI24 
prTKR2 
pCOL1
As pSP900 III with Eco Rl site 
introduced in Pst I site by linker.
Chapter 5
As pSP900 IV with 1.8kb Eco Rl-Eco Chapter 5
Rl neo gene fragment in same 5'-3' 
orientation as PPT-A gene.
As pSP900 V with neo in opposite Chapter 5
orientation to PPT-A gene.
5kb Bam HI-Bam HI fragment of Chapter 4
A.SPR12 in pKS+
8kb Bam HI-Bam HI fragment of Chapter 4
X.SPR13 in pKS+.
8.3kb Sst I- Eco Rl fragment of Chapter 4
A.SPR12 in pKS+.
Blunt-ended 1.8kb Eco Rl-Eco Rl neo Chapter 5
gene cloned into blunt-ended pSP7.2 
II Mlu I site in same orientation as 
PPT-A gene.
As pPPTNeo with neo in opposite 
orientation to PPT-A gene.
2.9kb pEMBL-derived cloning and 
sequencing vector.
Chapter 5 
Dente e to t 1983
1.3kb rat SPR gene cDNA in pSK+. YokotaSt a t
1989
0.5kb mouse genomic PPT-A PCR Chapter 3 
product in pDK101 vector.
(continued)
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(continued)
Plasmid Description Ref./Source
pCOL2 0.5kb rat genomic PPT-A PCR
product in pDK101 vector.
pSKNeo pSK- containing 1.8kb Eco Rl-
Eco Rl neo gene from pPNT.
pGEM11 .TK 2.9kb Eco Rl-Hind III thymidine
kinase gene cloned in pGEM11.
pSPR1.9 I 1.9kb Bam HI-Bst Ell fragment of
pSPR8 in pKS+.Bst vector.
pSPR1.9 II As pSPR1.9 I but with polylinker
HincAU site deleted by blunt-ended 
re-ligation.
pSPR2.1 2.1 kb Bam HI-Hind III fragment of
pSPR8 in pKS+.
pKS.TK 2.9kb Kpn \-Not I thymidine kinase
gene cloned in pKS+.
pSPORT®1 4kb cloning and sequencing vector
containing polylinker Mlu I site.
Chapter 3
Donald, 1994 
(pers. comm.)
Galagher,1994(pe 
rs. comm.)
Chapter 5
Chapter 5
Chapter 5 
Chapter 5 
BRL Ltd.
Figure 2.4 (continued): Plasmid vectors used and subclones generated during the 
research described in this text.
2.8.1 Plasmid Subclone Nomenclature
A system was selected to name the plasmid subclones. For plasmid 
pSP9, the 'SP' refers to the NK-1 gene (which encodes substance P) 
from which the subclone was derived and the '9' refers to the size 
(in Kb) of the plasmid insert. This nomenclature system was 
extended to the receptor gene NK-1 R (formerly the SPR gene) as well 
as NK-1 plasmid subclones. For example, a 5 kb subcloned fragment
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of the NK-1R gene was named pSPR5 where the 'SPR' refers to the 
old name for the NK-1R gene from which the subclone was derived, 
and the '5' refers to the size of the insert. The "R" distinguishes the 
receptor from the precursor gene subclones. If two subclones were 
generated which contained DNA inserts of the same size and were 
derived from the same gene, they were given the suffix a, b and so 
on, in lower case. (For example pSPR5a and pSPR5b). This further 
suffix was not required for the subclones detailed in this text.
MANIPULATION OF BACTERIOPHAGE
2.9 BACTERIOPHAGE PLATING CELLS
The E. coli strain LE392 was used in order to propogate 
bacteriophage lambda in liquid lysates, and for the generation of 
plated lawns of bacteria on which phage plaques were grown. The 
cells required for both methods were prepared by inoculating 2.5 ml 
of L-broth (supplemented with 1 ml of 20% maltose per ml of 
culture) with a single bacterial colony and incubating overnight at 
37°C, 250 rpm without antibiotic. The overnight culture was diluted 
1:100 in fresh L-broth and incubated for 3 hrs at 37°C until an OD600  
of 0.5 was reached. Cells were then centrifuged at 4000 x g for 10 
min at room temperature. The pellet was resuspended in 10 mM 
MgSC>4 to an OD600 of 2.0 and stored at 4°C. Plating cells were used 
for several weeks, but for optimum plating efficiencies, fresh cells 
were prepared on each occasion.
2.10 GROWTH OF BACTERIOPHAGE LIQUID LYSATES
Between 5 and 15 jjJ of high titre (approximately 1010 p.f.u. jnh1) 
bacteriophage stock was added to 100 jllI of LE392 plating cells, and 
incubated at 37°C, 250 rpm for 20 min to allow the phage to adsorb 
to the bacteria. 50 ml of pre-warmed (37°C) NZCYM broth was then 
added and the culture was incubated overnight in a 37°C shaker.
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Successful bacterial lysis and a high phage content is indicated by a 
clear culture containing clumps of aggregated lysed bacterial debris. 
Phage DNA can then be extracted from this lysate.
2.11 PLATING BACTERIOPHAGE ON NZCYM AGAR PLATES
*
In order to screen a bacteriophage genomic library, the phage have to 
be plated on NZCYM agar plates at a concentration which ensures 
that distinct plaques are visible. (Plaque sizes vary depending on 
the vector used.) To purify a particular identified phage, the phage 
are again plated on NZCYM agar plates but at a lower density to 
allow a single plaque to be removed without contamination by other 
neighbouring phage.
Bacteriohage were added to LE392 plating cells and incubated at 
37°C for 20 min to allow the phage to adsorb to the bacteria. The 
volume added depended on the titre of the phage stock and the 
number of plaques required on the plate. For small 82mm diameter 
round plates, 100 p.f.u were added. The cell/phage mix was then 
added to liquid NZCYM top agar (cooled to 459C) and then poured onto 
an NZCYM bottom agar plate (previously poured on a level surface and 
dried). Volumes were also dependent on the size of plate used, as 
described below.
Figure 2.5 : Plating Cells and Agar Volumes.
Plate Size
82mm (Diam.) 10mm x 10mm 245mm X 245mm
Plating cells (ml) 
Top Agar (ml)
0.2
3.0
0.5
7.0
2.0
30.0
Figure 2.5 : Volumes of plating cells and top agar used per NZCYM plate.
Once the plates have set on a level surface they are inverted (to 
minimise moisture smearing the plaques), and incubated at 37°C 
overnight. Before taking nylon membrane lifts from the plates (for
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hybridisation purposes), the plates were cooled to 4°C to prevent the 
top agar layer adhering to the membrane and preventing further 
duplicate lifts being taken.
2.12 TITRE OF BACTERIOPHAGE
*
To titre a particular lambda bacteriophage stock, serial dilutions of 
the stock were made by diluting 100 jxl in 900 ^l of SM phage buffer 
to produce a 10_1 dilution. That solution was similarly diluted to 
produce a 10-2 dilution and so on in sequence to at least a 10 '6 
dilution. 10 pJ of each dilution was then plated on NZCYM (82mm 
diam.) plates as described above and incubated at 37°C overnight. 
The following day, the number of plaques on each plate was counted 
and the titre calculated in plaque forming units (pfu). For example, 
500 plaques counted on the 10~6 dilution plate indicates a phage 
stock titre of 5x1010 pfu.mK
2.13 STORAGE OF BACTERIOPHAGE
Bacteriophage lysates were stored at 4°C in the presence of a drop 
of chloroform (50jj|t which was added to prevent the growth of any 
surviving bacteria. For long-term storage of bacteriophage, DMSO 
was added to a 7% concentration (v/v), mixed gently and placed in 
dry ice or liquid nitrogen for 20 min before being transferred to a - 
70°C freezer for storage. Phage stored under these conditions will 
remain viable indefinitely.
2.14 TRANSFER OF DNA TO HYBONP-N™ MEMBRANES
To screen lambda phage plaques for probe homology, duplicate lifts 
were taken from the phage plates whereby the DNAs to be screened 
were transferred to a filter membrane such as Amersham Hybond- 
N™ which was subsequently hybridised to probes in aqueous solution. 
The membrane retains the spatial orientation of the plaques relative
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to one another so that positively hybridised plaques can be located 
and isolated later.
Lambda phage NZCYM plates grown overnight were chilled at 4°0 for
1 hr to prevent the plaque-covered top agar layer sticking to the
membrane (leaving only the bottom agar layer when subsequent lifts
are made). A piece of membrane was cut which was slightly smaller
*
than the dimensions of the plate. The membrane was then placed on 
the plate for 30 sec during which time holes were made in three 
asymmetrical locations using a needle to pierce the membrane and 
the NZCYM layers. (Marking the holes in the media with India Ink 
after the first membrane lift allows the piercing of holes in 
subsequent filters to be localised to the same relative position as 
for the first lift.) After 30 sec the membrane was gently removed 
and placed plaque-side up on 3MM paper soaked in denaturing 
solution for 7 min. The membrane was then transferred to 3MM 
paper soaked in neutralising solution for 7 min. The filters were 
washed twice by submersion in 2X SSC buffer for 7 min then laid 
flat to air-dry. The DNA was then permanently fixed to the 
membrane by ultra violet cross-linking (using the auto-cross-link 
function on a Stratagene 'Stratalinker™' apparatus) or by baking at 
80°C for 1 hr minimum. The membrane which was used to make the 
second duplicate lift from the phage plate was placed on the plate 
for 1 min rather than 30 sec. The third and fourth lifts were placed 
on the plate for 2 and 3 min respectively then fixed as described 
above.
2.15 ISOLATION OF DNA FROM BACTERIOPHAGE LYSATES
200 ml of bacteriophage lysate was centrifuged at 10,000 x g for 10 
min to pellet any remaining bacterial debris. The cleared lysate was 
then incubated at 37°C with 100 | ig m l"1 DNAase and 100 ^g m l-1 
RNAase for 1 hr to degrade bacterial DNA and RNA. The phage were 
precipitated by adding 50 ml of 30% PEG (polyethylene glycol) and 
incubated on ice for 1 hr. Centrifugation at 12,000xg for 10 min 
pelleted the phage which were subsequently resuspended in 10 ml SM
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buffer. (This concentrated, cleared phage stock can be stored at 4°C 
for several months.) 0.5 ml of this stock was incubated with EDTA 
(to 20 mM) and proteinase K (to 50 jig m l-1) at 37°G for T hr to break 
open the phage heads and release the phage DNA. The volume was 
increased to 1 ml with dH2 0  then phenol and chloroform extracted.
The DNA was ethanol precipitated but not in the presence of one 
tenth volume of 3M sodium acetate as is standard practice, as salt 
carry-over can sometimes hinder digestion of the DNA. The DNA was 
resuspended in 100 p.1 of dH20. For subsequent restriction enzyme
digestions, 3 pi of this DNA was used per reaction.
ISOLATION AND MANIPULATION 
OF NUCLEIC ACIDS
2.16 GENOMIC DNA EXTRACTION FROM MAMMALIAN TISSUE
Genomic DNA was prepared from frozen mouse liver tissue 
previously dissected from fresh cadavers and stored at -70°C. 
Approximately 1 g of starting tissue was placed in a mortar and kept 
immersed in liquid nitrogen while ground to a fine powder with a 
pestle. The powder was then dispersed in 10 ml of extraction buffer 
(see solutions section) and incubated at 37°C for 1 hr. Proteinase K 
enzyme was then added to a concentration of 100 pg.m l’ 1, and 
incubated at 37°C for 3 hrs or overnight. An equal volume of phenol 
was then added and the two phases were mixed by slow and gentle 
end-over-end inversion for 10 min followed by 1 hr on a rolling 
shaker. The mix was then centrifuged at 5000xg for 15 min at room 
temperature. The upper aqueous phase was then gently removed with 
a cut-tip pipette (so as not to physically shear the DNA) and phenol 
extracted again twice. Extraction with an equal volume of 
chloroform was followed by precipitation of the DNA by addition of
0.2 volumes of 10M ammonium acetate and 2 volumes of 100% 
ethanol. On inversion, the DNA visibly precipitated as gelatinous 
strands which were removed using a hook-shaped pasteur pipette 
with its end sealed using a bunsen burner. The DNA was then
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centrifuged at 10,000xg for 15 min and washed twice in 70%
ethanol. The DNA pellet was then briefly air-dryed (over-drying
limits resuspension) and resuspended in 1 ml of distilled water by
rotation on a rolling shaker overnight. The OD2 6 O and OD280 are
measured so that the DNA concentration and degree of protein
contamination of the resuspension can be determined using a simple
equation (Sambrook et at, 1988). The DNA was then ready for
*
restriction enzyme digestion and other manipulations.
2.17 ISOLATION OF DNA FROM £. CPU CULTURES
Several methods were used for the isolation of plasmid DNA from £  
coli cultures depending on the quality and quantity of DNA required. 
The methods used are listed below.
2.17.1 Alkaline Lysis Method
The alkaline lysis method (Birnboim and Doly, 1979) was the used 
during the early stages of this project to isolate plasmid from small 
(1.5ml) or large (50-200ml) culture volumes of E. coli.
Reagents: Birnboim Doly 1 (B D i); 50 mM glucose, 25 mM Tris-HCI (pH
8.0), 10 mM EDTA. Immediately prior to use, lysozyme was added to
a working concentration of 2 mg.ml"1 . Birnboim Doly 11  (BD1 1 ); 0.2
M NaOH, 1% (w/v) SDS, stored in a non-glass container. Birnboim
Doly h i  (BD i i i ); 5 M KOAc (pH 4.8). Phenol: redistilled phenol
buffered w ith 0.5 M Tris-HCI (pH 8.0), 0.1% (w/v) 8-
h yd roxyq u ino lin e . DNAase-free RNAase A: Pancreatic RNAase
dissolved in dH20 to a concentration of 10 mgml-1 , heated to 100°C
stored iVx
for 15 min and cooled to room temperature. RNAase was^aliquots 
at -20°C.
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2.17.1.1 Small Scale Plasmid Prep
Plasmid DNA was isolated from 1.5 ml of overnight E. coli culture. 
Cells were pelleted by centrifugation in a microfuge tube at 
14,000xg for 30 sec, and resuspended in 100 j l l I  of B D m  (with 
lysozyme) by pipetting. Incubation at 37°C for 15 min was followed 
by addition of 200 \l \ B D i i i  and end-over-end inversion for 1 min. 
150 j l i I  of pre-chilled B D m  was then added and the mix placed on 
ice for 5 min. Most of the cell debris and chromosomal material was 
pelled by centrifugation at 14,000xg, 4°C for 10 min. The 
supernatant was then extracted with an equal volume of phenol then 
similarly with chloroform. The DNA was then precipitated with 0.1 
volume of sodium acetate (pH 5.2) and 2 volumes of 100% ethanol 
and pelleted by centrifugation at 14,000xg for 30 min. The pellet 
was washed twice in 70% ethanol and air-dried for 5min before 
resuspension in 50jxl dH20. Typically, 20 pg of plasmid was isolated
per 1.5 ml of starting culture of a quality suitable for most in vitro 
procedures.
2.17.1.2 Large Scale Plasmid Prep
200 ml of overnight stationary phase culture was pelleted in a 250 
ml polypropylene tube by centrifugation at 8000xg for 10 min. Cells 
were resuspended using a cut-tip pipette in 7.5 ml of B D i solution 
and incubated at room temperature to allow the lysozyme to break 
open the bacteria. The cell suspension was then placed in a 30 ml 
polypropylene tube containing 7.5 ml of B D n  and placed on ice for 5 
min and occasionally inverted. 7.5 ml of B D m  was then added and 
another 5 min incubation on ice follows. The bulk of the bacterial 
and chromosomal debris was then pelleted at 15,000xg for 25 min at 
4°C. The 22.5 ml of supernatant was then split into two clean 30 ml 
tubes containing 19 ml of 100% isopropanol and after a 15 min 
incubation at room temperature centrifuged at 12,000 x g for 20 
min. The DNA was further purified by equilibrium -density 
centrifugation on a caesium chloride-ethidium bromide (CsCI.EtBr) 
gradient. The nucleic acid pellet was resuspended in 3.9 ml of TE 
and added to 7.4 g of CsCI dissolved in 4 ml of TE to a density of 
1.58 gm l"1 . 300 pJ of ethidium bromide (10 mgml"1) was added,
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mixed and the solution was left in the dark for 1 hr. The solution 
was then ultra-centrifuged at 289,000xg for 16 hrs at 20°G in a 
Beckman Ti70 angled rotor/L8 Beckman ultra-centrifuge. The 
solution was then illuminated in the dark with a hand-held ultra­
violet lamp to permit visualisation of two distinct DNA bands. The 
upper band constitutes chromosomal and relaxed form plasmid DNA,
whereas the lower band constitutes supercoiled plasmid. The lower
*
band was removed by puncturing the tube below the level of the band 
with a 1 ml syringe and gently withdrawing the fluid. The ethidium 
bromide was then removed by repeated extraction with water- 
saturated N-butanol (butan-1-ol). Three volumes of dH20 was then
added prior to DNA precipitation with 6 volumes of 100% ethanol. 
The DNA was pelleted at 12,000xg for 30 min at 4°C, washed twice 
with 70% ethanol, and resuspended in 1 ml of dH20. The DNA is
suitable for most in vitro manipulations.
2.17.2 Quick Plasmid Preps
Technological advances during this project provided faster methods 
for the isolation of plasmid DNA which dispensed with the use of 
toxic reagents such as phenol. These methods are also based on the 
alkaline lysis methods (Birnboim and Doly, 1979). Specifically, 
Promega 'Magic Minipreps™1 replaced the small-scale protocol, and 
Qiagen 'Midi-Columns™1 were used in place of the time-consuming 
large-scale protocol detailed above.
2.17.2.1 Promeaa Maaic Minipreps ™
1 ml of culture was pelleted at 12,000xg for 30 sec. Cells were 
resuspended in 200 pJ of BD i (RNAase added to 100 ngm l"1), then 
200 pJ of B D n  was added and the suspension left at room 
temperature for 5 min. 200 \i\ of B D m  was added and the tube was 
inverted before centrifugation at 12,000xg for 5 min. The 
supernatant was mixed with 1 ml of Magic Miniprep Resin™ which 
specifically binds plasmid but not chromosomal DNA due to the pH- 
specific binding properties of the resin. Using a 2.5 ml syringe, the 
mix was pushed through a Promega mini-column which retains the
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resin-plasmid complex but not the other unwanted mix components. 
The column was washed with 2 ml of wash buffer (see solutions) and 
pulse centrifuged for 20 sec in a 1.5 ml microfuge tube. 50 \lI of 
dH 20  was added and the column pulse centrifuged to elute the DNA
while leaving the resin particles in the column. The typical yield of 
10 ng of DNA has minimal RNA contamination and is suitable for 
restriction but the quality can occasionally limit its use for other in  
vitro manipulations.
2.17.2.2 Qiagen™ Midi-Columns
This protocol is designed for isolation of as much as 100 *ig of 
plasmid from 30-150 ml of culture. 100ml of culture was pelleted 
by centrifugation at 12,000xg for 5 min and resuspended in 4 ml of 
P1 buffer (for P-buffers, see solutions) containing RNAase (100 
jig .m l"1). 4 ml of P2 buffer was added and mixed gently then 
incubated at room temperature for 5 min. The same volume of P3
buffer was added next and the solution mixed then centrifuged at
15,000xg for 30 min at 4°C. A second spin ensures removal of 
particulate material. The supernatant was then applied to a Qiagen 
Tip-100™ (previously equilibrated with 3 ml of QBT buffer; for Q- 
buffers, see Solutions). The column functions by the same principle 
as the Promega mini-columns whereby the plasmid DNA is
temporarily bound to the Qiagen column in a pH-specific manner.
When all of the supernatant had entered the column, it was washed 
with 10 ml of QC buffer. The plasmid DNA was then eluted with 5 ml 
of QF buffer, and precipitated with 0.7 volumes of isopropanol. The 
precipitate was then pelleted at 15,000xg for 30 min at room 
temperature. After two 70% ethanol washes, the pellet was air- 
dried for 5 min and resuspended in 1 ml of dH20.
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2.18 QUANTIFICATION OF NUCLEIC ACIDS
2.18.1 Double Stranded DNA
The nucleic acid concentration and the degree of protein 
contamination was determined by spectrophotometry using a Milton 
Roy Spectronic 1201 spectrophotometer. Measurements at OD2 6 O and 
OD280 were taken. An OD260=1 for double stranded DNA indicates a 
concentration of 50 jign-l'1 . A more precise, empirical value can be 
determined by multiplying the OD2 6 O value by 33 (multiplication
factor for double stranded DNA), and by the dilution factor (of the 
solution measured), to give a DNA concentration in jiginl"1 . For a 
given DNA solution, the value obtained by dividing the OD2 6 O 
reading by the OD280 reading indicates the extent of protein 
contamination. A value of >1.75 indicates protein contamination is 
negligible, where a value of 1.8 indicates a pure DNA solution. The 
presence of phenol can also lower these values (Sambrook et al, 
1988).
2.18.2 Single Stranded Oligodeoxynucleotides
The DNA concentration of single-stranded oligodeoxynucleotides 
used as hybridisation probes, or to make DNA linkers, was 
determined by measurement of OD260- This value was multiplied by
33 (multiplication factor for single-stranded DNA) and divided by 
the volume in \i\ of stock solution diluted for measurement. The DNA 
concentration ca lcu lated is in |ig |il"1 . A lte rna tive ly , the 
concentration in pmolesml"1 can be calculated by dividing the OD2 6 O 
reading by [the number of nucleotides in the deoxyoligonucleotide 
multiplied by 0.01].
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2.19 PRECIPITATION OF NUCLEIC ACIDS
2.19.1 Double Stranded DNA
Double stranded DNA was precipitated by addition of 1/10 volume of 
3M sodium acetate and 2 volumes of 100% ethanol followed by a 30 
min (minimum) incubation on ice. Alternatively DNA in water or TE 
was precipitated by addition of 0.7 volumes of isopropanol, and 
incubated at room temperature for 10 min (minimum). The DNA was 
pelleted by centrifugation at 12,000xg for 15 min, then washed 
twice with 70% ethanol, air dried for 5 min and resuspended in 
appropriate buffer/dH20.
2.19.2 Single Stranded Oligodeoxynucleotides
Single stranded oligodeoxynucleotides were precipitated with 1/10 
volume of 5.2M NaAc and 2 volumes of 100% ethanol, incubated at - 
20°C overnight or at -70°C for 1 hr. Precipitation was followed by 
centrifugation at 12,000xg for 30 min at 4°C, or at room 
temperature in the case of isopropanol precipitations. The DNA 
pellet was then washed twice with 70% ethanol and air-dried for 5 
min before being resuspended in the appropriate buffer/dH2 O.
2.20 DNA DIGESTION WITH RESTRICTION ENDONUCLEASES
Restriction enzymes were supplied by Bethesda Research 
Laboratories (BRL), Promega Corp. or New England Biolabs Ltd. 
Digestion of plasmid or phage DNA was typically carried out in a 
10jxl volume, constituting 1 \i\ DNA (0.2-2.0 jig), 1 p,l of appropriate 
10X (BRL REact™ for example) restriction enzyme buffer, 1jil of 
restriction enzyme (1-10 unitsng-1 DNA), and dH20 to a final volume 
of 10 \l\. For double or triple restriction enzyme digests where the 
buffers were incompatible, the Pharmacia One-Phor-AII™ buffer 
system was used. The reaction was incubated at 37°C for 1-2 hrs. 
Digestion of genomic DNA required longer incubation of up to 5 hrs.
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The reaction was halted either by addition of gel loading buffer, 
heat-inactivation appropriate to the enzyme being used, or by 
phenol/chloroform  extraction if subsequent digestion with a 
different enzyme/buffer was to follow. Digestion of larger amounts 
of DNA required each reaction component to be scaled up accordingly. 
Gel electrophoresis of samples was used to determine when
digestion was complete in such cases.
2.21 LIGATION OF RESTRICTED DNA FRAGMENTS
Two methods were used for ligation of DNA fragments. Firstly, 
conventional ligations requiring the addition of all reaction
components, and secondly, the more convenient Pharmacia Ready-To- 
Go™ ligation kit.
2.21.1 Conventional Ligations
Ligation of selected DNA fragments into plasmid vectors used a 
reaction volume of 20 \l\ with a total DNA concentration of 6 mgml"
1. The molar ratio of vector fragment to insert fragment ranged 
from 1:2 to 1:10 depending on the fragment sizes and the state of 
de/phosphorylation of the fragments. Vector and insert DNAs were 
mixed with 1/10 volume of 10X ligation buffer (Pharmacia), ATP to
a final concentration of 1 mM, and 1 unit of T4 DNA ligase/pg~1.DNA.
The volume was made up to 20 \l\ with dH2.0, and the reaction
incubated at 16°C overnight or room temperature for 4 hrs.
2.21.2 Ready-To-Go™ Ligation Kit
This protocol simply required the dilution of insert and vector DNA 
fragments in dH 20 to a final volume of 20 \l\. The solution was
added to a Ready-To-Go tube (Pharmacia) which contained 
dessicated ligation mix (ligase, buffer and ATP), and left at room 
temperature to allow re-hydration of the ligation mix for 5 min. 
After gentle pipetting to ensure complete resuspension, and brief
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centrifugation to remove any bubbles, the tube was placed at 16°C 
overnight. Ligation efficiencies were found to be improved 
considerably by the addition of 2 \i\ of 1 unitpil_ 1 T4 DNA ligase 
enzyme.
2.22 DEPHOSPHORYLATION OF RESTRICTED DNA FRAGMENTS
*
Removal of the terminal 5' phosphate group from restriction enzyme 
digested double-stranded DNA fragments prevents ligation of two 
otherwise compatible fragments. This reduces re-ligation of vector 
DNA which, under ligation conditions, competes with the preferred 
insert/vector ligation reaction. Vector re: ligation can reduce the 
number of successful vector recombinants containing insert. The 
dephosphorylation reaction was performed by Calf Intestinal 
Alkaline phosphatase (CIP), or Shrimp Alkaline Phosphatase (SAP). 
The former was used originally but phenol/chloroform extraction 
was required to remove it completely. This enzyme was superseded 
by SAP because SAP is irreversibly heat-inactivated (in Tris 
buffers, pH 8.0-8.5) by incubation at 65°C for 15 min.
2.22.1 Calf Intestinal Alkaline Phosphatase (CIP)
CIP enzyme is supplied by Boehringer Mannheim Ltd. Five pmoles of 
restriction enzyme digested DNA with protruding phosphorylated 5' 
ends (approxim ately 7 ^ig of 5kb DNA fragm ent), can be 
dephosphorylated by 0.1 units of CIP. The DNA and the enzyme are 
incubated in 1/10 volume of 10X CIP buffer at 37°C for 30 min. 
Phenol/chloroform extraction is followed by precip itation and 
resuspension in dH2 0 .
2.22.2 Shrimp Alkaline Phosphatase (SAP)
SAP enzyme is supplied by Amersham USB. To dephosphorylate 1 
pmole of DNA termini (2.5 \ig of 3 Kb fragment), different amounts of
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SAP are required depending on the kind of termini. The minimum 
amounts of enzyme required are listed below.
Figure 2.6 : Units of SAP used per Reaction.
Terminus____________ Units of Phosphatase (SAP)
5'-Protruding 0.1 unit
Blunt 0.2 unit
5-Recessed 0.5 unit
Figure 2.6 : Units of SAP used in dephosphorylation reactions.
The DNA and SAP enzyme are incubated in 1/10 volume of 10X SAP 
buffe r at 37°C for 30 min then heat-inactiva ted. The 
dephosphorylated DNA is then ready for ligation.
2.23 ORGANIC SOLVENT EXTRACTION
Proteins were removed from nucleic acid solutions by phenol, 
phenol/chloroform, and chloroform extractions. Chloroform was 
supplied by Prolabo Ltd., and phenol by Aldrich Chemicals Ltd. Prior 
to extraction, the volume of the nucleic acid solution was 
sometimes increased with dH2 0  to limit the amount of nucleic acid
inevitably lost during extraction. Re-distilled phenol was buffered 
with 500 mM Tris.HCI (pH 8.0) and contained 0.1% (w/v) 8- 
hydroxyquinoline. Phenol/chloroform constituted 50 parts phenol, 
49 parts chloroform and 1 part isoamyl alcohol.
Typically, an equal volume of phenol was added to the nucleic acid 
solution and mixed using a vortex mixer. The organic and aqueous 
phases were separated by centrifugation at 12,000xg for 5 min. 
This could be repeated several times until no protein precipitate 
was visible at the interface. The upper aqueous phase was removed 
and extracted with an equal volume of chloroform in the same way. 
The upper aqueous phase was again removed and precipitated with
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either ethanol or isopropanol. Precipitation also removed any 
lingering solvent in the nucleic acid soluton.
2.24 PREPARATION OF RADIOACTIVELY-LABELLED DNA 
PROBES
*
Probes were labelled with radioactive nucleotides by either random 
priming using Klenow enzyme, resulting in incorporation of [a32P]- 
labelled nucleotides into a newly synthesized complementary DNA 
strand, or by 5'-end labelling using T4 polynucleotide kinase, where 
a [t32P] ATP molecule donates a radioactive phosphate group which 
replaces the existing phosphate at the 5’-terminal ends of a DNA 
strand. Modifying enzymes were supplied by Promega Corp.
2.24.1 Random Primer Extension DNA Labelling Method
This method is based on the procedure of Feinberg and Vogelstein 
(1983 and 1984). A Boehringer Mannheim random priming kit was 
used to set up the following reaction.
25-50 ng of DNA fragment in a maximum volume of 10 \i\ was 
denatured at 95°C for 10 min then cooled immediately on ice.
5 |il (50 jiCi) of [a32P] dCTP (3000 Ci.mmol-1) was added.
- 2 jllI of reaction mixture containing random hexanucleotides and
10X reaction buffer was added.
1 jil of each unlabelled nucleotide, (in this case dATP, dGTP, and
dTTP), from a 0.5 mM stock was added.
1 jllI of Klenow enzyme from a 2 unitsjil-1 stock was added. 
dH2 0  was added to a total volume of 20 jil.
- The reaction was then incubated at 37°C for 30 min then halted by
incubation at 65°C for 10 min. The unincorporated dNTPs were 
removed, by Sephadex-G50 column chromatography.
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2.24.2 Sephadex G-50 Column Chromatography
To the random primer extension labelling reaction, 5 jil of 50 mg.ml- 
1 dextran blue dye and 5 jil of 50 mgmM phenol red dye was added. 
The sample was then loaded on to a Sephadex-G50 (Pharmacia) 
column, 4 cm long and 0.5 cm in diameter, pre-equilibrated with 
column buffer (10 mM Tris.HCI, 100 mM NaCI, 1 mM EDTA, pH 7.5), or 
a Pharmacia Nick-Column™. The labelled DNA and the template DNA 
was co-e lu ted w ith the dextran blue dye, whereas the 
unincorporated nucleotides were retained. The labelled DNA sample 
was then denatured by incubation at 95°C for 10 min then chilled on 
ice immediately.
2.24.3 5'-End Labeling of Oligodeoxynucleotides
Oligodeoxynucleotide probes were radioactively-labeled with fy ^ P ] 
using T4 polynucleotide kinase. The labelling reaction comprised:
- 50 ng of oligodeoxynucleotide.
1 jllI of 10X kinase buffer.
- 50 fxCi (5 jil) of [y32P] ATP (4500 Ci.mmoM).
1 jil (10 units) T4 polynucleotide kinase.
- d H 2 O t o 1 0 > l .
- The reaction was incubated at 37°C for 30 min.
The probe was used in this form and not treated by chromatography 
to remove unincorporated radioactively-labeled nucleotides.
2.25 AGAROSE GEL ELECTROPHORESIS
Horizontal neutral agarose gels were used to visualise and separate 
DNA. Typically, analytical gels were 0.5% (w/v) agarose in 1X TBE. 
Higher percentage gels were required to visualise smaller DNA bands 
such as PCR products. When recovering DNA from agarose gels 1x 
TAE buffer was used instead of 1x TBE.
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2.25.1 Mini Gel Electrophoresis
Pharmacia GNA-100 gel kits were used for rapid visualisation of
DNA restriction digests and to determine the extent of DNA recovery
after precipitation. 1.5 g of standard grade agarose was added to
300 ml of 1X TBE (or TAE), and heated to boiling and cooled to 60°C.
To this gel stock EtBr was added to a concentration of 200 ngml-1 .
%
30 ml of 60°C agarose was then poured into a 105 x 75 mm gel 
caster with an 11 well comb and allowed to set. When set the gel 
was placed in the gel tank containing 0.5 litres of 1X TBE. Mini gels 
were operated at 2-10 V c rrr i, typically 75 V for 45 min or longer 
depending on the band sizes and the .resolution required. DNA bands 
were visua lised on a 302 nm UVP Inc. 'Chrom ato-Vue' 
transilluminator
2.25.2 Large Gel Electrophoresis
Large gels were required to resolve large DNA bands, to accurately 
size bands, and to electrophorese samples for Southern analysis. A 
BRL Ltd. 'Horizon 11.14' gel kit was used where 100 ml of agarose 
was poured into a 140 x 105 mm gel caster with a 14 well comb and 
allowed to set. Genomic and lambda DNA digest samples were 
heated to 65°C for 5 min prior to loading. Gels were run for 6 hrs at 
40 V, or for genomic digests, overnight at a lower voltage in a lower 
percentage gel.
2.26 GEL PHOTOGRAPHY AND IMAGING
Gels containing EtBr were visualised on a transillum inator and 
either photographed (with Kodak Wratten filters) using Polaroid type 
67 film or 'imaged' with a Mitsubishi video copy processor printed 
on Mitsubishi high density thermal imaging paper for video printers.
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2.27 RECOVERY OF DNA FROM AGAROSE GELS
Restricton enzyme digested DNA fragments were recovered from 
agarose gels using Isogene™, Costar SpinrX™ columns, NA45 paper 
or by low melting point agarose organic extraction. The Isogene™ 
kit method was used for purification of PCR products. Costar Spin-X 
columns were originally used for the recovery of larger DNA bands 
for cloning purposes. However the recovery yield was found to 
sometimes be relatively low (as experience by this reseacher) and 
this method was superseded by the NA45 paper recovery method. 
This in turn was replaced by the low melting point agarose organic 
extraction method, as this method was found to give the highest 
yield of good quality DNA for use in ligations.
2.27.1 Isogene™ Method
The Isogene™ DNA purification and extraction kit was supplied by 
Perkin Elmer Cetus Ltd. DNA was bound to a finely particulate slurry 
in the presence of sodium iodide. These conditions favour the 
solubilisation of agarose and proteins and this facilitates extraction 
of DNA. Bound DNA is eluted with dH20. A weighed gel slice was
placed in a 1.5 ml microfuge tube containing 2 volumes of sodium 
iodide solution and incubated at 60°C for 10 min to solubilise the 
agarose. The tube was then vortexed briefly and incubated for 
another 5 min at 60°C. An appropriate volume of binding slurry 
(dependent on the volume of the gel slice, but approximately 100 \l\ 
in 1 ml of solubilised agarose solution) was added and mixed end- 
over-end at room temperature for 10 min. The supernatant was 
removed after a 10 sec centrifugation at 12000 x g. The pellet was 
resuspended and briefly centrifuged at 12000 x g for 10 sec three 
times in wash buffer (1 M Tris.HCI [pH 7.5], 1 M NaCI, 100 mM EDTA). 
After the final brief centrifugation, the pellet was resuspended in 
20 il\ dH2 0 , pulse centrifuged again and the supernatant removed and
retained. The elution step was repeated generating another 20 jil of 
DNA eluate which was pooled with the first. The sample was 
checked by electrophoresis then used.
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2.27.2 Spin-X™ Columns
The columns were supplied by Costar Ltd. The gel slice was placed
in the column and incubated at -20°C for 10 min. The column was
then centrifuged at 10,000 x g for 10 min. The top section of the
column containing the residual agarose was removed leaving the
lower section which contains the eluted DNA solution. The eluate
*
can then be used immediately for ligation if it is concentrated 
enough, or ethanol precipitated to concentrate the DNA and remove 
salts. The DNA was resuspended in dH20.
2.27.3 NA45 Paper Method
NA45 paper was purchased from Schleicher and Schuell Inc. Th is 
paper is a 0.45 pm DEAE membrane used for filtration and 
separation. The method is based on the temporary adhesion of DNA 
fragments to the paper at low salt concentrations and elution of the 
DNA under high salt/high temperature conditions. Firstly, the paper 
itself has to be activated by washing in 10 mM EDTA for 10 min 
and in 0.5 M NaOH for 5 min. The paper was then washed repeatedly 
in dH20 and stored at 4°C until required (up to several months). To
isolate a particular DNA band, a linear incision was made in the gel 
in front of the band (with respect to direction of migration), and a 
piece of activated paper inserted. The gel was run for a further 10 
min at 75 V. The paper (with the DNA on the surface) was then 
removed and washed three times in 500 pJ of low salt NET buffer. 
200 |il of high salt NET was next added and the paper/buffer 
incubated at 68°C for 15 min. The eluate was removed and another 
200 |il of high salt NET was added and the paper re-incubated for 30
min. The eluates were then pooled, ethanol precipitated and the DNA 
resuspended in dH2 0 .
2.27.4 Organic Extraction from L.M.P. Agarose Gels
A weighed slice from a low melting point (L.M.P) gel was placed in a
1.5 ml microfuge tube containing 3 volumes of buffer (1 mM EDTA
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[pH 8.0], 20 mM Tris.HCI [pH 8.0]). The solution was incubated at 
65°C for 5 min, vortexed and cooled slowly to room temperature. 
Phenol and chloroform extractions followed to remove the agarose. 
The upper aqueous phase was ethanol precipitated and resuspended 
in dH2 0 .
2.28 SOUTHERN TRANSFER ANALYSIS
Southern transfer analysis methodology is based on the procedure of 
Southern (1975). This technique was used to probe genomic DNA 
digests to optimise hybridisation conditions prior to screening 
mouse genomic lambda libraries. It was also used to probe 
re s tr ic t io n  enzym e d ig e s te d  la m b d a  c lo n e s  w ith  
oligodeoxynucleotides to locate exons.
Once the DNA had been resolved by electrophoresis and photographed 
alongside a ruler (so that positive bands could be identified later), 
the DNA was transferred by capillary transfer to Hybond-N™ 
membrane under alkaline conditions. One corner of the gel was 
trimmed for orientation purposes. The gel was then immersed in 
0.25 M HCI for 15 min, in denaturing solution (see solutions) for 45 
min, and neutralising solution (see solutions) for 30 min. The gel 
was equilibrated for 5 min in 10X SSC. The transfer of the DNA was 
initiated by placing the gel on a 3MM paper wick (supported by an 
inverted gel former) with both ends in a tank of 10X SSC placed 
underneath. Above the gel, a piece of Hybond-N™ membrane (with a 
corresponding corner trimmed) was placed. Buffer was drawn 
through the wick, the gel, and the membrane by placing a few 
centimetres of absorbent paper towels and a weight on top. After 
blotting overnight, the membrane was rinsed in 2X SSC to remove 
any agarose and baked at 80°C for a minimum of 1 hr. It was then 
ready for probing.
Chapter 2 Materials and Methods
2.29 AQUEOUS HYBRIDISATION CONDITIONS
2.29.1 Hybridisation Using Random Primed Probes
Prior to addition of labelled homologous probe DNA, the filters to be 
probed were pre-hybridised in hybridisation buffer using a Techne™ 
hybridisation oven. The buffer was filtered through a 0.4 jum Nalgene 
filter before the addition of salmon sperm DNA. Typically 1 ml of 
buffer is added per cm2 of membrane (usually 40 ml). The filters 
were pre-hybridised at 60°C for 3 hrs in a Techne™ hybridisation
flask. Labelled, denatured probe DNA was added to 7 ml of
hybridisation buffer and added to the pre-hybridised filters and 
incubated at 60°C for 16 hrs, or overnight.
After hybridisation, the filters were washed in 0.5 litres of 1X SSC,
0.1% (w/v) SDS at 60°C for 30 min. The washing stringency was
then increased by washing the filters in 0.2X SSC, 0.1% (w/v) SDS at 
60°C for 30 min. The filters were then heat-sealed individually in 
plastic bags and subjected to autoradiography. Should the filters 
need to be re-probed, the filters are stripped (if they have been kept 
moist since hybridisation) by the addition of 0.5 litres of boiling 
0.1% SDS solution and placing the submerged filters on a shaking 
platform until the solution cools to room temperature.
2.29.2 Hybridisation Using Oligodeoxynucleotide 
Probes
Filters were pre-hybridised in 20 ml of oligodeoxynucleotide 
hybridisation buffer at 45°C typically for 1 hr. The labelled 
oligodeoxynucleotide probe was added to 7 ml of hybridisation 
buffer and placed in a Techne™ hybridisation flask at 45°C for a 
minimum of 4 hrs. The filters were then washed once in 4X SET (see 
solutions), 0.1% SDS for 5 min at a temperature 5°C below the 
temperature at which the hybridisation had been performed, then 
secondly washed in the same buffer for 5 min at the same
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temperature at which the hybridisation had been performed. Filters 
were then sealed and subjected to autoradiography as above. 
Oligodeoxynucleotide-probed filters are stripped by addition of 0.1% 
SDS solution, heated to 80°C and allowed to cool to room 
temperature on a shaking table.
2.30 MANUAL DNA SEQUENCING
Manual DNA sequencing was carried out by the dideoxy termination 
method (Sanger et al, 1975), using double-stranded template. A 
Sequenase™ kit supplied by United States Biochemical Corp. (USB) 
was used. Template was prepared with 'Magic Minipreps™'. Buffers 
and mixes used below supplied by USB Corp.
Annealing: 1 pj of 1 M NaOH and 1 |nJ of 10 ngjxl” 1 primer was added 
to 5 p.l (3/4 pg) of template DNA and incubated at 37°C for 10 min to 
denature the template. 1 pJ of 1 M HCI and 2 pJ of 5X sequenase 
buffer was added (to neutralise the reaction) and incubated at 37°C 
for 10 min. The reaction was then chilled on ice for up to 2 hrs.
Labelling: To the chilled reaction, 1 jxl of 0.1 M DTT, 2 jllI of dilute 
labelling mix (diluted 1:5 in dh^O), 0.5 pJ of [a 35S]-dATP (1000 
Ci/mmol), and 2 p,l of dilute Sequenase enzyme (diluted 1:8 in 
enzyme dilution buffer) was added. The reaction was then incubated 
at room temperature for 2-5 min.
Term ination: 3.5 pi aliquots of the labelling reaction were added to
2.5 pi a liquots of the four pre-warmed dideoxy nucleotide 
termination mixes (ddGTP, ddATP, ddTTP, and ddCTP at 37°C). These 
reactions were incubated at 37°C for exactly 5 min then halted by 
the addition of 5 pi Stop Mix (which contains loading buffer, see 
Amersham Sequenase version 2.0 squencing kit protocol).
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2.30.1 Acrvlamide Sequencing Gels
2.5 jil of each of the four sequencing reactions per template was
loaded on an 8% acrylamide/7M urea sequencing gel, prepared for use
with a IBI-supplied 'Base-Runner™' apparatus. The samples were
heated to 80°C for 5 min prior to loading. The electrophoresis was
powered by a Pharmacia LKB multidrive powerpack operating at
*
2500 V, 60 W, and 20 mA. When resolved, the gel was transferred to 
3MM paper, vacuum dried (using a Hoeffer S.E. Ltd. gel drier), then 
incubated with autoradiographic film for between one and seven 
days. Sequence was then read directly from the autoradiograph when 
illuminated on an IBI digitizer lightbox.
2.31 AUTOMATED DNA SEQUENCING
2.31.1 Preparation of Template
A 5 ml E. coli culture was grown overnight in terrific broth with the 
appropriate antibiotic. Two 1.5 ml aliquots were pelleted and 
resuspended together in 200 pi of BDI buffer. 200 pJ of BDII buffer 
was added, mixed and incubated on ice for 5 min. 300pl of BDIII was 
next added, mixed and incubated on ice for 5min. Cellular debris was 
removed by centrifugation at room temperature for 10 min at 12,000 
x g. RNAase was added to a concentration of 20 pgm l-1 and 
incubated at 37°C for 20 min. The solution was then extracted with 
chloroform twice, ispropanol precipitated, washed in 70% ethanol 
and vacuum dried for 3 min. The pellet was dissolved in 32 pi dh^O
then precipitated with 8 pi of 4 M NaCI and 40 pi of 13% PEG. The
DNA was again pelleted at 12,000 x g for 20 min at 4°C, washed in 
70% ethanol, vacuum dried for 3 min then resuspended in 20 p I dH20.
2.31.2 Cycle Sequencing
This sequencing method is based on the incorporation of fluorescent 
dye-labelled terminator nucleotides into the synthesized DNA. All
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four termination reactions are performed in the same reaction tube
(0.5 ml thin-walled reaction tube). DNA cycle sequencing was
performed on a Perkin Elmer Cetus Ltd. GeneAmp 9600 PCR system.
The sequencing reagents were supplied as a Taq  DyeDeoxy™
Terminator cycle sequencing kit by Applied Biosystems Inc. (Refer
to Applied Biosystems Inc. automated sequencing training manual for
detailed cycle sequencing reaction reagents used and the ir
*
concentrations). The optimised cycle sequencing programme is 
detailed below.
The reaction was first incubated at 96°C for 2 min prior to thermal 
cycling.
- Rapid thermal ramp to 96°C.
- 96°C for 10 sec.
- Rapid thermal ramp to 50°C.
- 50°C for 5 sec.
- Rapid thermal ramp to 60°C.
- 60°C for 4 min.
This cycle was repeated 25 times, then the reactions were ramped 
to, and retained at, 4°C. The extension products then undergo spin 
column purification prior to loading on a sequencing gel using a NBL 
Centriflex™ gel filtration cartridge. Firstly the column is prepared 
by centrifugation at 1500 xg for 2 min to pack the column and to 
expel storage buffer into a centrifugation tube. The column is 
transferred to a fresh tube and the cycle sequencing sample is 
loaded onto the column. The column is centrifuged at 1500 xg for 4 
min and the eluate is precipitated with 65 jil of ethanol/3 M sodium 
acetate (12:1 v/v) and pelleted by centrifugation at 11000 x g for 5 
min. After a 70% ethanol wash, the pellet is air-dried for 10 min. 
The DNA is resuspended in 4 pj of loading buffer (supplied with cycle 
sequencing kit).
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2.31.3 Automated Sequencing Gel Electrophoresis and 
Analysis
Cycle sequencing reactions were resolved on a 6% acrylamide/urea 
gel. The sequencing machine used was an Applied Biosystems Inc. 
373 system where 32 samples, each comprising the four termination 
reactions, could be electrophoresed simultaneously. The collected 
data was analysed using Genejockey n  software. The collected 
data is presented as a graphical representation of the fluorescence 
of each of the four fluorescent nucleotides incorporated into the 
DNA template during cycle sequencing. The software package allows 
translation of the graphical information into a readable G,C,A or T 
format. Sequence can then be easily manipulated at the computer 
terminal. Quality sequence can then be selected for further analysis 
and immediate restriction mapping. The selected sequence can also 
be used to identify analogous or sim ilar sequences by way of 
database searches.
2.32 OLIGODEOXYNUCLEOTIDE MANIPULATIONS
Oligodeoxynucleotides of 20-30 bases were used as probes in 
aqueous hybridisations or w e re . annealed to generate linkers which 
were cloned as a means of introducing restriction sites into 
plasmids. Deoxyolig.onucleotides were synthesized on an Applied 
Biosystems DNA synthesizer or commercially by Cruachem Ltd. The 
commercially synthesized oligodeoxy-nucleotides were supplied as 
quantified, previously deprotected DNA pellets.
2.32.1 Deprotection of Oligodeoxynucleotides
The oligodeoxynucleotides synthesized using the departmental 
machine had to be deprotected by removing the glass beads (to which 
the DNA is bound) from the synthesis column and placing them in 1
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ml of 30% aqueous ammonia hydroxide in a nunc™ tube. This solution 
was incubated at room temperature for 2 hrs. The beads were then 
pelleted and the supernatant removed and kept. To the supernatant, 
another 1 ml of 30% aqueous ammonia hydroxide was added and 
incubated at 50°C overnight. This deprotected oligo in ammonia 
hydroxide solution was then stored at -20°C until the 
oligodeoxynucleotide was required whereupon the solution was 
ethanol precipitated, centrifuged and resuspended in dH2 0
2.32.2 Annealing Oligodeoxynucleotides to Generate 
Linkers
To introduce a particular restriction enzyme recognition sequence at 
a chosen locus in a DNA sequence, a pair of oligodeoxy-nucleotides 
of approximately 25 bases were designed and synthesized. The 
oligodeoxynucleotides were annealed to generate a double stranded 
linker sequence for sub-cloning. The oligodeoxynucleotides were 
complementary to each other for most of their sequence except for a 
few bases at the ends which would protrude when the 
oligodeoxynucleotides were annealed. The protruding bases were 
specifically designed to create double stranded termini which were 
compatable with term ini generated by a particular restriction 
enzyme. Ligation of linker to a selected, restricted DNA fragment 
was therefore possible. The oligodeoxynucleotides, when annealed, 
were designed so that a particular restriction enzyme recognition 
sequence was included between the linker termini. The introduced 
restriction site could then be used for further fragment sub-cloning.
The deoxyoligonucleotides were annealed by mixing 1 p.g of each DNA 
in a total volume of 100 \i\ and incubating for 10 min in a water bath 
at 70°C. The reaction was then allowed to cool to room temperature 
slowly by simply turning off the water bath. The reaction tube was 
left in the water bath overnight, so that the reaction would cool at 
the same slow pace as the water. The annealed oligodeoxynucleotide 
linkers were then phosphorylated with T4 polynucleotide kinase 
prior to ligation (see section 2.22).
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9.33 AUTORADIOGRAPHY
Autoradiography was performed in metal cassettes (medical chest 
X-ray type). The films used were Fuji medical X-ray film, and 
Amersham Hyperfilm™ (for sequencing and in situ studies). The 
intensity of the autoradiographic images was enhanced when the 
cassettes were placed at -70°C to expose in the presence of DuPont 
Cronex Lightening Plus intensifying screens. Amersham Hyperfilms 
were developed by hand and the regular Fuji films using an X-ograph 
Compact-X2 developing machine.
2.34 POLYMERASE CHAIN REACTIONS
Polymerase chain reactions were performed on genomic DNA, 
bacteriophage clones and plasmid DNA. A Perkin Elmer Cetus 'DNA 
Thermal Cycler' was used. The reaction constituted:
- 200-500 ng template DNA (denatured at 95°C for 5 min).
- 50 ng of each oligodeoxynucleotide primer.
- 2.5 |jl I Promega 10X Taq buffer (final 1X conc.).
- 0.5 fj\ 10 mM dNTP nucleotide mix.
- 0.5 jul Promega Taq polymerase (1 0u /jjI ).
- dH20 to 25 jiil.
- overlay with 20 jul of mineral oil to prevent evaporation.
The primers (18-25 bases) were designed so that their melting 
temperatures were roughly equivalent and in the range 55-65°C and 
their G+C content was ideally 50%. The first test PCR reactions 
were performed at low stringency conditions. The stringency is 
influenced by the annealing time and temperature, the magnesium 
ion concentration, the primer to template DNA ratio, the reaction 
extension time and the number of cycles. When a PCR product band 
of the expected size appeared (determined by gel electrophoresis), 
the reaction was optimised to reduce spurious background bands.
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The previously described stringency parameters were altered to 
achieve this.
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2.3S PREPARATION OF RNAase-FREE (R.F.) SOLUTIONS
For in situ hybridisation experiments, RNAase-free solutions were 
required. Diethyl pyrocarbonate (DEPC) is used to remove any 
RNAase from water, salt buffers, and the other solutions used in in  
situ hybridisation buffer. Under air extraction conditions, 0.5 ml of 
100% DEPC (w/v) is added per litre of the solution which is to be 
treated and the mix is shaken vigorously. The bottle of solution
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undergoing DEPC treatment is then left overnight in an operating 
fume hood with the bottles screw-cap loosened slightly. A fter 
autoclaving the solution is considered RNAase-free and ready for 
use.
Appendix I: Solutions
Please find below a list of the buffers which were made (rather than 
purchased commercially), and which were used in the experiments 
detailed in this text. The composition of those buffers and the pH 
values (where relevent) are given.
(1) Mini-prep column wash buffer. 200mM NaCI, 20mM Tris, 5mM
EDTA. Mixed 1:1 with 100% ethanol prior to use.
(2) Birnboim-Dolv solution P1 (BDh. (Lysis buffer) 50mM Glucose,
10mM EDTA, 25mM Tris (pH 8).
(3) Birnboim-Dolv solution P2 (BDIh. (Denaturing buffer) 0.2M NaOH,
1% SDS. This solution is freshly made prior to use.
(4) Birnboim-Dolv solution P3 (BDIIh. (Neutralising buffer) 5M KAc.
For 100ml; 60ml 5M KAc, 11.5ml glacial acetic acid, 28.5ml 
dH20. Stored at 4°C.
(5) Denaturing solution (Aaarose aelsl. 1.5M NaCI, 0.5M NaOH. Stored
at room temperature.
(6) Neutralising solution (Aaarose aelsl. _ 3M NaCI, 0.5M Tris (pH 7.6).
(7) 2QX SSC. 3M NaCI, 300mM Na3 Citrate, pH to 7.0.
(8) Pre- and Hybridisation buffer. 5X SSC, 0.1% SDS, 5X Denhardts
solution, 100p.g/ml denatured salmon/herring sperm DNA, 5% 
dextran sulphate.
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(9) 5QX Denhardts solution. 5g Ficoll, 5g polyvinylpyrolidone, 5g BSA
(bovine serum albumin), made up 500ml with dH20.
(10) Deoxyoliaonucleotide hybridisation buffer. For 50mls, 500jil 
10% SDS, 2.5g dextran sulphate, 5ml 50X Denhardts solution, 
10ml 20X SET, 1 ml 1M phosphate buffer (pH 6.8).
( 1 1 )!
(12) 20X SET buffer. To 1.51 dH20, add 350.64g NaCI, 96.88g Tris,
14.89g EDTA, then dH20 to 2 litres and pH to 8.0 with HCI.
(13) Low salt NET buffer. 100mM NaCI, 0.1 mM EDTA, 20mM Tris (pH 
8.0).
(14) High salt NET buffer. _ 1M NaCI, 0.1 mM EDTA, 20mM Tris (pH 8.0).
(15) Transformation buffer (TFBT 100mM rubidium Chloride, 10mM
MES, 45mM manganese chloride, 10mM calcium chloride, 3mM 
hexaminocobaltic acid.
(16) QBT buffer. 750mM NaCI, 50mM MOPS, 15% ethanol, pH7.0, 0.15%
triton X-100.
(17) QF buffer. IMNaCI. 50mM MOPS, 15% ethanol, pH 7.0.
(18) QC buffer. 1.25M Nal, 50mM MOPS, 15% ethanol, pH 7.0.
(19) 50X TAE. 242.5g Tris, 18g sodium acetate, 18g Na2EDTA.2H20 
made up to 1 litre with dH20 , pH 8.3.
(20) Extraction buffer. lOmM Tris-HCI (pH 8.0), 0.1 M EDTA (pH 8.0),
0.5% SDS, 20{igml-i boiled RNAase A.
(21) TE buffer. 10mM Tris-HCL, 1mM EDTA, pH 8.0.
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(22) 10X Kinase buffer. 0.5M Tris-HCI (pH 7.6), 100mM magnesium 
chloride, 50mM DTT, 1mM spermidine, 1mM EDTA.
(23) 1QX MOPS. 42g morpholinopropane sulphonic acid, 6.8g sodium 
acetate, 3.7g Na2 EDTA (pH 8.0) made up to 1 litre with distilled 
water.
*
(24) Aaarose gel loading buffer. 0.025% (w/v) bromophenol blue, 
0.025 (w/v) xylene cyanol, 25% (w/v) ficoll, 0.5% (w/v) SDS, 
50mM EDTA.
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CHAPTER 3 
RESULTS: CLONING
INTRODUCTION
This chapter describes the steps taken to clone the mouse 
preprotachykinin-A (PPT-A) gene and the neurokinin-1 receptor (NK- 
1R) gene which was formerly known as the substance P receptor 
(SPR) gene. The isolation of bacteriophage clones containing either 
PPT-A or NK-1R genomic sequence from a bacteriophage lambda 
library is described. The design of the DNA probes, the optimisation 
of the hybridisation conditions and the result of the library 
hybridisations are described and illustrated. This chapter is divided 
into two sections, the first dealing with the PPT-A gene and the 
second with the NK-1R gene.
CLONING THE MURINE 
PPT-A GENE
3.1 PPT-A PROBE DESIGN FOR GENOMIC LIBRARY SCREENS
The identification of positively-hybridising PPT-A bacteriophage 
clones from genom ic lambda libraries required a su itab le  
homologous sequence of genomic PPT-A DNA for use as a probe. No 
subcloned PPT-A genomic or cDNA sequence from either mouse or rat 
was available to allow the selection of a suitable probe. A 
polymerase chain reaction (PCR) based approach was adopted to 
generate a probe using mouse genomic DNA as the PCR template. 
Genomic DNA was prepared as described in section 2.16. From the
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published rat genomic DNA sequence (Carter e ra /, 1990), PCR 
primers were selected to amplify an exon-spanning sequence of the 
mouse PPT-A gene. Primers were designed to ideally be between 18 
and 28 bases in length, have a guanine/cytosine content of 50%, and 
to hybridise to loci separated by less than 1500 bp on the genomic 
template. Primers were selected which hybridised to highly 
conserved genomic regions, preferably within exons, and which 
would not anneal to each other to form 'primer dimers'. PCR 
products of a size within this range are synthesised routinely and 
were considered ideal in length for use as library hybridisation 
probes. Three different pairs of PCR primers were tried at low 
through to high PCR stringency conditions (see Section 3.1.4). These 
primers failed to generate PCR products of the predicted size. This 
was calculated from the published rat genomic DNA sequence (Carter 
et al, 1990). There is approximately 95% homology between rat and 
mouse species. The possibility therefore existed that, when mouse 
genomic DNA was used as template, the size of the subsequent PCR 
product could have been marginally different from that generated 
using the same primers but with rat genomic DNA as template. No 
bands of even an approximately similar size were generated using 
mouse DNA template. The fourth pair of primers to be tried were 
successful and generated a rat PCR product of the expected size 
(514 bp including the primers). The successful PCR primers were 
called CS6 and CS7.
3.1.1 Polymerase Chain Reaction Primer CS6
Primer CS6 is a 24-mer with a guanine/cytosine to adenine/ 
thymine (GC:AT) ratio of 10:14, and a melting temperature (Tm) of 
68°C. The Tm of PCR primers were calculated by summing the 
number of bases. A value of 4°C was allocated to each guanine or 
cytosine residue and 2°C to each adenine or thymine residue. The 
primer Tm can be calculated precisely using a formula (Erlich, 
1989). Primer CS6 hybridises to the centre of PPT-A exon 3 (97 bp 
in rat), and to the sense strand, priming 5'-3' (see Figure 3.1). The 
sequence of primer CS6 is identical to the rat genomic sequence and 
differs from the bovine sequence by 1 nucleotide (see Figure 3.1).
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This single base degeneracy does not alter the amino acid (leucine) 
translated from this codon in exon 3 of the rat (and cow) PPT-A 
genes. As a result of the expected high degree of homology with the 
corresponding mouse sequence, this primer was a strong candidate 
for successful PCR amplification using mouse DNA template.
Figure 3.1: Primer CS6 Sequence Homologies
(a) Primer CS6: Rat Genomic DNA and Amino Acid Sequence.
5 ' CCTCAG CAG TTCTTTG G ATTAATG  3 ' 
P r o G ln G ln P h e P h e G ly L e u M e t
(b) Corresponding Bovine DNA and Amino Acid Sequence.
5 ' C C TCAG CAG TTCTTTG G ATTG ATG  3 '
P r o G ln G ln P h e P h e G ly L e u M e t
(C) 1 1 0  2 0  3 0  4 0  5 0
5 ' tctagG AG G AAATG CCCG AG CCCTTTG AG CATCTTCTG CAG AG AATCG CTCG G AG A
i i i i i + i i i i i i i i i + i i i i i i i i r + i i i i i i i i i + i i i i i i i i i + i i i i i i t i i +
agatcC TCC TTTA CG G G C TCG G G A A AC TC G TA G A AG AC G TC TC TTA G C G A G C C TCT  
I  Start of rat PPT-A exon 3.
6 0  C S6 P r i m e r  8 0  9 0  9 5
CCCAAGCCTCAG CAG TTCTTTG G ATTG ATG G G C A A A C G G A T G C T G q ta a a a t 3 '
I I I I I I I I I + I I I I I I I I I + I I I I I I I I I + I I I I I I I I I + I I I I I I I I I + I I
G G G TTC G G A G TC C TC A A G A A A C C TA A C TA C C C G TTTG C C TA C G A C cactcta
Figure 3.1: (a) Rat genomic DNA sequence and corresponding amino acid sequence of 
PCR primer CS6. (b) Bovine genomic DNA sequence and corresponding amino acid 
sequence of PCR primer CS6. (c) DNA sequence of the 95 bp rat PPT-A exon 3. Bold 
and underlined sequence denotes the site where PCR primer CS6 hybridises. Capital 
letters denote exonic sequence and small case letters denote intronic sequence.
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3.1.2 Polymerise Chain Reaction Primer CS7
Like primer CS6, primer CS7 was a 24-mer but with a GC:AT ratio of 
11:13 and therefore a melting temperature of 70°C. This primer
hybridises to the 3' end of PPT-A exon 4 (which is 45 bp in rat) and
to the anti-sense DNA strand, priming 3 -5 ’ (as shown in Figure 3.2 
below). The sequence of this primer has 100% identity in both rat 
(Carter et al, 1990) and cow (Kotani et al, 1986) genomic DNA. This 
primer was also a good candidate for success ful PCR of the PPT-A 
gene with mouse genomic DNA template.
Figure 3.2 : Primer CS7 Sequence Homologies.
(a) Primer CS7: Rat Genomic DNA and Amino Add Sequence.
3 ’ CACCGGGACAATTTCCGGGAAATA 5 ’
V a lA la L e u L e u L y s A la L e u T y r
(b) Corresponding Bovine Genomic DNA and Amino Acid Sequence.
3 ' CACCGGGACAATTTCCGGGAAATA 5 ’
V a l A la L e u L e u L y s A la L e u T y r
(C)
5 ’ tcagA T T C C TC A A T TG A A A A G C A A G T G G C C C T G T T A A A G G C C C T T TA T G g taa  3 ’
I I I I + I I I I I I I I + I I I I I I I I I + I I I I I I I I I + I I I I I I I I I + I I I I I I I I I
3 ’ a a tc T A A G G A G T T A A C T T T T G C T T CACCGGGACAATTTCCGGGAAATAC c a t t  5 '
I  P r i m e r  CS7
S t a r t  o f  r a t  P P T -A  e x o n  4 .
Figure 3.2: (a) Rat genomic DNA sequence and corresponding amino acid sequence of 
PCR primer CS7. (b) Bovine genomic DNA sequence and corresponding amino acid 
sequence of PCR primer CS7. (c) DNA sequence of the 45 bp rat PPT-A exon 4. Bold 
and underlined sequence denotes the site where PCR primer CS7 hybridises. Capital 
letters denote exonic sequence and small case letters denote intronic sequence.
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3.1.3 Genomic Template Polymerase Chain Reactions
Polymerase chain reaction conditions are described in section 2.34. 
PCRs using primers CS6 and CS7 were conducted using rat genomic 
DNA as template in a bid to determine, in the first instance, whether 
or not the primers would successfully anneal to and consequently 
generate a PCR product of the expected size from template which 
was known to be 100% homologous.
At the annealing temperature of 64°C, the primers were successful 
and generated a single PCR product band of approximately 514 bp as 
visualised by electrophoresis on a 1% agarose gel. Each of the PCR 
reactions contained 500 ng of genomic DNA as template, and 25 ng of 
each primer. Control reactions included (a) reactions minus 
template and (b) reactions with only one or the other primer (as 
shown in Figure 3.3).
The successful rat genomic PCR reaction was repeated under the 
same conditions using mouse and then human genomic DNA as 
template. In both cases a single PCR product band of the expected 
size (approximately 514 bp) was generated. The same experimental 
controls were included as for the original rat genomic PCR.
3.1.4 Optimisation of Genomic PCRs
Non-specific PCR products are responsible for the background smear 
visualised when a sample of the PCR reaction is electrophoresed on 
an agarose gel. To reduce the amplification of non-specific PCR 
products, the stringency of the reaction was increased. By 
increasing the annealing temperature of the reaction incrementally 
by 1 °C, an optimal temperature of 68°C was found where minimal 
non-specific products were synthesized. An increase or decrease in 
[M g2+] concentration, genomic DNA template concentration or primer 
concentration did not affect the degree of background amplification 
significantly for this particular PCR.
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Figure 3.3 : Genomic DNA PCR Reactions
F ig u re  3.3: Rat, mouse and human genomic DNA PCR with primers CS6 and CS7.
(a) Rat genomic DNA template. Lane 1; 123 bp ladder, Lane 2; no template DNA, Lane 
3; primer CS6 only, Lane 4; primer CS7 only, Lane 5; test with 0.5 n9 template DNA, 
Lane 6; test with 1 jig template DNA. Lane7; 123 bp ladder.
(b) Mouse genomic DNA template. Lane 1; 123 bp ladder, Lane 2; no template DNA, 
Lane 3; primer CS6 only, Lane 4; primer CS7 only, Lane 5; test with 0.5 ng template 
DNA, Lane 6; test with 1 n9 template DNA., Lane 7;123 bp ladder.
(c) Human genomic DNA templates. Lane 1; no template DNA, Lane 2; primer CS6 
only, Lane 3; primer CS7 only, Lane 4; other test sample, Lane 5; other test sample, 
Lane 6; other sample, Lane 7; 0.5 ng template DNA, Lane 8; 123bp ladder.
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The successfully optimised mouse genomic PCR was repeated on a 
larger scale and e lectrophoresed.
The 514 bp band was excised and the DNA recovered
as
described in section 2.27.1. The recovered 514 bp PCR product was 
used as template for a further PCR reaction. Using this template, as 
opposed to genomic DNA, helped to reduce the number of non­
specific loci to which the primers could anneal. This increased the 
proportion of specific, expected PCR product relative to the non- 
specifc product which was synthesized utilising loci outwith the 
PPT-A gene sequence. The number of background PCR products was 
thus negligible while the 'purity' of the resulting PCR product was 
increased significantly. Under optimal PCR conditions, mouse, rat 
and human genomic DNA template continued to produce single bands 
of the predicted size.
F ig u re  3.4: Optimised Mouse Genomic DNA PCR Reactions
F ig u re  3.4: Optimised mouse genomic DNA template PCR (primers CS6 and CS7).
Lane 1; 123 bp ladder, Lane 2; 1 jil of PCR reaction (100 ng of mouse genomic DNA 
template in 20 p.l volume), Lane 3; 3 \i\ of PCR reaction (100 ng of mouse genomic 
DNA template in 20 i^l volume).
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A PCR product of predicted size does not conclusively demonstrate 
the authenticity of the PCR product. In order to verify that the PCR 
product was indeed an amplified PPT-A sequence, it was deemed 
necessary to subclone the PCR product and use DNA sequencing and 
endonuclease restriction analysis to ensure the product was from 
the correct amplified genomic location and therefore suitable for 
use as a hybridisation probe for the isolation o f, PPT-A-specific 
clones from a bacteriophage library. It was expected that the 
mouse PCR product sequence and restriction profile should resemble 
the equivalent published rat and bovine data.
3.1.5 Subcloning the Genomic PCR Products
Genomic PCR products were cloned into the plasmid vector pDK101 
which is a modified version of the pGEM5Zf(+) plasmid (Promega 
Corp.). This vector is also known as 'T-vector' (Kovalic, 1991) 
because of the single thymine residue which protrudes from the DNA 
strand at each end of the plasmid when it is linearized with the 
restriction endonuclease Xcm I (supplied by New England Biolabs 
Ltd). PCR products often have a single, protruding adenine residue 
gratuitously added to each end of the product by the Taq polymerase 
modifying enzyme used in polymerase chain reactions (but not 
always, Hu et al, 1993). The respective complementary overhanging 
thymine and adenine residues under DNA ligation conditions promote 
ligation of the PCR product to the plasmid vector and therefore the 
generation of recombinant DNA molecules (subclones).
3.1.5.1 Preparation of DNA Fragments for Liaation
The pDK101 plasmid was grown under ampicillin selection, and the 
DNA was isolated using the Qiagen Midi-Prep System as described in 
section 2.17.2.2. The vector plasmid was then linearized with Xcm I 
and electrophoresed on a 0.7% TAE/low melting point agarose gel. 
The restricted DNA fragment was recovered from the agarose slice 
using the Isogene™ method (section 2.27.1). The linear vector was 
dephosphorylated using calf intestinal alkaline phosphatase (section 
2.22.1), and was subsequently used in ligation reactions after the
Chapter 3 Results: Cloning
phosphatase enzyme was removed by phenol/chloroform extraction 
(section 2.23). If the phosphatase is not removed, the enzyme would 
proceed to dephosphorylate the insert fragment in the ligation 
reaction and therefore drastica lly reduce the frequency of 
successful ligation of insert to vector.
The insert fragments for ligation into the prepared vector, (the 
mouse and rat PCR products), were electrophoresed, excised and 
recovered in the same way as for the pDK101 vector (detailed 
above). However they were not dephosphorylated. The purified PCR 
products were synthesized by using previously band-isolated PCR 
product as template, as described above, to reduce the probability of 
cloning PCR artefacts.
3.1.5.2 Liaation of PCR Product into pDK101
The conventional method (as opposed to a ligation kit) was used to 
ligate the mouse and rat PCR products to pDK101 vector plasmid 
(section 2.21.1), where 100 ng of vector and 100 ng of insert (or 
multiples thereof) were added to each ligation in a total volume of 
10 |il. An insert to vector molar ratio of 3:1 was considered likely 
to generate the highest number of successful recombinants. A 
different PCR product (e t l-1, from Dr. P. Sheils, University of 
Glasgow), which had previously been cloned successfully was used 
as a control ligation insert. Controls lacking ligase enzyme were 
also included.
3.1.5.3 Transformation of PCR Product Ligations
The lig a tio n s  were p h e n o l/ch lo ro fo rm  ex tracted  be fore  
transformation because of the relatively high salt concentration in 
the ligation mix. This can reduce the transformation efficiency by 
causing the electroporation equipment to 'arc' (similar to short- 
circuiting). The ligations were transformed by electroporation 
(section 2.4.2) with competent E. co//XL1-Blue cells and plated on 
a m p + /te t+  agar plates. Transformation controls included: uncut 
plasmid only, cells plus linearized vector only, and a competent 
cells only transformation (plated on amp“/tet~ agar plates). Insert-
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containing recombinant clones were identified by blue/white visual 
selection with the aid of the indicator X-gal and the inducer IPTG. 
The positive and negative controls gave results as expected, and the 
test ligation/transformation plates displayed both blue and white 
colonies. Ten single white colonies were selected for further 
investigation from the mouse and rat PCR product/pDK101 ligation 
test plates. The colonies were streaked on selective plates and 
incubated at 37°C overnight before single colonies were again 
selected. The plasmid DNA was prepared from
these cultures and used as template for manual sequencing.
3.1.6 Analysis of PCR Product Subclones
To determine the authenticity of the PCR product sequences, 
prelim inary restriction fragment size analysis was conducted, 
followed by PCR analysis and DNA sequencing.
3.1.6.1 Restriction Fragment Size Determination
As a preliminary authenticity check, the restriction endonuclease 
N co l was used to release the insert DNA fragment from the vector. 
The insert size was compared to that of the original PCR product by 
electrophoresis. For each of the two PCR product ligations, one 
recombinant plasmid subclone shown to contain an insert of the 
correct predicted size was isolated. They were named pCOL1 and 
pCOL2 and contained the mouse and rat PCR products respectively.
3.1.6.2 Polymerase Chain Reaction Analysis
The subclone plasmids containing putative PCR products were 
further investigated to determine their integrity. The recombinant 
plasmids were used as templates for PCR reactions. The primers, 
CS6 and CS7, and the reaction conditions used were the same as 
those used originally to generate the PCR products prior to 
subcloning. Plasmids pCOL1 and pCOL2 each generated single PCR 
bands of approximately 514 bp as expected.
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3.1.6.3 Sequencing Analysis of Cloned PCR Products
Plasmid pCOL1 was prepared as a double stranded DNA sequencing 
template (section 2.17.1.1). The alignment of the 248 bp of sequence 
obtained from the cloned mouse PPT-A PCR product (pCOL1) was 
aligned with the published PPT-A rat sequence. The percentage 
identity was found to be 87.9% and is shown below.
Figure 3.5: pCOL1 Sequence Aligned with Rat PPT-A Sequence.
1 GATCTATCAGGCTACCTGGTCTGCATGCTTGCTCCTTCCCGGAGAACCCA 50
I I I I I I I I + I I I I I I I I + I I I I I I I I +1 I I I I I I I I + I I I I I I I 1 +
3 0 6  GGTCTATCAGGCTACCCGGTCTGCATGCCTGCTCCTTCCTGGAGCACCCA 3 5 6  
5 1  A A TG TCTCTTGTACTG GG AG TATAGATTTACACG CCTAAAG G CTTTTG AT 1 0 0
I I I I I I I I + I I I I I I I + I I I I I I I + I I I I I I I I + I I I I I I I 1 +
3 5 7  AGTG TC TCTTG TA C CG CG AG TA TA A TTTTA CA TG C C TAA A G A C TTTTG A T 4 0 6  
1 0 1  TTCCCAGAAGTCTTCGATCTACTTCACTAACTCTAGATCGTGGGGGGAGG 1 5 0
I I I I I I I I + I I I I I I I I +1 I I I I I +1 I I I I I 1+ I I I I I I I  1 +
4 0 6  TCCCTGAAGTCTTCGATCCACTACACTTGCACTAGCTCAAAGTGGAGAGG 4 5 6  
1 5 1  GAGGG GGGATCCATTTCTCTTGCTTCACTGCACCAAAGTGATGCAAATTG 2 0 0
I I I I I I I I I + I I I I I I I l + l l l l l l l l  +11.1111 l l  + l I I I I I I  +
4 5 7  GAGGGGGGATCCATTTCCCTTGCTTCACAGCACCAAGGTGACCCAAATTG 5 0 6  
2 0 1  GAAACTAACCTTAGCTAAACAGTCCTCTGACTAAAG ATCAAAATTACA 2 4 8
I I I I I I I I I + I I I I I I I I I + I I I I  I I I + I I I I I I  I I 1+ I I  I I I  I I
5 0 7  GAAACTAACCTTAGCTAAACACTCCCCTGACTAAAGATCCCAATTACA 5 5 4
F igure  3.5: Alignment of 248 bp of plasmid pCOL1 sequence (upper) with published 
rat NK-1 sequence (lower). Plasmid pCOL1 comprises the mouse PCR product 
(Section 3.1.6.2) subcloned into vector pDK101. The published rat NK-1 sequence 
was retrieved from the EMBL database (accession number m34160) and is defined as 
containing the sequence of rat PPT-A exons 3 and 4. NB. The PCR primers used to
generate the (subcloned) PCR product (primers CS6 and CS7) were designed to anneal
to exons 3 and 4 respectively. The (inter-species) percentage identity between the 
published rat and the PCR-cloned mouse sequence is 87.9% over this short stretch of 
sequence.
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Figure 3.6: pCOL2 Sequence Aligned with Rat PPT-A Sequence.
1 ............... . ..CTCAGCAGTTCTTTGGATTAATGGGCAAGCGGGATGCTGGTG 4 2
11 r111111111111111111111111 11111111111 ii
5 1  ACCCAAGCCTCAGCAGTTCTTTGGATTAATGGGCAAACGGGATGCTGGTG 1 0 0  
4 3  AGATGAGCAATAGTCACTAGATCTATCAGGCTACCTGGTCTGCATGCTTG 92
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II
1 0 1  AGATGAGCAATAGTCACTAGGTCTATCAGGCTACCCGGTCTGCATGCTTG 1 5 0  
9 3  CTCCTTCCTG G AG AACCCAAATGTCTCTTGTACTGG GAGTATAGATTTAC 1 4 2
I I I I I I I I I I I I I I I I I I I  I I I I I I I I I I I I I I I I I I I I I I I I I
1 5 1  CTCCTTCCTG G AG CACCCAAGTGTCTCTTG TACCGGCAGTATAATTTTAG 2 0 0
1 4 3  ACG CCTAAAG G CTTTTG ATTCCCAG AAG TCTTCG ACT..................... .. ...........  1 7 9
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
2 0 1 . ATG CCTAAAGACTTTTG ATTCCCTG AAG TCTTCG ATCCACTAACACTTGC 2 5 0
Figure  3 .6: Alignment of 179 bp of sequence from plasmid pCOL2 (upper sequence) 
with the published rat PPT-A sequence (lower sequence). Plasmid pCOL2 comprises 
the rat PCR product (Section 3.1.6.2) subcloned into vector pDK101. The published 
rat PPT-A sequence was retrieved from the EMBL database (accession number 
m34160) and is defined as containing the sequence of rat PPT-A exons 3 and 4. NB. 
The PCR primers used to generate the (subcloned) PCR product (primers CS6 and CS7) 
were designed to anneal to exons 3 and 4 respectively. The percentage identity 
between the published rat and the PCR-cloned rat sequence is 91.1% over this short 
stretch of sequence.
The PCR, sequencing and restriction analysis of the subclones pCOL1 
and pCOL2 did verify their expected authenticity. Subclones pCOL1 
and pCOL2 contained, respectively, the subcloned mouse and rat exon 
3/4-spanning PPT-A PCR products of the expected size and sequence 
identity.
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3.2 TEST HYBRIDISATIONS WITH PPT-A PROBE
Prior to using the above 514 bp PCR-derived PPT-A probe in 
bacteriophage library hybridisation experiments, it was necessary 
to determine the optimal hybridisation conditions for this particular 
probe. Southern analysis was employed to do this, where restricted 
mouse genomic DNA was transferred by capillary blot to a nylon 
membrane (Hybond-N) which was subsequently probed using the PCR- 
derived probe sequence. The stringency of the hybridisation 
conditions, such as the hybrid isation tem perature, the salt 
concentration of the hybridisation buffer, the washing temperature 
and the salt concentration of the wash buffer, was increased 
increm entally. Optimal hybridisation conditions were visually 
determined when there was minimal background hybridisation signal 
and when a strong positive hybridisation signal was visible on 
autoradiographed, probed membranes.
3.2.1 Radioactively-Labelling the PCR-Derived PPT-A
Probe
DNA hybridisation probes are typically radioactively-labelled by the 
random primer extension method (section 2.24.1) using random 
oligodeoxynucleotides (hexamers) as primers. In order to label PCR 
products, the primers used in the original PCR reaction can be used 
as specific rather than random prim ers ('specific prim ing'). 
Alternatively, where a PCR product has been subcloned, it can be 
used as template in a 'hot PCR'. In such cases, the combined dNTP 
mix in the PCR reaction is replaced by three unlabelled nucleotides 
('cold' dATP, dGTP and dTTP for example) and one 'hot' labelled 
nucleotide (7-dCTP for example). This results in simultaneous 
incorporation of the radioactive label and PCR synthesis of the probe 
DNA. Band purification of the 'hot' labelled PCR product follows or a 
sample of the PCR reaction can be denatured and used directly as a 
probe for hybridisations. For the following NK-1 Southern analysis 
experiment and the primary screen of the Glaxo library (section 
3.3.3), the hot PCR method was used, where pCOL1 plasmid was used 
as template. The 'specific priming' labelling method was favoured
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for the secondary screen of the Glaxo library and was used to label 
the PCR-derived probe for all subsequent hybridisations.
3.2.2 Southern Hybridisations with PPT-A Probe
A restricted genomic DNA membrane was prepared for use in test 
hybridisations. To do this 10 pug of mouse and rat genomic DNA was 
restricted with either EcoR I and Pst I. Samples of each reaction 
were checked by electrophoresis to ensure complete digestion as 
demonstrated by the appearance of 'satellite' type bands and a DNA 
'smear' in the restricted sample lanes (see Figure 3.7 below). When 
fully digested, the remaining reaction was electrophoresed
to ensure
adequate separation of the restricted DNA bands over a gel distance 
of 16 cm. The gel was then capillary blotted overnight and the DNA 
fixed to the membrane by ultra-violet cross-linking. The lanes from 
the gel were marked on the membrane to allow alignment and sizing 
of bands later. The membrane was prehybridised in a hybridisation 
oven with 15 ml of hybridisation buffer for 6 hrs at 60 °C.
25 |il of mouse genomic PCR reaction, containing 125 ng of DNA was 
used as probe after denaturation The probe
was added to 6 ml hybridisation buffer and
incubated with the membrane for 14 hrs. There was 20 ng
of probe DNA per ml of hybridisation buffer, with approximately 1.8x 
109 dpm.p,g-1 and incorporation of 70%. After incubation, the filter 
was washed _ then exposed
to autoradiographic film for 24 hrs. This film displayed significant 
non-specific background hybridisation. However, strong positively 
hybridising bands could be seen, where three bands were visible in 
the Psfl digested mouse and rat genomic DNA lanes. The wash 
stringency was then increased to 1.5 x SSC and then to 1 x SSC, 
while the temperature and the duration of the washes remained the 
same. The membrane was again exposed to autoradiographic film for 
24 hrs. The developed film displayed a considerable reduction in 
background signal. The number of. positively hybridising bands in the 
mouse and rat Pst\ digested lanes was also reduced from three to
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one (see Figure 3.8). The PCR-derived PPT-A probe was shown to 
hybridise specifically to mouse (and rat) genomic DNA under these 
hybridisation and washing conditions. These optim ised hybridisation 
conditions were deemed satisfactory to permit the use of this probe 
in bacteriophage library screening experiments.
F ig u re  3 .7  : Electrophoresed. Digested Mouse and Rat Genomic DNA.
F i g u r e  3 . 7 : Electrophoresed, endonuclease digested mouse and rat genomic DNA. 
Lane 1; lambda/HiriD III marker, Lane 2; incompletely digested marker, Lane 3; 10 ng 
rat genomic DNA digested with EcoR I, Lane 4; 10 ng rat genomic DNA digested with 
Psi I, Lane 5; 10 ng mouse genomic DNA digested with EcoR I, Lane 6; 10 ng mouse 
genomic DNA digested with P$t I. (Lanes 3, 4, 5 and 6 are repeated in lanes 7, 8, 9 
and 10, and also lanes 11,12, 13 and 14 respectively).
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F ig u re  3 .8  : Autoradiographs of Southern Blotted Mouse and Rat Genomic DNA
(a)
F i g u r e  3 .8 :  Autoradiographs of EcoR I and Pst l-digested, Southern blotted mouse 
and rat genomic DNA (see Section 2.28). (a) This Southern filter was hybridised with 
the mouse PPT-A exon 3 and exon 4-specific PCR product probe radioactively labelled 
internally by the 'hot PCR' procedure (as described above). This Southern filter 
comprises 4 lanes and is a direct capillary blot of the digested DNAs photographed and 
shown in figure 3.7 (above), (b) This Southern filter was used as a control in the NK-1 
primary bacteriophage library hybridisation which is detailed later in this text (see 
Section 3.3.3.1). Lane 1; 10 i^g mouse genomic DNA digested with EcoR I, Lane 2; 10 
ug mouse genomic DNA digested with Pst I , Lane 3; 10 jj.g rat genomic DNA digested 
with Eco R I, Lane 4; 10 p.g rat genomic DNA digested with Pst I.
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3.3 ISOLATION OF PPT-A GENOMIC LIBRARY CLONES
3.3.1 The Construction and Source of the Genomic
Bacteriophage Libraries
Genomic mouse preprotachykinin-A clones were isolated from two 
separate bacteriophage lambda libraries. Both libraries were 
constructed from strain SVJ129 mouse genomic DNA so that the 
cloned DNA would be com patib le for use in homologous 
recombination experiments using SVJ129 mouse strain embryonic 
stem (ES) cells. A higher targeting efficiency will be found when 
DNA from the same strain as the ES cells into which it is 
transfected, is used. This is due to the high levels of intra-strain 
DNA homology. The first library to be screened by aqueous 
hybridisation and successfully to yield PPT-A clones was a library 
supplied courtesy of Dr. Francois Conquet, Head of the Transgenics 
Unit at the Glaxo Institute of Molecular Biology in Geneva, 
Switzerland. This library was constructed so as to include 
restricted mouse genomic DNA inserts of between 9 kb and 20 kb. 
The genomic DNA was restricted with BamHI prior to size selection 
and vector/insert ligation. The bacteriophage vector was X FIX 
(Sambrook et al, 1988). The second library to be screened 
successfully was supplied courtesy of Dr. Andrew Smith at the MRC 
Centre in Cambridge. This library was also constructed using 
SVJ129 strain mouse genomic DNA, with insert fragments of 
between 9 Kb and 20 Kb cloned into the lambda vector X2001 
(Sambrook et al, 1988). Libraries were supplied as high titre liquid 
bacteriophage suspensions (>1010 pfuji H).
3.3.2 Titre Calculation. Plating and Storage of
Libraries
The concentration of bacteriophage in the original library master 
stock was determined by titration. Having accurately determined 
this, one million bacteriophage were plated as described in Section 
2.12. The quantity of genomic DNA in one million library
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bacteriophage inserts was at least equivalent to one whole mouse 
genome. The probability of cloning any selected mouse genomic 
sequence from this number of bacteriophage is therefore high. One 
hundred thousand (105) bacteriophage were plated on each of ten 
245mm x 245mm plates. Each batch of 105 phage were mixed with 
2ml of LE392 cells, incubated at 37°C for 30 min, and added to 30 ml 
of pre-warmed NZCYM top agar. This mixture was poured on to a 
plate and allowed to set prior to incubation overnight at 37°C. Four 
replica lifts using Hybond-N™ membrane (see section 2.14) were 
taken from each plate (two for immediate use, and two for storage). 
When lifts had been taken, the plates were overlayed with 3MM paper 
soaked in 25% (v/v) glycerol, wrapped in parafilm and stored at - 
70°C.
3.3.3 PPT-A Screen of the Glaxo Library
3.3.3.1 Primary PPT-A Screen of the Glaxo Library
Two of the four identical replica filters taken from each of the ten 
bacteriophage plates were pre-hybridised for 4 hrs with 10 ml of 
hybridisation buffer in revolving hybridisation flasks (see section 
2.29). The filters were divided so that one from each pair of replica 
membranes was placed in each of the two flasks. Sufficient probe 
was labelled (and denatured) to generate 10 ml of hybridisation 
buffer containing 100 ng of labelled probe per ml. 5 ml of 
probe/buffer solution was then added to each of the two flasks and 
hybridised. A series of mouse genomic
DNA digests which had been Southern blotted onto Hybond-N 
membrane and had previously been probed successfully were used as 
a positive control. 1 fxI of 100 n g . jil-1 denatured, w ild-type
bacteriophage lambda DNA was spotted on to a piece of Hybond-N
membrane, as was 1pJ of a 10_1, 10'2 and a 10~3 dilution of this DNA,
and then fixed to the membrane by UV cross-linking. Two identical
filters like this were made, one for each flask. These 'dot-blot' 
filters were used as the negative control for this experiment, and 
were placed in the flasks along with the replica and the positive 
control filters. After hybridisation, the filters were washed as
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described in section 3.2 .2 , and placed at -70°C w ith 
autoradiographic film for 3 days. On development, the films 
indicated that 6 ,of the 10 filters (numbers 2, 5, 6, 7, 8 and 10) 
displayed clear positive signals duplicated at the same location on 
the equivalent partner filter (hybridised in a separate flask).
*
Figur 3.9: PPT-A Bacteriophage Clones Isolated from Primary Glaxo Library Screen
Clone Pair of Number of Strength of
Number Library Filters Duplicate Clones Signal
1 No. 2 1 Medium
2 No. 5 1 Strong
3 No. 6 1 Faint
4 No. 7 1 Very Strong
5 No. 8 1 Medium
6 &7 No. 10 2 Both Faint
Figure  3.9: The number and the strength of the hybridisation signals generated by 
PPT-A bacteriophage clones isolated from the Glaxo library in the primary screen.
In total, seven distinct (duplicated) locations on six different 
master plates demonstrated positive PPT-A hybridisation signals 
due to this primary library screen. Using the orientation marks on 
the filters and the autoradiographs, the corresponding areas on the 
m aster plates, from which the hybrid isation signals were 
emanating, were located. A zone of approximately 1 cm2 , 
encompassing the proposed source of the signal, was then cut from 
the master plate using a razor blade. This area was estimated to 
contain 50 distinct bacteriophage plaques (each with potentially a 
different insert), any of which could be the single clone containing 
the PPT-A sequence. This isolate, which contained frozen NZCYM 
medium, bacterial cells and bacteriophage, was placed in 1 ml of 
phage buffer and incubated at 4 °C overnight to resuspend the 
bacteriophage in solution. The low temperature minimised bacterial 
growth.
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3.3.3.2 Secondary PPT-A Screen of the Glaxo Library
The resuspended bacteriophage from the seven master plate isolates 
were titred as before. An appropriate volume of the bacteriophage 
suspension was plated on 125 mm x 125 mm NZCYM plates so as to 
generate two hundred phage plaques per plate. Two replica filter 
lifts were taken from each plate. The f ilte rs ' were probed 
independently in the presence of positive and negative control 
filters (Genomic DNA Southern blots and non-homologous plasmid 
dot-blots, respectively). Of the seven primary clones isolated and 
screened, only five displayed duplicate hybridisation signals at the 
secondary stage. The signals varied in strength and some non­
specific background signal was noted. Positive signals emanating 
from the same location on duplicate filters were selected for 
further, tertiary screening and were isolated.
3.3.3.3 Tertiary PPT-A Screen of the Glaxo Library
The clones isolated from the secondary screen were resuspended and 
titred. The 5 clones were plated again, but at a lower density to 
ensure a phage-free zone of about 0.5 cm between each plaque. For 
each clone, 100 plaques were grown on a plate. The hybrid-isation 
was repeated as before. All five were successfully identified in the 
tertiary screeen and isolated accordingly.
3.3.3.4 Quaternary PPT-A Screen of the Glaxo Library
A quaternary hybridisation was conducted to ensure the purity of the 
isolated clones. Regarding the density of plaques on the tertiary 
plates, the proximity of the plaques to each other was thought, with 
hindsight, to be too close to guarantee the isolation of single 
plaques. This was also a concern because of possible lateral 
diffusion of bacteriophage through the medium from one plaque to 
another. In order to ensure the purity of an isolated plaque, the five 
isolated putative clones from the tertiary screen were re-plated at 
the very low density of twenty plaques per (small square) plate. 
Duplicate lifts from each plate were probed as before. Positive, 
duplicate hybridisation signals were generated by all five clones. On
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one of the five quaternary phage plates, every one of the twenty 
plaques on the plate produced a strong signal (see Figure 3.11 
below). A single plaque at least 2 cm from the nearest neighbouring 
plaque was isolated from each plate. The isolated clones were 
named A. PPT1, X PPT2, X PPT3, X PPT4 and X PPT5.
To ensure that the five purified clones were retained indefinitely, 
two 4°C (liquid) and two -70°C (frozen) stocks were made for each 
clone (see section 2.13). The original phage 'plug' isolated from the 
quaternary plate was also stored at 4°C in the presence of a small 
amount of chloroform should the re-isolation of the clone become 
necessary. The original phage ’plugs' isolated from the primary, 
secondary and tertiary plates described previously were stored at 
4°C in the same way.
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F ig u re  3 .10  : Duplicate Filters from Tertiary PPT-A Screen of Glaxo Library.
•  X
f
F ig u re  3.10: A pair of duplicate filters from the tertiary hybridisation of the 
candidate bacteriophage clones (from the Glaxo library) probed with the PPT-A- 
specific probe. A single duplicate hybridisation signal is located in the centre of the 
filters. This plaque was isolated and was purified further by way of a quaternary 
hybridisation screen (see figure 3.11). 2 day exposure at -70*C.
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3.3.4 PPT-A Screen of the Cambridge Library
Each plaque isolated from the Glaxo library at the quaternary stage 
was used to generate a 100 ml bacteriophage lysate containing only 
one type of bacteriophage. From the lysate, DNA was prepared for 
use in the mouse PPT-A gene characterisation experiments 
described in chapter 4. (The characterisation of the JMK-1R gene is 
also described in chapter 4.) However, at this stage, it suffices to 
say that early characterisation experiments indicated that of the 
five clones isolated, none contained exon 1 or the rest of the 5' 
region of the mouse PPT-A gene upstream of exon 3. Exons 3 through 
to 7 were however included in one or other of the isolated phage 
clones. To characterise the mouse PPT-A gene adequately, it was 
deemed necessary to clone the whole gene and certainly all of the 
seven (expected) exons.
To remedy this, another library, the Cambridge library described in 
section 3.3.1, was screened with the same PCR-derived PPT-A probe 
used for the Glaxo library screens. The probe was labelled by the 
'specific priming' method (section 3.2.1). The Cambridge library was 
titred, plated and stored in the same way as the Glaxo library (see 
section 3.3.2). Twenty pairs of duplicate filter lifts were made 
from the Cambridge library master plates (small square plates). 
They were used in the following hybridisations.
3.3.4.1 Primary PPT-A Screen of the Cambridge Library
The twenty pairs of Cambridge library filters were separated from 
their partner filters and prehybridised independently for 6 hrs at 
60°C in two flasks. Labelled probe was denatured and added to 10 
ml of hybridisation buffer to a concentration of 100 ng of labelled 
probe per ml. 5 ml of probe/buffer solution was then added to each 
of the two flasks aM hybridised. A
series of mouse genomic Southern filters were used as positive 
controls. The filters were washed as before and incubated at -70°C 
with autoradiographic film for three days. From the twenty filter 
pairs, eleven candidate clones were identified which demonstrated 
hybridisation signals emanating from the same approximate location
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on both filters. The clones were isolated from the master plates and 
titred as before.
Figure 3.11: PPT-A Clones Isolated from Primary Cambridge Library Screen
Clone Pair of Number of , Strenath of
Number Librarv Filters Duplicate Clones Sianal
1 &2 No. 8 2 Both faint
3 &4 No.11 2 Strong. Faint
5 No. 12 1 Strong
6 No. 15 1 Medium
7 &  8 No. 17 2 Strong. Faint
9, 10&11 No. 19 3 2 Strong. Faint
Figure  3 .11 : The number and strength of signal generated by the PPT-A bacterio­
phage clones isolated from the Cambridge library in the primary screen.
3.3.4.2 Secondary PPT-A Screen of the Cambridge Library
The secondary screen of the Cambridge library was similar to that 
of the Glaxo library (prehybridise for 4 hours, hybridise for 10 
hours). The filte rs  were washed and incubated w ith 
autoradiographic film for 4 days. Of the 11 primary candidate 
clones, 6 were successfully identified at the secondary stage.
3.3.4.3 Tertiary PPT-A Screen of the Cambridge Library
Five of the 6 clones from the secondary screen generated strong, 
duplicate te rtia ry  hybridisation signals. Single plaques were 
isolated and master stocks made for each (section 2.13). The 5 
clones isolated were named ?iPPT6 through to XPPT10. The 5 clones 
isolated from the Glaxo library together with the five isolated from 
the Cambridge library were used in the characterisation of the 
mouse PPT-A gene as described in Chapter 4 and to generate 
targeting vectors as described in Chapter 5.
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F igu re  3 .12  : Duplicate Filters from the Primary. Secondary and Tertiary PPT-A
Screens of the Cambridge Library
V
*
F i g u r e  3.12: Duplicate filters from (a) primary, (b) secondary and (c) tertiary 
hybridisations of the Cambridge library with the PPT-A probe. Exposure times: for 
the primary, 4 days; secondary, 2 days; tertiary, 24 hrs.
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CLONING THE MURINE 
NK-1R GENE
3.4 DESIGN OF NK-1R PROBE FOR GENOMIC LIBRARY SCREENS
In order to isolate clones containing genomic NK-1R sequence from a 
bacteriophage lambda library, a suitable probe for use in 
hybridisation experiments was required. The previously described, 
PCR-based approach used to generate the NK-1 probe was not 
necessary because a suitable NK-1R cDNA cloned from another 
species (rat) was available. The NK-1R probe was derived from a 
plasmid named prTKR2 which was supplied courtesy of Dr. Shigetada 
Nakanishi at the University of Kyoto, Japan. The 6.4 Kb prTKR2 
plasmid constituted a 3408 bp rat NK-1R gene cDNA insert cloned 
into the 2.9 Kb plasmid vector pBluescript SK(+) (Yokoto etal, 1989).
3.4.1 Sequence analysis of the Rat NK-1R cDNA Sub­
clone prTKR2
The first step in choosing a particular probe, based on the cDNA 
sequence and. the endonuclease restriction profile of that sequence, 
was to determine the authenticity of the prTKR2 insert by sequence 
analysis. The plasmid was prepared for manual sequencing as a 
double stranded template as described in section 2.30. Using the 
chain termination sequencing method (Sanger, 1975) and the 17 
nucleotide deoxyoligonucleotide primer T7 which anneals to the 
polylinker of pBluescript SK(+), 251 bp of sequence was obtained 
from prTKR2 and is shown below. The sequence was then processed 
by a 'FASTA' search of the GENEMBL database. The prTKR2 sequence 
obtained demonstrated a 98.4% identity to the published rat NK-1R 
cDNA sequence. This high percentage identity was demonstrated 
over a 255 bp sequence where the four mis-matched nucleotides in 
the prTKR2 sequence was attributed to sequencing error. That 
sequence and its alignment with the published sequence is shown 
below. The authenticity of the prTKR2 plasmid was verified by the 
sequence analysis.
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Figure 3.13 : prTKR2 Sequence Aligned with Rat NK-1R cDNA.
10 20 ■ 30
prTKR2/T7 CTGGCAGGTGAGAATGCTGTTCCTTTCCGG
l l l l l l l l l l l l l l l l l l l l l l l l l l  II I 
Ratspr ACTTTGCATCCTGAGATGGCTTCAGGACCCCTGGCAGGTGAGAATGCTGTTCCTTTCC-G
1780 1790 1800 1810 1820 1830
40 50 60 70 80 90
prTKR2/T7 TCTCAGATGTGACTGGAAGCGAAAGCTTCATGTGACAT+CGTGAACATCCTCATGGTTCA
11111111 +111111111 +111111111 +1111111111111111111 +1 M 111111 +1
Ratspr TCTCAGATGTGACTGGAAGCGAAAGCTTCATGTGACATCCGTGAACATCCTCATGGTTCA
1840 1850 1860 1870 1880 1890
100 110 120 130 140 150
prTKR2/T7 GATAATTGGATGCACAAAAGCTCTATTCATCGTGTCAGAAAAAACAAGGCNACCCACCAC
I I I I I I I l  + l I  I I I I I I l  + l I  I I I I I I l  + l I  I I I I I I l  + l I  I I I I I I l  + l : I I I I I I l  + l
Ratspr GATAATTGGATGCACAAAAGCTCTATTCATCGTGTCAGAAAAAACAAGGCCACCCACCAC
1900 1910 1920 1930 1940 1950
160 170 180 190 200
prTKR2/T CAGGATTTATAACTTCTGCCAGCCTTGTTGAATCAAACATTTTGAGGACATCGGCAT--C
I I I I I I I I +1 I I I I I I I I +1 I I I I I I I I +1 I I I I I I I I +1 I I I I I I I I +1 I I I I I I I I
Ratspr CAGGATTTATAACTTCTGCCAGCCTTGTTGAATCAAACATTTTGAGGACATCGGCATACC
1960 1970 1980 1990 2000 2010
210 220 230 240 250
prTKR2/T7 TGGAGAAGGCAAGATTTATACAGAAGTAATATAAACCAGAAA
m i  11 i i i i m  i i i i i i i  i + i i i i i i i M + i i i i i  i i i  m
Ratspr TGGAGAAGGCAAGATTTATACAGAAGTAATATAAACCAGAAAAAAAGAAAAGGAAAAGAA
2020 2030 2040 2050 2060 2070
Figure  3.13: 251 bp of sequence from rat cDNA plasmid subclone prTKR2 obtained 
using the T7 sequencing primer by manual sequencing. Alignment of that sequence with 
the published rat NK-1 R cDNA sequence stored in the GENEMBL database. Letters in 
bold denote comparative differences most likely due to sequencing artefacts. Sequence 
identity was found to be 98.4%.
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3.4.2 Restriction Endonuclease 'Mapplot' of prTKR2
A fragment of the 3.4 kb prTKR2 insert was selected for use as the 
NK-1R probe. The chosen fragment was selected so as to comply 
with several criteria. The probe fragment came from the protein 
coding region of the (rat NK-1R) cDNA. Within this region, the 
genomic sequence is most highly conserved between, species. Since 
the effectiveness of the probe is dependent on the degree of 
homology between the probe and the target sequence, this is an 
important factor to consider when selecting a probe sequence. 
Since the probe for the library hybridisation was to be labelled using 
the random primer extension DNA labelling method, the fragment 
should be within the recommended size range (see section 2.24.1). 
The probe fragment was conveniently released from the rest of the 
cDNA insert by restriction with only one endonuclease. To help in the 
selection of a suitable probe fragment, a linear 'Mapplot' of the full 
rat NK-1R cDNA sequence (GENEMBL access number J09057.Gb_Ro) 
was generated with the help of GCG software for the Viglen 
c o m p u te r. This produced a linear representation of the cDNA 
sequence onto which the relative cleavage sites of several 
restriction endonucleases (individually) were added. It became clear 
by visually scanning the restriction patterns which endonuclease 
generated the most appropriate probe fragment.
3.4.3 Selection of the NK-1R Probe Fragment
From the rat cDNA mapplot, several candidate probe fragments were 
considered. The fragment finally chosen was a 965 bp Bsg \-Bsg I 
fragment which originates wholly from within the protein coding 
region of the rat NK-1 R cDNA. The restriction endonuclease Bsg  I 
has a seven base pair recognition sequence, and cleaves eukaryotic 
DNA relatively infrequently. This enzyme cleaves the 3408 bp rat 
NK-1 R cDNA only five times. The 965 bp fragment was the largest 
generated by this restriction where the next largest fragment was 
350 bp. The chosen 965 bp fragment did comply with the 
aforementioned criteria. It was therefore considered appropriate
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for use as the NK-1R probe in hybridisations to identify mouse NK- 
1R clones from a bacteriophage lambda genomic library.
3.5 PREPARATION OF NK-1R PROBE FOR GENOMIC LIBRARY 
SCREENS
3.5.1 Purification of the NK-1R Probe Fragment.
The Bsg I restriction pattern of plasmid prTKR2 predicted by the 
mapplot was confirmed by digestion. The restriction reaction was 
electrophoresed on a 1% agarose gel and the band sizes were 
determined. When the restriction pattern generated by the small 
scale reaction was deemed satisfactory, the digestion was scaled up 
so that 20 p,g of prTKR2 was restricted in one reaction. The large 
scale reaction was electrophoresed
The 965 bp fragment was isolated from the gel with a 
scalpel and the DNA recovered from the gel
method (see section 2.27.2). After precipitation, the
recovered DNA was resuspended in dh^O to a concentration of 50 
ng.jd as determined by a spectrophotometer and was ready for 
labelling.
3.5.2 Radioactively-Labelling the NK-1R Probe
The purified 965 bp NK-1R probe fragment was labelled using the 
random prim er extension method (section 2.24.1). Random 
deoxyoligonucleotides were used as primers where the DNA was 
labelled to a specific activity of 1.8 x 109 dpnp'jig. Prior to use, the 
labelled probe was denatured
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3.5.3 Test Hybridisations with NK-1R Probe
As a means of determining the proficiency of the labelled NK-1R 
probe to hybridise to NK-1R sequences and differentiate between 
those and non-NK-1R sequences, a test hybridisation was conducted. 
This experiment tested whether or not the hybridisation conditions 
which had been optimised previously for the NK-1' library screen 
(section 3.3.2) would be suitable for the NK-1R probe. DNA which 
was known to contain NK-1R sequence (prTKR2 plasmid, above) and 
DNA which was known not  to contain NK-1R sequence (plasmid 
pCOL1, section 3.1.6.1) was spotted on to a Hybond-N™ nylon 
membrane. 1 pi samples from each of a series of DNA dilutions, 
ranging from 100 ngpl down to 0.1 ngfil, were denatured and spotted 
onto the membrane and fixed by baking (a "dot blot"). The
probe was 100 % homologous to, and was therefore expected to 
hybridise to, the prTKR2 DNA whereas the pCOL1 DNA acted as the 
negative control.
The dot blot was pre-hybridised for 4 hours. 50 ng of the 965 bp 
prTKR2/Bsg I DNA fragment was labelled as described above. The 
probe was added to 8 ml of
hybrid isation buffer to a concentration of 50 ng.ml. The 
hybridisation was incubated at 60 °C and washed at the
same stringency as for the NK-1 library screens described 
previously (section 3.2). The membrane was incubated with 
autoradiographic film for 2 days. When developed, the film clearly 
demonstrated that the probe positively hybridised to the DNA 
containing NK-1R sequence down to the 0.1 ncjfjJ level, but not to the 
DNA lacking NK-1R sequence at any level. The hybridisation 
therefore demonstrated that the labelled NK-1R probe could 
distinguish specifically between NK-1R and non-NK-1R sequences 
under these hybridisation conditions. It was not necessary to 
optimise a set of hybridisation and washing conditions specifically 
for the NK-1R probe. Consequently, the hybridisation and washing 
conditions used to screen the Glaxo and Cambridge libraries for NK-1 
clones (sections 3.3.3 and 3.3.4) were used in the following 
hybridisations undertaken to identify NK-1R clones from the Toronto 
library.
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3.6 ISOLATION OF NK-1 R GENOMIC LIBRARY CLONES
3.6.1 Source and Construction of NK-1R Probed 
Library
Genomic mouse neurokinin-1 receptor clones were isolated from a 
bacteriophage lambda library. The library was constructed from 
strain SVJ129 mouse genomic DNA so that the cloned DNA would be 
compatible for use in homologous recombination experiments using 
SVJ129 mouse strain embryonic stem (ES) cells. The library which 
was screened by aqueous hybridisation and successfully yielded NK- 
1R clones was supplied courtesy of Dr. Alexandra Joyner, Toronto, 
Canada. This library was constructed so as to include restricted 
mouse genomic DNA inserts of between 9 Kb and 20 Kb. The genomic 
DNA was partially restricted with Sau3A1 prior to size selection and 
vector/insert ligation into the bacteriophage vector was A.DASH. 
The 'Toronto' library was supplied as a high titre  liquid 
bacteriophage suspension.
3.6.2 Titre Calculation. Plating and Storage of 
Toronto Library „
The concentration of bacteriophage in the original Toronto library 
master stock was determined by titration, as previously described 
for the libraries used to isolate NK-1 precursor clones (section
3.3.2). One million bacteriophage were plated on 20 small square 
NZCYM agar plates (50,000 per plate). Four replica lifts, using 
Hybond-N™ membrane, were then taken from the each plate.
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3.6.3 NK-1R Screen of the Toronto Library
3.6.3.1 Primary NK-1 R Screen of the Toronto Library
A pair of identical replica filters were taken from each of the 
twenty bacteriophage library plates. Six of these pairs were probed 
in itia lly. They were pre-hybridised for 4 hrs
(see section 2.29). The 
filter pairs were split and probed independently. Labelled and 
denatured NK-1R probe was added to
a probe concentration of 100 ng per ml. 5 ml of 
probe/buffer solution was then added to each of the two flasks and 
.. hybridised A series of 'dot-blotted'
prTKR2 and pCOL1 plasmid dilutions were used as positive and 
negative con tro ls  respective ly for th is hybrid isation. A fter 
hybridisation, the filters were washed as described in section 3.2.2, 
and incubated with autoradiographic film. On
developing the film, strong and weak hybridisation signals, all of 
which were duplicated on their partner filter, were identified. The 
signal from non-specific background hybridisation was minimal. The 
areas on the six library master plates from which the duplicate 
signals were emanating were located, isolated, resuspended and 
stored as described previously (section 3.3.3.1). In order to identify 
as many NK-1R candidate clones as possible, the 14 remaining pairs 
of Toronto library filters which had not been probed, were probed in 
exactly the same way as for the initial six pairs of filters.
In total 186 candidate bacteriophage NK-1R clones were identified
as a consequence of the primary screen. Despite identical exposure
times, the strength of the hybridisation signals generated by the
numerous clones varied considerably. This can be seen below on the ($«z 3-hT
au to ra d io g ra ph ^  All 186 clones were isolated from the twenty 
master plates and stored as 4 °C stocks. On average, each plate 
displayed 8 duplicate candidate clones.
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3.6.3.2 Secondary NK-1 R Screen of the Toronto Library
Of the 186 candidate clones identified at the primary stage, 20 were 
selected for further analysis and were screened again by aqueous 
hybridisation. One clone was selected from each of the 20 master 
plates. Clones which generated both strong and weak hybridisation 
signals were chosen so as to represent the range in 'the strength of 
signal noted at the primary stage. Since the NK-1R probe was 
derived from the rat NK-1R cDNA, the probe may well have 
hybridised to bacteriophage clones containing one or more mouse 
NK-1R exon. Theoretically the greater the number of mouse NK-1R 
exons contained in a bacteriophage insert, the greater the amount of 
target sequence present for the probe to hybridise to. Therefore the 
number of exons may account for the variation in signal strength. 
The approach of selecting a range of clones was adopted to ensure 
that as many exons as possible were contained in the 20 clones 
screened at the secondary stage.
The 20 clones were titred, plated and replica membrane lifts were 
taken from the bacteriophage plates as described (Section 3.3.3.1). 
The bacteriophage were plated at the density of 100 plaques per 
plate. The pre-hybridisation and the probe labelling were the same 
as for the Toronto library primary screen (above). The hybridisation 
was incubated at 60 °C for 18 hrs. The filters were washed and 
incubated with autoradiographic film for 2 days. Of the 20 clones 
probed at the primary level, 19 were identified at the secondary 
stage and underwent the tertiary hybridisation.
3.6.3.3 Tertiary NK-1 R Screen of the Toronto Library
The 19 isolated clones were resuspended, titred and plated again but 
at the lower density of 50 plaques per plate. The NK-1R 
hybridisation was repeated as before. The exposure time was 4 days. 
Of the 19 NK-1R clones isolated from the secondary screen, 14 were 
identified by the tertiary hybridisation. The clones were isolated 
from the master plates and 4 °C and -70 °C stocks were made for 
each of the bacteriophage clones (which were named kSPRI through 
to X SPR14).
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Figure 3.14 : Filters from Toronto Lihrarv/NK-1 R Probe Hybridisations.
F igure  3.14: Pairs of filters from (a) primary hybridisation, and (b) secondary 
hybridisation of the Toronto bacteriophage library with the NK-1 R-specific probe. The 
duplicate hybridisations signals are clear on the partner filters.
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3.7 CLONING THE MOUSE NK-1R EXON 2
Preliminary characterisation of the NK-1R bacteriophage clones, as 
described in depth in Chapter 4, indicated that each of them 
contained at least one NK-1R exon. However, not one of the 14 
positive NK-1R clones contained the mouse NK-1R exon 2. In rat, the 
NK-1R gene has 5 exons, where exons 3, 4 and 5 are'all to be found 
within a 3 kb genomic region while exon 2 is separated from exons 1 
and 3 by introns of approximately 15 and 23 kb respectively 
(Hershey, 1991). Bearing in mind that there is on average 95% 
identity between the rat and mouse species at the genetic level, it 
was thought likely that the mouse NK-1R gene also had 5 exons and 
that the mouse exon 2 would be flanked by introns of a comparable 
size to that in the rat. This was later confirmed to be the case 
(Sundelin et al, 1992), and at the time was considered a reasonable 
explanation why none of the 14 mouse NK-1R bacteriophage clones 
contained exon 2.
For the mouse NK-1R gene, it was considered important to clone the 
mouse NK-1R exon 2 because while the the other four were 
subcloned, this exon remained only in a bacteriophage clone. The 
exon 2-specific oligodeoxynucleotide probe (CS10) shown above was 
therefore used to screen the 186 NK-1R candidate clones which had 
been isolated from the Toronto library as a result of the primary 
library screen which used the prTKR2/Bsg I 965 bp rat cDNA 
fragment as probe. Of the 186 isolated bacteriophage plaques, 20 
had been screened at the secondary stage and had been shown to lack 
NK-1R exon 2 and were not screened again. Of the remaining 166 
primary clones, 38 were chosen randomly to be further screened for 
mouse NK-1 R exon 2 sequence.
3.7.1 NK-1R Exon 2 Oligodeoxynucleotide Probe Design
All 14 clones lacked exon 2 as determined by hybridisation using a 
oligodeoxynucleotide probe known to be 100% homologous to the 
mouse NK-1R exon 2 (see Figure 3.12). This probe (CS10) was used 
in the NK-1 R exon 2-specific hybridisations described here. The
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design of this probe was based on the known mouse exon 2 sequence 
which was obtained from Sundelin etal, (1992).
Figure 3.15 : Sequence of Murine NK-1 R cDNA from which Oligodeoxynucleotide
CS10 was Designed.
(a )  P r i m e r  CS10
5 ' ATACATGGCCATCATCCACCCTCTTCAGCCCCGGCT 3 ' ( c o n t d . t o  1 9 4  b p )
I I I I I I I I l + l I I I I I I I I I I I I I I I I I I I I I I I I I
TATGTACCGGTAGTAGGTGGGAGAAGTCGGGGCCGA
I
S t a r t  o f  m o u s e  SPR e x o n  2 s e q u e n c e .
F igure  3 .15 : (a) 37 bp of the mouse NK-1R exon 2 (194 bp) sequence indicating the 
sequence from which the oligodeoxynucleotide CS10 was derived. CS10 was used as a 
probe to identify genomic sequences containing the mouse NK-1R exon 2. The 
sequence of primer CS10 is shown in bold.
3.7.2 Hybridisations using the Exon 2-Specific Probe
All of the hybridisations which used the deoxyoligonucleotide CS10 
as the p robe . were conducted in accordance with the protocol 
described in section 2.29.2. The hybridisation temperature was 45 
°C and the probe was radioactively-labelled using polynucleotide 
kinase (section 2.24.3).
The 186 plaques which had been isolated from the library master 
plates after the primary screen had each been stored, in the interim, 
in 1 ml of bacteriophage buffer (see solutions) at 4 °C. Under these 
conditions for several weeks, the bacteriophage had resuspended. 
Each of the 38 randomly selected primary clones were plated on 
small square NZCYM plates and incubated at 37°C overnight. The 
next day, the plates were chilled at 4°C before replica filter lifts 
were taken from each.
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3.7.3 Re-Probing the Primary Toronto Library Screen 
Clones
The replica lift filters taken from the 38 re-plated primary screen 
clones were pre-hybridised for 1 hr and hybridised for 3 hrs. This 
hybridisation was equivalent to a secondary screen, as all 38 clones 
had been screened previously all be it with the cDNA^derived, rather 
than the oligodeoxynucleotide probe. The washed filters were 
incubated with autoradiographic film for 4 days. Of the 38 clones 
re-plated and re-screened with the exon 2-specific probe, only 2 
(clones number 17 and 32) generated duplicate signals and were 
analysed further.
For the final, tertiary screen, clones 17 and 32 were plaque isolated 
from the secondary plates, resuspended, titred and re-plated at low 
plaque density (50 plaques per plate) as described before. Replica 
membrane lifts were made which were probed with the exon 2- 
specific probe again. The filters were washed and incubated with 
film overnight. Both clones were successfully detected at the
tertiary stage. Single plaques were isolated c
The two clones
containing mouse NK-1R exon 2 sequence were called XSPR15 and 
XSPR16.
The 14 clones isolated from the Toronto library by the original 
cDNA-derived probe, together with the two exon 2-containing clones 
which were isolated later from the same library, were used in the 
characterisation of the mouse NK-1R gene as described in Chapter 4. 
(They were named A.SPR1 through to A.SPR16). They were also used in 
the design and construction of homologous recombination targeting 
vectors for the mouse NK-1 R gene as described in Chapter 5.
The following text, chapter 4, describes the chalacterisation of the 
murine NK-1 and NK-1 R genes.
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Figure 3.16 : Linear Alignment of PPT-A Clones Showing the Overlap and the Exons
Contained in Each Clone.
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F ig u re  3.16: Linear schematic alignment of the NK-1 precursor bacteriophage
clones to demonstrate the extent of overlap and the exons contained in each clone. 
The bacteriophage clones are represented relative to the publihed genomic DNA 
organisation of the rat NK-1 gene (shown at the top, Carter etal, 1990).
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Figure 3.17___: Linear Alignment of NK-1 R Clones Showing the Overlap and the Fxnns
Contained in Each Clone.
Q-V/l
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f i gure— sLlZ i Linear alignment of the NK-1R receptor bacteriophage clones to 
demonstrate the extent of overlap and the exons contained in each clone. The 
bacteriophage are represented relative to the published genomic DNA organisation of 
the rat NK-1 R gene (shown at the top of the figure, Sundelin et at, 1992).
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CHAPTER 4 
RESULTS: CHARACTERISATION
INTRODUCTION
The goal of this chapter is to describe the characterisation of the 
genomic structures of the mouse PPT-A and NK-1R genes. The
purpose of this was to establish the authenticity of the genomic
DNAs cloned in Chapter 3 and which were believed to contain the 
mouse PPT-A and NK-1R genes. To do this, the positively- 
hybridising mouse PPT-A and NK-1R bacteriophage clones were
analysed in several ways. Based on that analysis, the generation of
exon-containing plasmid subclones is described. The aim of 
generating such subclones was to fac ilita te  the m olecular 
characterisation of the mouse PPT-A and NK-1R genes to as full a 
degree as possible. Using those subclones, the relative genomic 
location of the exons and some exonic sequence was determined in 
addition to the generation of a map of the restriction sites within 
each subclone. This procedure is described for each gene 
individually, starting with the PPT-A precursor gene. The results 
detailed in this chapter were subsequently used in the design of the 
gene targeting vectors which are described in Chapter 5 and are 
required for homologous recombination experiments.
4.1 ANALYSIS OF THE PPT-A/GLAXO LIBRARY CLONES
The five positive PPT-A bacteriophage clones which had been 
isolated from the Glaxo genomic DNA library were named APPT1 
through to XPPT5. As briefly mentioned in Chapter 3 (Section
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3.3.3.4), these bacteriophage clones were analysed initially so as to 
determine how many of the seven (putative) PPT-A exons were 
contained within the insert DNA of each clone. This analysis was 
conducted by the polymerase chain reaction and by aqueous 
hybridisation using an exon-specific oligodeoxynucleotide probe.
4.1.1 PCR Analysis of Clones Clones PPT1/2/3/4 & 5
In an attempt to authenticate the existence of mouse PPT-A genomic 
DNA sequence within the insert sequence of the isolated 
bacteriophage clones ?iPPT1/2/3/4 and 5, polym erase chain 
reactions were performed. Bacteriophage DNA was used as template 
and was prepared as described in Section 2.1.5. The PCR reaction 
conditions used to synthesize the original probe fragment (for PPT- 
A library hybridisations, Section 3.1) were also used in the clone 
analysis PCRs. Therefore, successful generation of a 514 bp PCR 
product from both the bacteriophage clone template and the mouse 
genomic DNA template (Section 3.1.3) would indicate that the clone 
contained genomic mouse PPT-A sequence. 100 ng of bacteriophage 
DNA template was used per reaction. 5 jul of each reaction was 
electrophoresed Each of the
five bacteriophage clones successfully displayed a single PCR band 
of 514 bp in length. Primers CS6 and CS7 were designed to hybridise 
to PPT-A exons 3 and 4 respectively. Therefore, the successful PCR 
analysis indicated that each of the five clones contained at least 
mouse PPT-A exons 3 and 4.
4.1.2 Restriction Analysis of PPT-A/Glaxo Clones
Bacteriophage DNA was digested as described in Section 2.20. 
Clones >iPPT1/2/3/4 and XPPT5 were digested with the endonuclease 
BamY\ I for 2 hrs and electrophoresed The
resulting restriction profile was identical for clones XPPT3 and 
?iPPT4. A different but consistent restriction pattern was generated 
by clones A.PPT1, ?iPPT2 and ?iPPT5. Each of these two subsets of 
PPT-A clones were found to contain the same genomic DNA insert.
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This demonstrated that only two distinct PPT-A clones had been 
isolated from the Glaxo library.
4.1.3 Location of Exons 3 and 4 in PPT2 and PPT4
In addition to the PCR analysis (Section 4.1.1), further evidence that 
the Glaxo clones XPPT2 and XPPT4 contained PPT-A exons 3 and 4 
was provided by hybridisation analysis. A series of digestions were 
conducted on both XPPT2 and XPPT4 DNA (representing the two 
distinct clones) using the endonucleases Sal I, Bgl II, HinD III, BamH 
I, Not I, Kpn I and EcoR V. The reactions were electrophoresed
and capillary blotted 
The DNA was fixed to the membrane by UV cross-linking. 200 ng of 
the original PCR-derived mouse PPT-A probe fragment (Section
3.1.3) was radioactively-labeled by 'specific priming' (Section 2.2.4). 
The membrane was probed and washed in the same way as for the 
library hybridisations described previously (Section 3.2). A DNA 
dot-blot was used as the control. An exposure of only 3 hrs was 
required to produce a clear and distinct positive image on the film 
as a consequence of the very strong signal generated (see Figures 
4 - 1 and 4-2 below). The result reiterated the difference between 
the genomic inserts in XPPT2 and ?iPPT4 as demonstrated by 
restriction analysis (above). The existence of common sequence in 
both clones was demonstrated by the positive signal which emanated 
from the 1.4 kb HinD III/Sal I DNA fragment of both A,PPT2 and 
?iPPT4. This in turn implied that the clones had overlapping genomic 
DNA inserts.
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Figure 4.1: Digestion and Hybridisation of PPT-A Bacteriophage Clone PPT2 
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F i g u r e  4 . 1 :  (a) 1 of clone >iPPT2 digested with several endonucleases and 
electrophoresed on a 0.7% agarose/TBE gel. Lane 1, Sal I; lane 2, HinD I I I /Sa l  I; lane 
3, Bgl  II; lane 4, BamH I; lane 5, HinD III; lane 6, BamH  I/Not I, lane 7, HinD 111 /Kpn  I; 
lane 8, HinD \ \ \ /BamH  I; and lane 9, EcoR V. The '1KB' lane is 1 kb DNA ladder marker 
lane. Please ignore lane 'M' which is another marker lane containing partiallydigested 
DNA. (b) the corresponding autoradiograph for the above ?iPPT2 DNA, digested, 
capillary blotted and probed with the PPT-A exon 3 and 4-specific probe (see Section 
4.1.3).
..... . ..................
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Figure 4.2: Digestion and Hybridisation of PPT-A Bacteriophage Clone PPT4
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Figure 4.2: (a) 1 ng of PPT-A bacteriophage clone 7PPT4 digested with several 
endonucleases and electrophoresed on a 0.7% agarose/TBE gel. Lane 1, Sal I; lane 2, 
HinD I W/Sal  I; lane 3, HinDWUBamH  l ; M ;H//?D III; lane 5 with Sal I IBamW I; lane 6, 
BamH I; lane 7, BamR I/A/of I; lane 8, Bgl II; and lane 9, EcoR V. The '1KB' lane is 1 kb 
DNA ladder marker lane. Please ignore lane M .
(b) the corresponding autoradiograph for the above APPT4 DNA, digested, capillary 
blotted and probed with the PPT-A exon 3 and 4-specific probe (see Section 4.1.3).
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4.1.4 Location of 5' and 3' Regions of Clones PPT2 and 
PPT4
Having confirmed that only two distinct PPT-A bacteriophage clones 
had been isolated from the Glaxo library (i.e., ?iPPT2 and APPT4), and 
that both clones contained exons 3 and 4, it was considered 
necessary to determine if either clone contained the 5' and/or the 3' 
end of the mouse PPT-A gene. In order to do this, 
oligodeoxynucleotides specific to the first and last PPT-A exons, 
namely exons 1 and 7, were designed and synthesized based on the 
published rat genomic sequence (Carter, 1990).
4.1.4.1 Oliaodeoxvnucleotide Hybridisation to Exon 1
The oligodeoxynucleotide CS8 was designed to hybridise to the 
central region of the 100 bp rat exon 1. This region of the rat exon 1 
sequence, and the equivalent bovine sequence, is not translated (see 
below). The bovine differs from the rat sequence by three 
(interspersed) nucleotides. Oligodeoxynucleotide CS8 was a 19-mer 
with a GC:AT ratio of 13:6 and a melting temperature of 64°C.
Figure 4.3: Oligodeoxynucleotide CS8 aligned to Rat PPT-A Genomic Sequence
5 ' 1 1 0  20  3 0  4 0
actAGAGCGCACTCGGACCAGCTCCACTCCAGCACGCCGGCGGAGGAGAGCG
I I l + l I I I I I I I l + l I I I I I I I l + l I I I I I I I l + l I I I I I I I l + l I I I I I I I
tgaTCTCGCGTGAGCCTGGTCGAGGTGAGGTCGTGCGGCCGCCTCCTCTCGC
5 0  P r o b e  C S 8  7 0  80  9 0  3 '
AGGAGCGCCCAGCAAGTGCGCACCTGCGGAGCATCACCGGGTCCGACCGCAata
I l + l I I I I I I I l + l I I I I I I I l + l I I I I I I I l + l I I I I I I I l + l I I I I I I I l + l
TCCTCGCGGGTCGTTCACGCGTGGACGCCTCGTAGTGGCCCAGGCTGGCGTcac
Figure 4 .3: 100 bp of rat PPT-A exon 1 genomic sequence (Carter, 1990). Exon 1 
specific oligodeoxynucleotide probe CS8 is shown as bold, underlined text. Capital 
letters denote exonic sequence and lower case letters denote non-exonic sequence. 
Rat PPT-A exon 1 is not translated.
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XPPT2 and ?tPPT4 DNA was restricted with several endonucleases 
(Sal I, Nco I, BstE II, BamH I), electrophoresed, capillary blotted and 
fixed to Hybond membrane and probed as described previously 
(section 3.7). A DNA dot-blot was used as the control for this 
experiment. Plasmids containing the rat (Nakanishi, 1986) and 
bovine (Harmar, pers. comm.) PPT-A cDNAs were used as the positive 
controls, whereas pBluescript and prTKR2 (Section 3.5) DNA was 
used as the negative controls. 1 ng of each DNA was denatured and 
spotted on to the membrane and immobilised. 50 ng of 
oligodeoxynucleotide CS8 was radio-labelled by the polynucleotide 
kinase method and added to hybridisation buffer to a
concentration of 10 ng per ml. The hybridisation reaction was 
incubated at 45°C after which the membrane was washed
and incubated with autorad iographic film  overnight. The 
autoradiograph for the control dot-blot membrane indicated that 
specific hybridisation had worked. However, the test membrane 
bearing restricted A.PPT2 and ?iPPT4 DNA did not produce any 
positive signal. This indicated that bacteriophage clones XPPT2 and 
A.PPT4, which earlier had been shown to contain mouse PPT-A 
genomic sequence, lacked exon 1 and the adjacent 5' region of the 
gene.
4.1.4.2 Oligodeoxynucleotide Hybridisation to Exon 7
To ascertain whether clone XPPT2 and/or clone ?iPPT4 contained the 
3' region of the PPT-A gene, the same approach to that used to 
locate the 5' end of the gene was adopted (Section 4.1.4.1). Based on 
the rat PPT-A sequence (Carter et al, 1990) an oligodeoxynucleotide, 
which was designed to hybridise to the (translated) 5' end of the 593 
bp exon 7, was synthesized. This oligodeoxynucleotide was named 
CS3. Because the sequence of CS3 was derived from the translated 
part of the rat exon 7 it was considered most likely to be conserved 
between rodent species (rat to mouse) and therefore be of use as a 
homologous oligodeoxynucleotide probe to the mouse exon 7 
sequence.
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Figure 4.4: Oligodeoxynucleotide CS3 Relative to Rat PPT-A Genomic Sequence
5 ' 1 P r o b e  CS3 20 30 40
t a c a qTGGCTTATGAAAGAAGCGCAATGCAGAACTACGAAAGAAGCGTAAATAAA
I I I I l + l I I I I I II l + l I I I I I I I l + l I I I I I I I l + l I I I I I I I l + l I I I I I I I I
a cg tcA C C G A A T A C TT T C T T C G C G TT A C G T C TT G A T G G TT T C T T C G C A T T T A T T T  
Va 1A1 a T v rG l uA rcrS erA l aMe t G l  nAsn T y rG l u A rgA rgL ysE nd
50 60 70 3 '
C C G TG TA A C G C A C TA TC TA TTC A TC TC . . . ( e x o n  c o n t i n u e d  t o  5 9 3  b p )
+ 1 I I I I I I l + l I I I I I I I l + l I I I I I I
GGCACATTGCGTGATAGATAAGTAGAG
Figure 4 .4 : The first 77 bp of the 593 bp rat PPT-A exon 7 genomic DNA sequence 
(Carter et al, 1990). Oligodeoxynucleotide CS3 relative to that exonic sequence is 
shown in underlined, bold text. Exonic sequence is shown in capital letters whereas 
intronic sequence is shown in lower case text. Amino acids translated from this exon 
are shown in italics. Bold italics denote the amino acids translated from within the 
CS3 sequence. Translated sequence is highly conserved between rat and mouse.
Probe fragment CS3 constituted 21 nucleotides, had a GC:AT ratio of 
10:11, and a melting temperature of 62°C. The hybridisation 
experiment which used probe CS3 was conducted under the same 
conditions as for probe CS8 (Section 4.1.4.1). Clone XPPT2 and 
XPPT4 DNA was restricted with the endonucleases Kpn I, Nco I and 
Sal I, electrophoresed simultaneously on a 0.5% agarose gel and 
blotted on to Hybond-N membrane. The control DNA dot-blot was the 
same as in the CS8 hybridisation detailed above. The test membrane 
was probed with radioactively-labelled (exon 7-specific) probe CS3, 
washed in 0.1 x SET buffer and autoradiographed. The developed film 
displayed strong positive hybridisation signals emanating from 
fragments of both PPT-A bacteriophage clones. The positive and 
negative controls for this experiment worked. The result indicated 
that each of the PPT-A bacteriophage clones, ?iPPT2 and XPPT4, 
isolated from the Glaxo library lacked the 5' region of the gene 
(including exon 1) but did comprise the 3' region of the gene 
(including exon 7).
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Figure 4.5: Clones XPPT2 and xPPT4 Hybridised with an Exon 7-Specific Probe
Figure 4.5: Autoradiograph of endonuclease digested XPPJ2 (lanes 1-4) and XPPT4 
(lanes 5-8) electrophoresed, capillary blotted and hybridised with exon 7-specific 
oligodeoxynucleotide probe CS3. Lanes 1 and 5; Kpn I, lanes 2 and 6; Kpn I /Not I, 
lanes 3 and 7; Not I, lanes 4 and 8; Sal I/ Not \.
4.2 ANALYSIS OF THE PPT-A/CAMBRIDGE LIBRARY CLONES
With respect to both gene characterisation and design of a gene 
ta rge ting  vector, it was cons idered  necessary  to iso late 
bacteriophage clones containing the 5' region of the PPT-A gene. On 
account of this a different library, the Cambridge genomic DNA 
library, was screened (Section 3.3.4) and the five isolated clones 
were named >iPPT6 through to A.PPT10. The same PCR-derived, exon 
3/4-specific probe as was used to screen the Glaxo library was used 
to screen the Cambridge library. Therefore clones XPPT6 through to 
?tPPT10 were analysed to determine which, if any, contained exon 1 
and the adjacent 5' region of the mouse PPT-A gene.
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4.2.1 Oligodeoxynucleotide Hybridisation to Exon 1
Bacteriophage clones A,PPT6 to 10 were analysed by aqueous 
hybridisation. In order that the clones could be screened rapidly, 
they were analysed in an unusual but effective way which did not 
require the preparation of bacteriophage DNA or the bacteriophage 
clone lysates from which DNA is prepared.
After the tertiary library hybridisation described in section 3.3.4.3 a 
single bacteriophage plaque was isolated from the library master 
plate for each of the five identified PPT-A clones. Each plaque was 
incubated in 1 ml of phage buffer to allow the bacteriophage to 
resuspend. A small square NZCYM media plate was overlayed with 
NZCYM top agar mixed with LE392 plating cells and allowed to set 
(Section 2.11). (This differed from the standard procedure in that 
the top agar/plating cell mix lacked bacteriophage). For each of the 
five PPT-A/Cambridge library clones, 2 pJ of the single-plaque 
resuspension was spotted onto the NZCYM plate, prepared as 
described above, leaving several centimetres between each 'spot'. 
The plate was then incubated at 37 °C overnight. The following day, 
as expected, the plate displayed five d istinct plaques of 
approximately 1 cm diameter representing bacteriophage clones 
APPT6 to 10.
Duplicate replica membrane lifts were made from the plate (Section 
2.14). The membranes were then hybridised using the same exon 1- 
specific oligodeoxynucleotide probe as used to screen clones XPPT1 
to 5 in Section 4.1.4.1. A dot-blot membrane was used as the control 
for this experiment. A plasmid which contained the bovine PPT-A 
cDNA was used as the positive control and pBluescript was used as 
the negative. The hybridisation was successful and allowed the 
identification of clones containing exon 1. Clones ?tPPT6, ?iPPT7, 
?iPPT9 and APPT10 were shown to contain exon 1 while only clone 
?iPPT8 was shown to lack this exon.
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4.2.2 PCR Analysis of Ciones PPT6/7/8/9 and 10
Clones ?tPPT6/7/8/9 and 10 were anlysed by polymerase chain 
reaction in the same way and under the same reaction conditions as 
clones A.PPT1 to 5 (Section 4.1.1). The analysis was equally 
conclusive in demonstrating that clones APPT6 to 10 contained 
exons 3 and 4 because a single 514 bp PCR product was generated 
from the bacteriophage clone DNA template using primers CS6 and 
CS7. Further confirmation that clones ?iPPT6 to 10 contained exon 3 
was provided by successful hybridisation of the exon 3-specific 
probe CS6 (Section 3.1.1) to each of the clones.
4.2.3 Oligodeoxynucleotide Hybridisation to Exon 7
DNA from clones APPT6/7/8/9 and 10 was digested with the 
endonucleases Nco I and Sal I, electrophoresed, blotted and probed 
with oligodeoxynucleotide CS3 (as in Section 4.1.4.2). The same 
controls were successfully included. Hybridisation indicated that 
PPT-A clones ?tPPT6, >iPPT7, >.PPT9 and >.PPT10 did indeed contain 
exon 7 and the 3' end of the mouse PPT-A gene. XPPT8 did not.
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4.2.4 Occurence of Exons in PPT-A Bacteriophage 
Clones PPT1 Through to PPT10 (Figure 4.5)
Figure 4.6 : Exons Contained in PPT-A Bacteriophage Clones ?lPPT1 to APPT10
Exon
Clone 1 2 3 4 5 6 7
A.PPT1 V V V V V
XPPJ2 V V V V V
XPPT3 V V V V V
XPPT4 V V V V V
XPPT5 V V V 11 V
XPPT6 V V V V V
XPPJ7 V V V V V V V
XPPT3 V V V
XPPT9 V V V V V V V
X PPT10 V V V V V
Figure  4 .6 : Table detailing the exons contained in PPT-A bacteriophage clones 
XPPT1 to kPPTIO  as determined by positive aqueous hybridisation using 
oligodeoxynucleotides specific to each exon. The sequence of the oligodeoxynucleotide 
probes was based on the published rat genomic (Carter et al, 1990) and mouse cDNA 
(Kako etal, 1993) sequences.
4.3 SUBCLONING THE MOUSE PPT-A GENE
The rat PPT-A gene has been shown to contain 7 exons and be 8 kb in 
size (Carter eta l, 1990). The mouse PPT-A gene was predicted to be 
of similar genomic organisation due to the high rat/mouse species 
homology. DNA probes specific to exons 1 ,3 ,4  and 7 had been shown 
to hybridise to clone ?iPPT9. On that basis, it was considered likely 
that this clone, with a genomic DNA insert of between 10 and 20 kb, 
would contain the whole mouse PPT-A gene. Clone ?iPPT9 was
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therefore selected for further analysis and subcloning. ?iPPT9 DNA 
was digested with several endonucleases in order to identify one 
which would digest the bacteriophage lambda (vector) DNA 
infrequently while digesting the insert DNA at a few loci so as to 
generate fragments of between 5 and 10 kb. Insert fragments of this 
size were considered ideal for subcloning. Endonucleases with 
recognition sequences of six or eight nucleotides, such as Not I, Nco 
I and Sal I, were tested. The restricted DNAs were electrophoresed, 
transferred to membrane and probed with exon 1 and exon 7-
specific oligodeoxynucleotide probes (as described in Sections
4.1.4.1 and 4.1.4.2 respectively). The endonuclease Nco I was chosen 
because it generated insert-derived DNA fragments of 1.8, 4.3, 7.2, 
and 9.5 kb. Of these fragments, the 7.2 kb fragment contained exon 1 
and the 9.5 kb fragment contained exon 7. As these two DNA 
fragments contained the 5' and 3' regions of the mouse PPT-A gene 
respectively they were selected for subcloning. (It was later 
demonstrated that the 7.2 and 9.5 kb fragments were adjacent with 
respect to the genomic organisation of the gene and between them 
contained all seven of the mouse PPT-A exons).
4.3.1 Shotgun Ligation: Subclone pSP9
5 jLxg of ?iPPT9 DNA was restricted with 10 units of Nco I because 
this digestion had previously been shown to generate a 9 kb 
fragment containing PPT-A exons 1, 2, 3 and 4 (see Section 4.1.2). A 
sample of the reaction was electrophoresed on an agarose gel to 
confirm that restriction of the DNA was complete. On completion, 
the endonuclease was removed from the reaction by organic 
extraction with phenol and chloroform (Section 2.23). A plasmid, 
namely pGEM®5Zf(+), was selected as a suitable subcloning vector 
because of the Nco I site located in the multiple cloning site. 5 jig 
of pGEM®5Zf(+) vector DNA was restricted with Nco I. Complete 
restriction of the vector DNA was also determ ined by gel 
electrophoresis. The buffer concentration of the reaction was 
altered to facilitate the dephosphorylation of the restricted vector 
DNA with the modifying enzyme CIP (section 2.21.1). After 
incubation, the CIP and Nco I enzymes were removed from the
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reaction by extraction with phenol and chloroform. 'Conventional' 
ligation reactions were then performed as described in section 
2.21.1. The ligations were transformed into E. coli strain DH10B 
cells by the heat-shock method (section 2.4.1). Transformants 
containing plasmids with ?tPPT9-derived genomic DNA inserts were 
distinguished by blue/white selection (see Section 2.4). White 
colonies were picked, grown under ampicillin selection and plasmid 
DNA was prepared from each bacterial culture by the alkaline lysis 
method detailed in section 2.17.1. 1 \ig of subclone DNA was
restricted with Nco I and electrophoresed alongside DNA marker (1 kb 
ladder) so that the size of the insert could be determined visually. 
One such plasmid subclone was found to contain the 9 kb XPPT9/Nco 
I DNA fragment and therefore exon 1 of the mouse PPT-A gene. This 
subclone was named pSP9 (see Section 2.8.1 for nomenclature 
criteria).
4.3.2 Subclone pSP7
The white colonies obtained from the A.PPT9/pGEM®5Zf(+) shotgun 
ligation transformation (Section 4.3.1) were fully analysed. None of 
the subclones had the 7.2 kb XPPT9I Nco I fragment as an insert. 
This DNA fragment had to be subcloned into the vector pGEM®5Zf(+) 
specifically rather than by the shotgun ligation method. A,PPT9 DNA 
was restricted with Nco I and electrophoresed on a 0.5% 
agarose/TAE gel. The 7.2 kb DNA fragment was band-isolated from
the gel and the DNA recovered using a (section
2.27.2). The purified 7.2 kb DNA fragment was used in ligations
which were, in turn, transformed into competent E. coli strain
DH10B. White colonies were selected, cultured and analysed by 
digestion with Nco I. The plasmid subclone with the 7.2 kb 
XPPT9/Nco I fragment as an insert was named pSP7.
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4.4 RESTRICTION MAPPING THE PPT-A SUBCLONES pSP9 AND 
pSP7
PPT-A plasmid subclones pSP9 and pSP7 were restriction 
endonuclease mapped in the same way. The vector DNA was the same 
for both subclones. The full restriction map of the vector DNA 
(pGEM®5Zf+) was known (Promega Corp. catalogue). Each subclone 
was digested, in the first instance, with each of the 30 standard 
endonucleases kept in the laboratory. From the restriction pattern 
generated, the number of restriction sites in the insert was 
determined for each enzyme. Only endonucleases which were found 
to cut the insert DNA less than four times were more extensively 
mapped. In order to do this, a unique restriction site in the multiple 
cloning site of the vector DNA, and which did not cut the insert DNA, 
was located; for example EcoRM. The insert restriction sites were 
then located relative to that known polylinker site. When the newly 
located restriction sites for the several test enzymes were plotted, 
a comprehensive linear restriction map for each subclone was 
constructed.
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Figure 4.7: Restriction Maps of Plasmid Subclones pSP9 and pSP7
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Figure 4.7: Linear map of the restriction sites located within the cloned inserts of 
plasmid subclones pSP7 and pSP9. Exons were localised to the smallest known DNA 
fragment by hybridisation using exon-specific oligodeoxynucleotides. C; C!a I, Ev; 
EcoR\J, P; Pst I, H; HinD  III, M; Mlu I, Bg; Bgl II, P1; Pvu I, B; BamH I, X; Xba I, N; 
Nco I, S; Sst I, Bs; BstE II.
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4.5 LOCATING THE MOUSE PPT-A EXONS
In order to construct the restriction maps of the plasmid subclones 
pSP9 and pSP7 (Section 4.4), the single and double endonuclease 
reactions were electrophoresed on 0.7% agarose gels (up to 10 
reactions per gel). The gels were photographed so that the DNA 
fragments could be accurately sized and a map made. Instead of 
discarding the gels, they were Southern blotted onto nylon membrane 
and stored. The membranes were later probed by aqueous 
hybrid isation using radioactive ly-labelled oligodeoxy nucleotides 
specific to each of the seven exons in order to define which DNA 
fragm ent of which subclone contained which exon. All 
hybridisations detailed in Sections 4.5.1 to 4.5.6 were performed at 
45 °C and by the protocol described in Section 2.29.2 and with DNA 
dot-blot membranes as positive and negative controls. In each case, 
the controls indicated that the hybridisations were both successful 
and specific.
N.B. By this stage of the project, the mouse PPT-A gene was known 
to contain seven exons as demonstrated by Kako (1993). This 
publication detailed the mouse PPT-A cDNA sequence which, rather 
than the ra t PPT-A genomic sequence (Carter 1990), was 
subsequently used in the design of deoxyoligonucleotide probes 
specific to mouse PPT-A exons.
4.5.1 Mouse PPT-A Exon 1
As a result of restriction mapping subclone pSP9, the DNA fragments 
were electrophoresed and blotted onto membrane. Each membrane 
bore between 5 and 10 blotted pSP9 DNA restrictions reactions. The 
reactions were typically doubles where two endonucleases had been 
incubated simultaneously. Eleven such membranes were probed with 
the exon 1-specific oligodeoxynucleotide CS8 (Section 4.1.4.1). The 
probe hybridised to a 2.7 kb Nco IIBstE  II fragment (Figure 4.7, lane 
3) and a 2.7 kb Cia I/ Cla I fragment (not shown). Thus, the mouse 
PPT-A exon 1 was localised to the 800 bp Cla I IBstE  II fragment of 
subclone pSP9: the overlap of the two fragments which hybridised 
positively.
Chapter 4 Results: Characterisa tion p (&&
Figure  4.8; Location of PPT-A Exon 1 in Plasmid Subclone pSP9
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F i g u r e  4 .8 :  Upper image: Photograph of plasmid subclone pSP9 digested with 
several endonucleases and electrophoresed on a 0.7% agarose/TBE gel. Lower image: 
This gel was capillary blotted onto Hybond-N and hybridised with the PPT-A exon 1- 
specific probe CS8 to generate the autoradiograph shown beneath. Note the 2.7 kb 
Bst E 11/A/co I fragment in lane 3 of both images. IW A usiuJ WnS 1 kb L a d d .
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4.5.2 Mouse PPT-A Exon 2
The same 11 membranes as were probed in Section 4.5.1 were probed 
w ith an exon 2-specific  probe. The sequence of th is 
oligodeoxynucleotide, named CS14, was based on the mouse PPT-A 
cDNA sequence published by Kako (1993). Oligodeoxynucleotide CS14 
was a 20-mer which hybridised to the 5' end of the mouse exon 2 
sequence, had a GC:AT ratio of 10:10 and a melting temperature of 
60 °C.
Figure 4.9: Sequence of Exon 2-Specific Oligodeoxynucleotide CS14
5' 3'
ATGAAAATCCTGTGGCCGTG
Figure 4.9: Sequence of the oligodeoxynucleotide CS14 as used in hybridisations to 
locate mouse PPT-A exon 2 in subclone pSP9. Sequence based on the published mouse 
PPT-A cDNA sequence of Kako et al (1993). According to the published mouse 
sequence, the first nucleotide of the above oligodeoxynucleotide sequence is the 12th 
nucleotide from the 5' end of the mouse exon 2 sequence. The mouse PPT-A exon 2 
comprises 135 bp in total.
The CS14 probe hybridised to the 2.7 kb Nco I IBstE  II fragment and 
the 2.7 kb Cla \ICIa I fragment of pSP9. Therefore, the mouse PPT-A 
exon 2 was, like exon 1, localised to the same 800 bp Cla I IBstE  11 
fragment of subclone pSP9.
4.5.3 Mouse PPT-A Exons 3 and 4
Oligodeoxynuclotides CS6 and CS7 (Section 3.1.1 and 3.1.2) were 
used to locate exon 3 and exon 4 respectively. The 11 filters bearing 
restricted pSP9 DNA were stripped and re-hybridised using these 
probes. Both probes hybridised to a 900 bp Mlu IIMIu I DNA fragment 
of subclone pSP9. This fragment was later subcloned as part of the
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gene targeting vector construction (Chapter 5). Both probes also 
hybridised to an 800 bp Mlu I/Pst I fragment. The Pst I restriction 
site was also found to be of importance during vector construction 
(for insd’tion of the neomycin resistance gene; see Section 5.1.3.2).
4.5.4 Mouse PPT-A Exon 5
Four membranes bearing capillary blotted, restricted subclone pSP7 
DNA were used in the localisation of exon 5. An exon 5-specific 
oligodeoxynucleotide, named CS15, was synthesized based on the 
mouse PPT-A cDNA sequence (Kako e ta l, 1993) and used in aqueous 
hybridisations. CS15 had a GC:AT ratio of 10:10 and a T m of 60°C.
Figure 4.10: Sequence of Exon 5-Specific Oliqoeoxvnucleotide CS15
5' 3'
ACATGGCCAGATCTCTCACA
F ig u re  4.10: Sequence of oligodeoxynucleotide CS15 which was used in the 
hybridisation to localise the mouse PPT-A exon 5 in subclone pSP7. This sequence is 
based on the published mouse PPT-A cDNA sequence of Kako et al (1993). According 
to the published mouse sequence, the first nucleotide of the above 
oligodeoxynucleotide sequence is the 1st nucleotide at the 5' end of the mouse exon 5 
sequence. The mouse PPT-A exon 5 comprises only 24 bp in total.
Probe CS15 was found to hybridise to a 200 bp Nco I/Bgl II fragment 
of subclone pSP7.
4.5.5 Mouse PPT-A Exon 6
The four pSP7 membranes which had been probed previously were 
s tr ip p e d  and re -h yb rid ise d  w ith  an exon 6 -s p e c ific  
oligodeoxynucleotide probe. The probe, which was a 20-mer with a
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melting temperature of 64°C, was derived from the mouse cDNA 
sequence (Kako etal, 1993) and was named CS16.
Figure 4.11: Sequence of Exon 6-Specific Oligodeoxynucleotide CS16
5' 3'
ACATGGCCAGATCTCTCACA
F ig u re  4.11: Sequence of oligodeoxynucleotide CS16. CS16 was used in the
hybridisation to localise the mouse PPT-A exon 6 in subclone pSP7. The sequence of 
this oligodeoxynucleotide is based on the published mouse PPT-A cDNA sequence (Kako 
et al, 1993). According to the published mouse sequence, the first nucleotide of the 
above CS16 oligodeoxynucleotide sequence is the 3rd nucleotide at the 5' end of the 
mouse exon 6 sequence. The mouse PPT-A exon 6 comprises 53 bp in total. CS16 
lies within the translated sequence of exon 6 from which the neuropeptide substance K 
(neurokinin-A) is encoded (Kako etal, 1993).
Probe CS16 was found to hybridise positively to both the 3.2 kb HinD  
III/BamH  I and the 3.8 kb HinD III/HinD  III fragment. Mouse PPT-A 
exon 6 was further localised to the 600 bp HinD III/Xba I fragment of 
subclone pSP7.
4.5.6 Mouse PPT-A Exon 7
The pSP7 membranes were stripped and re-hybridised with the exon 
7-specific oligodeoxynucleotide CS3 (Section 4.1.4.2). This probe
hybridises to the 5' end of exon 7. The probe selectively hybridised 
to 2.5 kb Psfl fragment, the 2.7 kb BamH \/Nco I (shown below) and 
the 2.2 kb HinD III fragment. The 5' end of the mouse PPT-A exon 7 
was therefore localised to the 350 bp HinD I I I /P s t I fragment of 
subclone pSP7.
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4.6 SEQUENCE OF THE MOUSE PPT-A GENE
Once purified, the DNA from the bacteriophage clones isolated 
from the Glaxo and Cambridge genomic libraries (see Sections
3.3.3 and 3.3.4, respectively) were analysed, by endonuclease 
digestion (Section 4.1.2) and also by PCR analysis (see Section 
4.11). This, however, did not provide sufficient evidence to 
confirm that the cloned DNAs did indeed contain mouse PPT-A 
sequence; further evidence was required to authenticate this.
In order to do this, DNA sequencing was performed using the 
plasmid subclones derived from the isolated bacteriophage, as 
templates. A number of sequencing primers were used to do this. 
The short oligodeoxynucleotide primers (of between 18 and 22 bp 
in length) which had been used in earlier experiments as PCR 
primers (see Section 3.1.3) were also used as sequencing primers. 
Similarly, using the published rat PPT-A sequence (Carter et al, 
1990), further PPT-A exon-specific sequencing primers were 
designed, synthesized and used. Furthermore, standard plasmid 
vector primers such as T7 primer, which anneals to the multiple 
cloning site sequence of pBluescript KS+, were used (also T3 and 
SP6 primers, see Stratagene catalogue).
Both manual and automated sequencing was performed using the 
methodologies described in Sections 2.30 and 2.31. Novel DNA 
sequence was obtained and is presented in this text. In the 
alignments shown below, novel sequence is referred to as "query 
sequence". The query sequence was aligned with the DNA entries 
which have been published and are held on computerised DNA 
databases (such as that of the European Molecular Biology 
Laboratory; GenEMBL). In the alignments shown below, this 
sequence is referred to as "database sequence". For each of the 
query sequences analysed in this way, a number of alignments 
were generated with different degrees of sequence identity. 
Alignments representing several different intronic and exonic 
regions of the mouse PPT-A gene (for example the 5' upstream 
region) were obtained using this approach. Only the closest
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("best-fit") alignment between the query sequence and the 
database sequence was selected and is given below (although 
other alignments with lower percentage identities were also 
generated). The origin of the database sequence, the accession 
number and the percentage sequence identity are given for each 
alignment. Additionally, the primer used to generate the query 
sequence is specified for each alignment.
4.6.1 Murine PPT-A Gene 5' Flanking Sequence
The plasmid subclone pSP9 (see Section 4.3.1) was used as 
sequencing template in combination with the T7 sequencing 
primer which anneals to the T7 RNA polymerase transcription 
initiation site in the plasmid vector pBluescript KS+ (both primer 
and vector from Stratagene). 83 bp of the mouse genomic DNA 
sequence was found to align with database sequence flanking the 
5' region of the rat PPT-A gene. That database sequence is 
derived fom the 4247 bp sequence entered onto the database from 
the species Rattus norvegicus and which has the accession 
num ber gb |L07328 |R A T P P T 5F L  . The alignment of those 
sequences, as shown below, demonstrates a 93% sequence 
identity between the query and database sequences. This is in 
line with predicted mouse to rat species DNA sequence identities.
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Figure 4.12: Alignment of Murine and Rat PPT-A Gene Sequence Upstream of 
Exon 1 in the 5' Flanking Region
A: Query: 83 CTTCCTCTGTCTCCTACTCTCTTCAGAAATCGAACATGAAAATCCTCGTGGCCGTGGCGG 24
I I I 11111111 11 I 11 I 11 I M I N I M  M M M M I M M M M M I  M M M I
B: Data : 3855 CCTTCTCTGTCTCCTACTCTCTCCAGAAATCCAACATGAAAATCCTCGTGGCGGTGGCGG 3914
Query: 23 TCTTTTTTCTCGTTTCCACTCAA 1
M M M M M M M M M M M I
Data: 3915 TCTTTTTTCTCGTTTCCACTCAA 3937
Figure 4 .12 : Analysis of the murine PPT-A sequence upstream of exon 1 which 
was generated during this research; aligned with the corresponding published rat 
PPT-A gene sequence (GenEMBL database, see Section 4.6.1 above). 93% identity 
shown.
4.6.2 Murine PPT-A Gene Exons 1 and 2 Sequence
Plasmid subclone pSP7.2 (Section 5.1.2) was used as sequencing 
template with the sequencing primer T7. 130 bp of the generated 
mouse genomic sequence was found to align with the rat PPT-A 
gene exon 1 and exon 2 database sequence. The rat sequence is 
derived from the 1757 bp Rattus norvegicus sequence database 
entry (accession number gb|M34159|RATPPTA1). The figure 
below demonstrates that 120 of 133 deoxynucleotides align 
exactly giving a 90% sequence identity.
Figure 4.13: Alignment of Murine and Rat PPT-A Exon 1 and Exon 2 Sequence
A: Query: 405 GTCTTCAGGCTTGAGAGTGTGGGTCAGTGGGTAGGGGACTGGGACGCTGAGACTCAAGGA 346
I l l l l l l l l l l  I 111 I 11 11 I 11 I 11 I 11 I I I 11 I I I I I I  I I Mi l l  III II
B: Data: 1108 GCCTTCAGGCTTCGGAGTGTGGGTCAGTGGGTAGGGGGCTGGGACGTTGAGAGGCAAAGA 1167
Query: 345 GAGGAGGATTTGAGGCTCTTTGGCGCCTCAGGAGCCTTCTTAAAGGGTTTGGAGAAGTGT 286
l l l l l l l l  I I 11 11 111 I 11 11 I I INI  11 I I I I 111 I 111 I I I I 1111 I 11 III
Data: 1168 GAGGAGGACTTGAGGCTCTTTGGCACGTCAGTAGCCTTCTTAAAGGGTTTGGAGAAATGT 1227
Query: 285 TCGACCTGGTGGG 273
I I I I I I I I I I I I I
Data: 1228 TCGACCTGGTGGG 1240
Figure 4 .13: Analysis of the murine PPT-A exon 1 and exon 2 sequence; aligned 
sequence from subclone pSP7.2 (generated with T7 primer) and the corresponding 
published rat PPT-A gene sequence (GenEMBL database, see Section 4.6.3 above). 
90% identity shown.
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4.6.3 Murine PPT-A Gene Exon 3 Sequence
The plasmid subclone pSP7.2 (section 5.1.2) was used as 
sequencing template with the primer CS6 (Section 3.1.1). 35 bp
of the mouse genomic sequence was found to align with the 
bovine PPT-A gene exon 3 database sequence (197 bp B. taurus 
DNA fragment, accession number emb|X01396|BTPPT3). The 
figure below shows the plus strand to plus strand alignment of 
those sequences where 29 of 35 nucleotides align precisely 
giving a 82% sequence identity.
Figure 4.14: Alignment of Murine and Bovine PPT-A Exon 3 Sequence
A: Query: 5 CACGCGGGATGCTGGTGAGATGAGCAATAGTCACT 39
II I I I I I I I I I I I I I I I I I I III I III II
B: Data: 134 CAAACGGGATGCTGGTGAGATGGGCAGTCGTCCCT 168
Figure 4.14: Analysis of the murine PPT-A exon 3 sequence; aligned sequence 
from subclone pSP7.2 (generated with CS6 primer) and the equivalent published 
bovine PPT-A gene sequence (see Section 4.6.3 above). 82% identity shown.
4.6.4 Murine PPT-A Gene Exon 3 and Exon 4 Sequence
The sequencing template was plasmid subclone pSP7.2 and the 
primer was CS6 (Section 3.1.1). 150 bp of the query mouse
genomic DNA sequence was found to align with the rat PPT-A 
gene exon 3 and exon 4 database sequence (875 bp Rattus 
norveg icus  DNA sequence, w ith the accesion number 
gb |M 34160|R ATPPTA2). The figure below shows the plus strand 
to plus strand alignment where 132 of 150 nucleotides align to 
give an 88% sequence identity.
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Figure 4.15: Alignment of Murine and Rat PPT-A Exon 3 and Exon 4 Sequence
A : Query: 5
B: Dat: 270
Query: 65
Dat: 330
Query: 125
Dat: 390
CACGCGGGATGCTGGTGAGATGAGCAATAGTCACTAGATCTATCAGGCTACCTGGTCTGA 6 4
II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
CAAACGGGATGCTGGTGAGATGAGCAATAGTCACTAGGTCTATCAGGCTACCCGGTCTGC 329 
ATGCTTGTTCCTTCCTGGAGAACCCAAATGTCTCTTGTACTGGGAGTATAGATTTACACG 124
I I I I II I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I
ATGCCTGCTCCTTCCTGGAGCACCCAAGTGTCTCTTGTACCGCGAGTATAATTTTACATG 389 
CCTAAAGGCTTYGGATTCCCAGAAGTCTTC 154
l l l l l l l  III l l l l l l l  MINIMI
CCTAAAGACTTTTGATTCCCTGAAGTCTTC 419
Figure 4.15: Analysis of the murine PPT-A exon 3 and exon 4 sequence; aligned 
sequence from subclone pSP7.2 (generated with CS6 primer) and the equivalent 
published rat PPT-A gene sequence (see Section 4.6.4 above). 88% identity 
shown.
4.6.5 Murine PPT-A Gene Exon 7 Sequence
Plasmid subclone pSP10.6 (Section 5.1.1) was used as a 
sequencing template along with T3 primer (Stratagene). 129 bp 
of mouse genomic sequence was found to align with the rat PPT-A 
gene exon 7 database sequence (779 bp Rattus norvegicus DNA 
sequence, accession number gb|M34162|RATPPTA4). The figure 
below demonstrates the plus strand to minus strand alignment 
where 112 of 119 nucleotides align precisely giving an 94% 
sequence identity between mouse and rat in the region of exon 7.
Figure 4.16: Alignment of Murine and Rat PPT-A Exon 7 Sequence
A: Query: 249 TGCAGTGGCTTATGAAAGAAGCGCGATGCAGAACTACGAAAGAAGACGTAAATAAACCCC 190
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
B: Data: 2 TGCAGTGGCTTATGAAAGAAGCGCAATGCAGAACTACGAAAGAAGGCGTAAATAAACCCT 61
Query: 189 GTAACGCACTATCTATTCATCTTCATCTGTGTCAGTGAGCAGTGAACGGTAAAATAAAA 131
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
Data: 62 GTAACGCACTATCTATTCATCTCCATCTGTGTCCGCGAGCAGTGAGCGGTAAAATAAAA 120
Figure 4 .16: Analysis of the murine PPT-A exon 7 sequence; aligned sequence 
from subclone pSP10.6 (using primer T3) and the equivalent published rat PPT-A 
gene sequence (see Section 4.6.5 above). 94% identity shown.
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4.7 ANALYSIS OF THE NK-1R/TORONTO LIBRARY CLONES
Sixteen positively-hybridising NK-1R bacteriophage clones, named 
A,SPR1 through to A.SPR16, were identified as a result of the 
hybridisation screen of the Toronto bacteriophage library (Section 
3.6.3). Of these, clones ^SPR15 and ?iSPR16 were known to contain 
mouse NK-1R exon 2 genomic sequence (Section 3.7). In order to 
determ ine which bacteriophage clone contained which of the 
remaining NK-1R exons, the clone DNA was analysed by aqueous 
h yb rid isa tio n  using exon spe c ific  o lig od e o xynu c le o tid e s . 
Endonuclease restriction mapping was also used as an indicator of 
which bacteriophage clones contained which exons by means of 
determining common restriction site patterns.
4.7.1 Restriction Analysis of Clones SPR1 to 14
DNA was prepared from bacteriophage clones ?^SPR1 to ?iSPR14 
(Section 2.15). 2 jig of each DNA was digested with the endonuclease 
BamH I and electrophoresed on a 0.5% agarose gel. The gel was 
capillary blotted onto nylon membrane where the DNA was 
immobilised. Initial restriction analysis of the clones demonstrated 
that there were four subsets of NK-1R bacteriophage clones which 
had identical inserts, namely clones >.SPR1 and 4, clones ^SPR3 and 
6, ?iSPR5,11 and 14, as well as clones ?iSPR9 and 12. It was found 
that of the 14 clones isolated from the Toronto library (as a 
consequence of the first library screen) there were only 9 which had 
distinct genomic DNA inserts. Clone ?iSPR15 was known to contain 
the same (exon 2-specific) insert as ?iSPR16. When this is taken 
into account, there were a grand total of 10 distinct NK-1R 
bacteriophage clones.
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4.7.2 Oligodeoxynucleotide Probes for NK-1R Exons
N.B. By this stage of the project the mouse NK-1R gene, like the rat 
NK-1R gene, was known to comprise 5 exons as demonstrated by 
Sundelin et al (1992). The sequence of each exon is detailed in that 
publication.
The following oligodeoxynucleotides were used as probes to localise 
each of the exons in the NK-1R bacteriophage clones. Probes CS9, 
CS11, CS12 and CS13 were used to probe exons 1, 3, 4 and 5 
respectively. The sequence of the oligodeoxynucleotides was based 
on the published mouse NK-1R sequence (Sundelin e ta l, 1992) where 
the first (5') nucleotide of each oligodeoxynucleotide sequence 
corresponds to the first (5') nucleotide of each mouse NK-1R exon 
respectively. The probe used to localise exon 2 is detailed in 
section 3.7.1. The oligodeoxynucleotides CS9, CS11, CS12 and CS13 
have melting temperatures of 58, 60, 56, and 64 °C respectively.
Figure 4.17: Sequence of Oligodeoxynucleotides CS9. CS11. CS12 and CS13
Homologous to Mouse NK-1R Exons 1.3.4 and 5
5' 3 '
(a) CS9: ATGGATAACGTCCTTCCTGT
(b) CS11: GTACCACATCTGTGTGACCT
(c) CS12: GTGGTCAAAATGATGATCGT
(d) CS13: GTTCCGTCTGGGCTTCAAGC
Figure 4.17: Sequence of oligodeoxynucleotides CS9, CS11, CS12 and CS13. The 
oligodeoxynucleotides hybridise to mouse NK-1R exons 1, 3, 4 and 5 respectively. 
The sequence of exon 2-specific oligodeoxynucleotide CS10 is detailed in Section 
3.7.1. Each of the oligo deoxynucleotides is shown in the 5'-3' orientation.
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4.7.3 Exonic Content of Clones SPR1 to SPR14
A nylon membrane bearing ?tSPR1-14 clone DNA restricted with 
BamH I (Section 4.8.1) was probed with oligodeoxynucleotides CS9, 
CS10, CS11, CS12 and CS13 in turn. The hybridisations were 
performed as described in section 2.29.2. The positive and negative 
controls in each case indicated that hybridisation had been 
successful. In addition to determining the number of exons in each 
NK-1R clone, the hybridisations served to identify DNA fragments of 
a suitable size for plasmid subcloning.
Exon 1-specific probe CS9 was found to hybridise to clones ?iSPR8 
and A,SPR13 only. A common 8.5 kb BamH \/BamH I fragment from 
each of these clones was identified as containing the mouse NK-1R 
exon 1 DNA sequence. The 8.5 kb BamH VBamH I fragment of ?iSPR13 
was selected for further analysis and was subcloned.
The exon 2-specific probe (CS10) failed to hybridise to any of the 14 
?tSPR clones. However, the controls indicated that the hybridisation 
had worked. It was therefore concluded that none of the clones 
contained the mouse NK-1R exon 2 sequence. As a result of this 
finding the bacteriophage clones isolated as a result of the primary 
screen of the Toronto library were re-hybridised but with probe 
CS10 (Section 3.7). Two bacteriophage plaques which positively 
hybridised for exon 2 sequence were successfully isolated in this 
way and were named X SPR15 and X SPR16.
The exon 3-specific oligodeoxynucleotide CS11 was found to 
hybrid ise to 10 clones of which 6 were d istinct, namely 
?lSPR1/2/5/7/9 and ?tSPR10. A positive signal emanated from a 5.1 
kb DNA fragment of these clones. The 5.1 kb Bam H  I fragment of 
?lSPR12 was subcloned and analysed further.
Exon 4-specific probe CS12 was found to hybridise to 12 of the 14 
clones. Of those, only 7 clones were distinct (namely clones 
?iSPR1/2/3/5/7/9 and 10). NK-1R exon 4 was also localised to 5.1 
kb BamH \/BamH I fragment of ASPR12 as exon 3 (above).
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Exon 5-specific oligodeoxynucleotide CS13 hybridised to the same 
seven clones as for exon 4. Exon 5 was also localised to the 5.1 kb 
BamH \IBam H  I fragment of XSPR12 which was subcloned and 
analysed in depth later in this text.
Figure 4.18: Mouse NK-1R Exons Contained in the Isolated Bacteriophage Clones
Exon 1 Exon 2 Exon 3 Exon 4 Exon 5
XSPR 1 * V V V
XSPR2 V V V
?tSPR3 ** V V
?tSPR4 * V V V
?tSPR5 ° V V
A.SPR6 ** V V
XSPR7 V V V
XSPR8 V
XSPR9- V V V
?iSPR10 V V V
A.SPR11 ° V V
?iSPR12 * V V V
?iSPR13 V
?iSPR14° V V
XSPRJ\5 + V
?.SPR16 + V
Figure 4.18: The NK-1R exons contained in the NK-1R phage clones isolated from 
the Toronto library by aqueous hybridisation using oligodeoxynucleotide probes. 
Clones with common superscript symbols were shown by digestion to contain common 
inserts.
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4.8 SUBCLONING THE MOUSE NK-1R GENE
The above table (4.12) demonstrates that no single bacteriophage 
clone contained all five mouse NK-1R exons. Therefore, more than 
one DNA fragment had to be subcloned to allow a more detailed 
characterisation of the mouse NK-1R gene.
4.8.1 Subclone pSPR8.5
The 8.5 kb BamH \/BamH  I fragment of XSPR13 was shown by 
hybridisation to contain NK-1R exon 1 sequence. In order to subclone 
this fragment, 10 p,g of ?iSPR13 DNA was digested with BamH\ and 
electrophoresed on a TAE buffer/agarose gel. The 8.5 kb DNA 
fragment was recovered from the gel using a Spin-X column (Section
2.27.2). The plasmid vector pBluescriptll KS(+) was prepared in the 
same way. The isolated DNA fragments were used in ligation 
reactions. The ligations were transformed into E. coli strain TG1 
b a c te ria l ce lls  (which dem onstra te  high tra n s fo rm a tio n  
efficiencies). White colonies were picked and cultured. DNA was 
prepared from each culture and restricted with BamH I to determine 
the insert size. A plasmid with an 8.5 kb insert was identified. The 
subclone with the 8.5 kb \S P R ^ 3 /BamH I fragment as an insert was 
named pSPR8.5.
4.8.2 Subcloning the NK-1R Exon 2: pSPR6.8
Bacteriophage clones containing NK-1R exon 2 sequence (>.SPR15 and 
A-SPR16) were isolated from the Toronto library (Section 3.7) using 
an exon 2-specific oligodeoxynucleotide probe (CS10). In order to 
select a suitable fragment for subcloning, DNA was prepared from 
bacteriophage XSPR15 and >.SPR16 lysates and incubated separately 
with the endonucleases BamH I, Nco I and EcoR V. The restriction 
reactions were electrophoresed capillary
blotted The membrane was hybridised with
probe CS10 as detailed in section 3.7.2 (a control DNA dot-blot was
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included and was successful). The resulting autoradiograph 
confirmed the existence of a common genomic DNA insert in both 
XSPR15 and ?iSPR16 (as indicated earlier by restriction analysis). 
The autoradiograph also demonstrated that a 6.8 kb Nco \INco I 
fragment of both ?iSPR15 and 16 hybridised positively for the mouse 
NK-1R exon 2. This fragment was subcloned into the polylinker Nco I 
site of pGEM5Zf(+) to generate the subclone pSPR6.8. This subclone 
was restriction mapped accordingly. Due to time restraints, the 
hybridisation experiment to localise the mouse NK-1R exon 2 within 
subclone pSPR6.8 was not conducted and remains outstanding.
4.8.3 Subclone pSPR5.1 (Exons 3. 4 and 5)
The 5.1 kb BamH \/BamH I fragment of >.SPR12 was shown to contain 
SPR sequence from exons 3, 4 and 5 (Section 4.8.3). This DNA 
fragment was subcloned in the same way, and into the same vector, 
as the 8.5 kb fragment (described in Section 4.9.1). The plasmid 
subclone with the 5.1 kb >.SPR12 BamH \/BamH I fragment as an 
insert was named pSPR5.1.
4.9 Restriction Mapping the NK-1R Subclones pSPR8.5 and 
pSPR5.1
The mouse NK-1R gene subclones, plasmids pSPR8.5, pSPR6.8 and 
pSPR5.1, were restriction mapped in the same way as the NK-1 
plasmid subclones (Section 4.4) where known restriction sites in the 
vector polylinker were used to orientate restriction sites in the 
insert. In order to generate a restriction map of each subclone, 
restriction reactions were electrophoresed
Fragment
sizes were then translated into a linear map. The DNA was then 
capillary blotted from the gel on to nylon membrane and 
immobilised. The membranes were stored at 4°C for later use.
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4.10 LOCATING THE MOUSE NK-1 R EXONS
The Southern blotted membranes generated in section 4.10 and 
bearing subclone DNA were probed using oligodeoxynucleotide probes 
specific to the NK-1R exons (as in section 4.8.2). The probes were 
labelled using polynucleotide kinase (section 2.24.3).
4.10.1 Mouse NK-1R Exon 1
Membrane-bound restricted pSPR8.5 DNA was hybridised with 
labelled oligodeoxynucleotide CS8. The probe hybridised to the 1.5 
kb S s t \/S s t I and the 1.7 kb BamH  IIP s t I fragments of this 
subclone. Therefore, mouse NK-1R exon 1 was localised to the 250 
bp Sst I IPst I fragment of pSPR8.5.
4.10.2 Mouse NK-1R Exon 3
When hybridised with an exon 3-specific probe (CS11), several 
restricted DNA fragments of subclone pSPR5.1 generated a positive 
signal. From this, NK-1R exon 3 was localised to the 600 bp Pvu 
W/Ava II fragment of subclone pSPR5.1.
4.10.3 Mouse NK-1R Exon 4
The restricted pSPR5.1 DNA membranes were stripped and re­
hybridised with oligodeoxynucleotide CS12. Consequently, mouse 
NK-1R exon 4 was localised to the 400 bp Bgl IIlAva  II fragment of 
subclone pSPR5.
4.10.4 Mouse NK-1 R Exon 5
To locate mouse NK-1R exon 5, the same hybridisation as for exon 4 
(above) was performed, but using the oligodeoxynucleotide CS13 as 
the probe. Exon 5 was localised to the 500 bp Ava II/EcoR  I 
fragment of subclone pSPR5.1 (lane 2, Figure 4.14, below). To 
further confirm this, the probe was shown to hybridise to both the 
700 bp EcoR 11 EcoR I (lane 4) and the 1.6 kb Ava U/Xho I fragment 
(lane 8).
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Figure 4.19: Restriction Map of NK-1 R clones pSPR5.1. pSPR8.5 & nSPR6.8.
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Figure 4.20 : Subclone pSPR5.1 Hybridised with Exon-5-Specific Probe CS13
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F ig u re  4.20: Autoradiograph of 0.5 |ig of subclone pSPR5.1 DNA digested with 
endonucleases, electrophoresed, capillary blotted and hybridised with exon-5-specific 
probe CS13. Lanes '1KB' contain 1 kb DNA ladder. Lane 1; Ava II/Sst I, lane 2; Ava 
U/EcoR I, lane 3; Ava IIIPst I, lane 4; Ava IItXho I, lane 5; Ava II/Sst I, lane 6; Ava  
II, lane 7; Nco I, lane 8; Nco \/EcoR I, lane 9; Nco I /Pst I, lane 10; Nco I IXho I, lane 
11; Nco I /Sst I, lane 12; Stu I, lane 13; Stu I I EcoR I, lane 14; Stu I /Pst I, lane 15; 
Stu I/ Xho I, lane 16; Stu I/ Sst I.
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CHAPTER 5 
RESULTS: GENE TARGETING VECTORS
INTRODUCTION
Chapter 5 describes the steps taken to construct gene targeting 
vectors for the cloned mouse PPT-A and NK-1R genes. The vectors 
were constructed to fa c ilita te  hom ologous recom bination 
experiments in tissue cultured mouse embryonic stem (ES) cells 
with a view to generating transgenic mice lacking the functional 
form of either the PPT-A or the NK-1R gene. Two gene targeting 
vectors were made for the PPT-A gene whereas only one NK-1R 
construct was completed. The genes are dealt with in turn where 
the PPT-A gene is detailed first and is followed by the NK-1R 
gene.
GENE TARGETING VECTORS 
FOR THE MOUSE PPT-A GENE
5.1 DESIGN AND CONSTRUCTION OF PPT-A GENE TARGETING 
VECTOR No. 1
When designing gene targeting vectors, several basic criteria are 
taken into account. These important criteria are believed to have a 
direct and significant bearing on the ability of a particular vector to 
promote specific, targeted DNA recombination events. One such 
criteria refers to the size of the two genomic DNA fragments which
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flank the neomycin resistance gene and which constitute regions of 
homology between the genomic target DNA and the genomic DNA 
contained in the targeting vector. When the PPT-A vectors were 
designed, in order to get a workable targeting frequency, the 
minimum combined length of those two flanking fragments which 
was thought to be in the region of 6 kb. The recommended ideal 
length is approximately 10 kb. Above 15 kb, the targeting frequency 
remains roughly the same. Additonally, the higher the degree of 
conservation within the flanking fragments, the higher the targeting 
frequency. In order to comply with this criterion, a single DNA 
fragment containing all seven mouse 'PPT-A exons was subcloned. 
The targeting efficiency has also been shown to be higher when
isogenic DNA is used, where the genomic DNA in the vector is
derived torn the same strain of mouse as the ES cells in to which 
they are to be transfected.
5.1.1 Subclones pSP10.6
Plasmid subclones pSP7 and pSP9 (Section 4.3) were generated by 
subcloning 7 kb and 9 kb Nco \-Nco I restricted DNA fragments of 
bacteriophage clone XPPT9 respectively. From the restriction maps 
of these subclones, it was noted that each contained a single Sst I 
restriction site estimated to be separated by 10.6 kb of genomic 
DNA (based on the assumption, later proved correct, that the two 
cloned inserts were contiguous genomic sequences). Restriction 
analysis of >.PPT9 confirmed this size estimate. One Sst I site was 
found to lie upstream of exon 1 while the other was downstream of 
exon 7. This 10.6 kb Sst I/Sst I fragment was later shown (by
restriction map alignment with subclones pSP7 and pSP9, see Figure
5.1) to contain all 7 mouse PPT-A exons and was subcloned into the 
vector pBluescript KS+. This subclone was named pSP10.6, the 
restriction map for which is shown below.
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Figure 5.1 : Alignment of PPT-A Subclones SP9. SP7. SP10.6 and dSP7.2
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5.1.2 Subclones pSP7.2 and pSP7.2 II
A smaller fragment of the pSP10.6 subclone was selected for 
further subcloning on the basis of the restriction sites that would 
be available for the insertion of the neo and thymidine kinase 
resistance genes. These genes are inserted at a later stage in the 
vector construction. From the restriction map of pSP10.6, two BstE  
II sites were noted lying immediately upstream of exon 1 and 
upstream of exon 7. A BstE II digestion of pSP10.6 generated a 7.2 
kb fragment which lacked the PPT-A exon 7 but was of a appropriate 
size and sequence for use in a targeting vector. In order to subclone 
this 7.2 kb BstE W^BstE II fragment of subclone pSP10.6, a suitable 
plasmid vector with a BstE II site in the multiple cloning site (MCS) 
was required. No such vector was commercially available so one 
was constructed by introducing a BstE II restriction site into the 
MCS of pBluescriptKS+.
To do this, two oligodeoxynucleotides were designed so as to anneal 
to each other and in so doing, generate a BstE II recognition sequence 
flanked by overhanging Kpn I cohesive termini. This would result in 
the formation of a short double stranded DNA linker sequence 
suitable for cloning into the Kpn I site of pBluescriptKS+ . The 
sequence of the oligodeoxynucleotides, and the linker they combine 
to create, is shown below (Figure 5.2).
Oligodeoxynucleotides CS19 and CS20 were synthesized by Cruachem 
Ltd. and supplied as quantified, precipitated DNA pellets. Both DNAs 
were resuspended, annealed and phosphorylated as described in 
section 2.32.2. Conversely the pBluescript KS+ DNA was restricted 
with Kpn I,
The linearized DNA was then 
dephosphorylated by shrimp alkaline phosphatase (SAP, Section
2 .22 .2 ) which was later heat inactivated. The linker DNA was 
ligated to the linearized pBluescript DNA. The ligation reactions 
included a range of vector to insert DNA ratios (from 1:1 to 1:10) and 
the appropriate positive and negative contro ls which were 
demonstrated by way of transformation to have worked. A 2 jllI 
sample of the ligation was transformed into E. coli (TG1 strain) and
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bacterial clones were selected, cultured and analysed by restriction 
with BstE II. This allowed identification of a plasmid which was 
linearized by BstE II and therefore contained the newly introduced 
BstE  II restriction site (the short linker sequence). This 
recombinant plasmid was named pKS+.BstE II.
Plasmid pKS+ .BstEII was used as the recipient DNA for the 7.2 kb 
BstE II-BstE II fragment of plasmid pSP10.6 (Section 5.1.1) which 
was cloned to generate the subclone named pSP7.2 (version 1). The 
authenticity of this subclone was verified by restriction analysis 
and alignment of its restriction map with that of subclones pSP10.6, 
pSP9 and pSP7.
At a later stage, and as a means of increasing the ligation efficiency 
of a troublesome ligation, plasmid pSP7.2 was modified to create a 
derivative subclone named pSP7.2 II. Plasmid pSP7.2 II differed 
from the original plasmid pSP7.2 (version 1) in that the 900 bp Mlu 
I/M lu  I restriction fragment (which contained exons 3 and 4) was 
removed from pSP7.2 (version 1) by Mlu I digestion. The Mlu I- 
digested DNA was then ligated to itself and transformed into E. coli 
TG1 cells. One re-ligated plasmid transformant lacking the 900 bp 
Mlu I-Mlu I fragment was isolated and named pSP7.2 II (version 2).
Figure 5.2: Sequence of Oligodeoxynucleotides CS19 and CS20
(a ) 5' CGGTGACCGGATC 3' (CS19)
I I I I I I I I I
3' CTAGGCCACTGGC 5' (CS20)
(b ) (1 )  (2 ) (3 )
C GGTGACC GGATC
( K p n l  End) | I I I I I I I ( K p n l  End)
CTAGG CCACTGG C
Figure 5 .2: Sequence of the oligodeoxyonucleotides CS19 and CS20. Part (a) shows 
the oligodeoxynucleotides annealed to each other, and part (b) shows the linker 
diagramatically sub-divided to show the component sections; (1) a Kpn I cohesive 
terminal, (2) a BstE II recognition sequence, and (3) a Kpn I cohesive terminal.
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Figure 5
IV
.3: Restriction Map of Subclones pSP7.2. pSP7.2 II. pSP7.2 III and pSP7.2
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Figure  5.3: Linear representations of the endonuclease recognition sites in the 
insert of the PPT-A subclones pSP7.2, pSP7.2 II (for both, see Section 5.1.2), pSP7.2 
III and pSP7.2 IV (for both, see sections 5.1.4). M; Mlu I, Bs; Bst E II, E1; EcoR I.
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5.1.3 Cloning the Neomycin Resistance Gene into PPT-
A Targeting Vector No. 1
5.1.3.1 Subclonina PPT-A Exons 3 and 4: Plasmid pSP900
As detailed in Chapter 1, the PPT-A gene encodes several 
neuropeptides. The neo gene was inserted into the targeting vector 
in order to disrupt the transcription of the gene and to prevent (in a 
targeted mouse) the subsequent translation of the neuropeptide NK-1 
specifically. The selection of a partcular genetic location for the 
insertion of the neo  gene within the targeting vector was therefore 
important. An ideal insertion site to do this lay within the NK-1- 
encoding exon 3 of the PPT-A gene. On examination of the 
restriction map of subclone pSP9 (containing PPT-A exons 1, 2, 3 
and 4), two 'unique' Mlu I restriction sites were noted which were 
shown to flank exons 3 and 4. The Mlu I sites were found to be 900 
bp from each other and were located in introns 2 and 4. The 900 bp 
Mlu I-Mlu I fragment of subclone pSP9 was subcloned into the 2.9 kb 
plasmid vector plBI24 (Dente et al, 1983) to generate the subclone 
which was named pSP900 (version 1, see Figure 5.4). Using the 
published mouse PPT-A cDNA sequence and the University of 
Winconsin GCG sequence analysis computer software, a restriction 
map of exons 3 and 4 was assembled. The authenticity of the insert 
was confirmed both by digestion and by PCR analysis using the 
primers specific to exons 3 and 4, primers CS6 and CS7 respectively 
(as before, see Section 3.1).
5.1.3.2 Deletion of the Polvlinker Pst I Site: pSP900 II
A Pst I site in exon 3 was noted and confirmed (by restriction 
enzyme digestion) to be unique within the insert of plasmid pSP900. 
Based on the published mouse cDNA sequence (Kako et al, 1993) this 
Pst I site was shown to be located 35 bp from the 5' end of the 97 bp 
exon 3 and 13 bp immediately upstream of the short exonic sequence 
which is translated to produce the 11 amino acid neuropeptide NK-1. 
This site was chosen as the insertion site for the neo  gene because 
the upstream insertion location would prevent the transcription of 
the downstream NK-1-encoding sequence. However, the multiple
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cloning site (MCS) of plasmid pSP900 (derived from the vector 
plBI24) also contained a Pst I recognition sequence. This second P st 
I site meant that the one located within exon 3 could not be 
considered unique and as such would complicate the cloning of the 
neo  gene into the exonic Pst I site. To ensure this site remained 
unique, the polylinker Pst I site of subclone pSP900 was deleted. To 
do this, another two unique restriction sites, namely Sal I and Xho I 
sites, were used. DNA cleaved by Sal I generates cohesive termini 
which are compatible with those generated by Xho I. Those termini 
can therefore be ligated to each other. In this instance, this 
approach would result in the rem oval'o f the problematic Pst I site 
lying between the Sal I and Xho I sites in the pSP900 MCS. This 
approach was successfully used to generate the plasmid subclone 
pSP900 II (version 2; i.e., a modified second version of the original 
plasmid subclone pSP900). Plasmid pSP900 II can therefore be
linearised by incubation with Pst I (see Figure 5.4).
5.1.3.3 Deletion of the Polvlinker EcoR I Site: pSP900 III
Although the unique Pst I site located in PPT-A exon 3 (which was 
introduced into plasmid pSP900 II) was chosen as the site for 
insertion of the neo gene, the 1.8 kb neo  cassette itself was only 
available when released from the EcoR I site in the polylinker of
vector pBluescriptSK+ (Dr. D. Donald, pers. comm.). To utilise this 
cloning feature, an EcoR I site was introduced into the Pst I site of 
pSP900 II using a linker (see Section 5.1.3.4) in order that the neo 
gene could be introduced directly. Conversely, the EcoR I site in the 
polylinker of plasmid pSP900 II was deleted. To do this, 2 ng of
pSP900 II DNA was cut with EcoR  I,
The
protruding DNA termini were then blunt-ended by incubation with 
dNTPs and the (DNA polymerase I fragment) Klenow enzyme.
A modified pSP900 II plasmid clone which was not 
linearized by the endonuclease EcoR I, and therefore lacked the 
polylinker EcoR I recognition sequence, was identified, and was 
named pSP900 III (see Figure 5.4).
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Figure 5.4: Restriction Maps of pSP9QQ. pSP900 II. pSP90Q III and pSP900 IV
F ig u re  5.4: Linear representations of the PPT-A plasmid subclones pSP900, 
PSP900 II, pSP900 III and pSP900 IV (for details see Sections 5.1.3.1, 5.1.3.2, 
5.1.3.3 and 5.1.3.4 respectively). The subclones are intermediates in the construction 
of the NK-1 targeting vector no. 1. X; Xho I, S; Sal I, M; Mlu I, P; Pst I, E1; Eco R I.
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5.1.3.4 Insertion of an EcoR I Site into Exon 3: pSP900 IV
A small double stranded DNA linker sequence (shown below) was 
ligated into the Pst I site of subclone pSP900 III in order to 
introduce an EcoR I site at that location within exon 3. Two 
oligodeoxynucleotides were designed for this purpose. When 
annealed, the complimentary oligodeoxynucleotides generated a Pst 
I cohesive terminal at one end and a EcoR I cohesive terminal at the 
other end of the resultant double stranded DNA linker sequence.
Figure 5.5: Design and Sequence and Compon'eht parts of the Pst I- EcoR I linker
( a ) 5 ' GTATCCTAGAGG 3 '
I I I I I I I I I I I I
3 ' ACG TCATAG G ATCTCCTTAA 5
( b )  ( 1 )  ( 2 )  ( 3 )
G TATCCTAGAG G
( P s t  I  E n d )  | I I I I I I I I I I I (E c o R  I  E n d )
ACGTC ATAG G ATCTC C TTA A
(c) EcoR I Site
GTATCCTAGAGG A A TTC CTCTAGGATACTG CA
( P s t  I  E n d )  I I I I I I I I I I I I I I I I I I I I I I I I I I I I ( P s t  I  E n d )
ACGTCATAGGATCTCC TTA A G GAGATCCTATG
F ig u re  5 .5 : Sequence of the Pst I -EcoR  I linker comprising two
oligodeoxynucleotides which were synthesized, annealed to each other, 
phosphorylated, self-ligated, Indigested with Pst I and cloned into the Pst I site of the 
plasmid pSP900 III to generate a modified plasmid plamid named pSP900 IV. Part (a) 
shows the oligodeoxynucleotides annealed, whereas part (b) shows the linker sub­
divided to demonstrate the component sections; (1) a Pst I cohesive terminal, (2) 10 
bp of random, complimentary sequence, and (3) an EcoR I cohesive terminal. Part (c) 
shows the arrangement of the linker after self-ligation and restriction with Psfl. In 
this form, an intact, central EcoR I recognition sequence was generated flanked by 
two Pst I cohesive termini. This was therefore ideal as a means introduce an EcoR I 
site into a chosen Ps1\ site. In part (c), the ligated linkers are differentiated from 
each other using bold text. The EcoR I recognition sequence is underlined.
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Originally, the strategy for cloning the neo gene into the (Pst I site) 
of the third exon of the PPT-A gene involved ligating the above 
single linker (Figure 5.5, part b) onto the compatible EcoR I- 
restricted ends of a neo gene DNA fragment. This DNA fragment was 
generated by restriction of the neo gene plasmid subclone, pSK+A/eo, 
with EcoR I. This cloning step proved difficult whereapon an 
alternate strategy was adopted.
The above oligodeoxynucleotides were synthesized by Cruachem Ltd. 
and 200 ng of each DNA was annealed to the other as described in 
Section 2.32.2. The annealed double stranded DNA linker was 
phosphorylated by polynucleotide kinase (Section 2.21.1) and ligated 
to itself under standard conditions. The ligation was demonstrated 
to have been successful by electrophoresis and visualisation of a 
sample on a 1.5 % agarose gel. Of the total 10 pJ ligation reaction, 2 
pi was electrophoresed alongside a sample of non-ligated linker. 
The smear which was visualised in the 'ligated linker' lane, but not 
in the other, indicated the existence of a range of multimers of this 
short DNA linker successfully ligated to itself. Obviously, the 
linkers had the capability to self-ligate at both the Pst I and EcoR I 
ends. However, only linker doublets constituting Pst I sticky ends 
flanking an intact EcoR I site were required for cloning purposes. 
Therefore, a sample of extended linker ligation reaction was 
restricted with Pst I to generate the extended linker shown above in 
figure 5.5, part (c). To remove any remaining endonuclease the 
reaction was phenol and chloroform extracted, ethanol precipitated 
overnight and resuspended in dH2 0  to a concentration of 10 ng.pl.
This cleaned-up extended linker DNA was then incubated under 
'conventional' (see Section 2.21.1) ligation conditions with a sample 
of plasmid pSP900 III DNA which had been restricted with Pst I and 
dephosphorylated with SAP (Section 2.22.2). A number of ligation 
reactions, including controls, were performed including a range of 
insert to vector DNA ratios. A 5 pi sample of ligation reaction was 
transformed into competent E. coli TG1 cells. Ten colonies were 
picked and cultured overnight. DNA was extracted and then analysed, 
in the first instance, by digestion with EcoR I. 9 of the 10 clones 
analysed were indeed linearized by EcoR I. Clone number 1 was 
further analysed with the endonucleases Mlu I and Pst I (plus EcoR I
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again and combinations of the three) and was shown to contain the 
correct extended linker insert. This clone was named pSP900 IV.
5.1.3.5 Insertion of the Neomvcin Resistance Gene: pSP900 V
and pSP900 VI
To summarise, subclone pSP900 (version 1) was modified several 
times (as detailed above) so as to create a plasmid which contained 
a unique EcoR I site within exon 3 and upstream of the NK-1- 
encoding sequence. This was achieved in the form of the plasmid 
pSP900 IV (version 4). The 1.8 kb 'neomycin resistance gene, as 
mentioned briefly in section 5.1.3.4, was released from its vector 
plasmid by EcoR I restriction and was cloned into the EcoR I site of 
pSP900 IV.
5 (ig of plasmid pSP900IV was linearized with EcoR I to generate a
3.8 kb DNA fragment which was recovered from an agarose gel by the 
Spin-X method (Section 2.27.2) and dephosphorylated with SAP. The 
two DNA fragments were ligated under standard conditions and a 2 
H.I sample of the reaction was transformed into E. coli TG1 cells. 20 
colonies were selected, cultured and analysed by restriction with 
EcoR I. Several positive recombinant clones bearing the 1.8 kb neo 
gene inserted into the EcoR I (formerly Pst I) site of plasmid pSP900 
IV were identified. One clone was shown (using known restriction 
sites in the insert DNA) to contain the insert in the op po s ite  573' 
orientation as the PPT-A gene into which it was inserted and was 
named pSP900 VI (version 6). In another clone, the 573' orientation 
of the newly inserted neomycin resistance gene was the same as for 
the PPT-A gene into which it was inserted. This plasmid was named 
pSP900 V (version 5) and was used in the subsequent cloning step.
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Figure 5.6: Restriction Maos of PPT-A Subclones pSP90Q IV. dSP90Q V & pSP900 
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Figure 5.6: Linear maps of the PPT-A subclones pSP900 IV, pS900 V and pSP900VI 
(for details, see sections 5.1.3.4, 5.1.3.5 and 5.1.3.5 respectively). Plasmid pSP900 
V contains the neo gene cloned in the correct 5' to 3' orientation for use in the next 
step of targeting vector construction. M; Mlu I, P; Pst I, E1; Eco R I.
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5.1.4 Re-assem blv of the PPT-A Gene: pSP7.2 III and 
PSP7.2IV
To recapitulate, originally, the 900 bp Mlu I-M lu  I fragment of 
plasmid pSP9, which contained PPT-A exons 3 and 4, was subcloned 
to generate the plasmid pSP900 (Section 5.1.3.1). This subcloned 
900 bp fragment was modified so as to incorporate a neo cassette at 
a precise location in exon 3 (generating plasmid pSP900 V, section
5.1.3.5). This 900 bp fragment plus the neo insert amounted to the
2.7 kb total insert of plasmid pSP900 V. This 2.7 Kb was then cloned 
into the Mlu I site of plasmid *pSP7.2 II (Section 5.1.2). 
Consequently, the original genomic organisation of the mouse PPT-A 
gene (between exons 1 and 6) was re-assembled except for the 
desired insertion of the neo  gene into exon 3 (and the unavoidable 
introduction of the short DNA linker). This cloning step generated 
subclones pSP7.2 III and pSP7.2 IV which differed only in the 
orientation of the 2.7 Kb Mlu I/Mlu I insert (see Figure 5.3).
To do this, plasmid pSP900 V was digested with Mlu I to release the
2.7 Kb neo/NK-1 exons 3 and 4 insert which was purified as before. 
The plasmid pSP7.2 II (which differed from the original pSP7.2 in 
that it lacked the 900 bp Mlu I-Mlu I fragment, (Section 5.1.2) was 
linearized with M lu  I to generate a 9.3 kb fragment (which was 
dephosphorylated with SAP). The 2.7 and 9.3 kb Mlu I-M lu  I 
fragm ents were ligated under conventional ligation condition 
(Section 2.21.1) and transformed into E. coli nova blue competent 
cells. Transformants were picked, cultured and analysed by 
restriction with several endonucleases to confirm both the presence 
of the 2.7 kb Mlu I insert and its orientation. The insert was noted 
in two different clones but in the opposite orientation to each other. 
The modified pSP7.2 II plasmid which contained the 2.7 kb insert 
from plasmid pSP900 V in the oppos ite  5' to 3' orientation to the 
PPT-A gene into which it was inserted, was named pSP7.2 III. The 
recombinant plasmid with the 2.7 Kb insert in the same  orientation 
as the PPT-A gene into which it was inserted was named pSP7.2 IV. 
This plasmid was of particular interest because it was further 
modified (see below).
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5.1.5 Insertion of the Thymidine Kinase Gene
In order to select positive recombinant ES cell clones which had 
been generated as a result of homologous recombination with the 
completed PPT-A targeting vector, the thymidine kinase (TK) gene 
from herpes sim plex  virus 1 (HSV1) was introduced into the 
targeting vector pSP7.2 IV for the purpose of counter-selection. The 
TK gene was inserted into the polylinker of plasmid pSP7.2 IV so 
that it immediately flanked one of the two genomic DNA fragments 
in that plasmid, (which in turn flanked the recently inserted neo 
gene, section 5.1.3.5). The 2.9 kb TK gene was cloned from the 7239 
bp plasmid pPNT (E. Gallagher, pers. comm.) into the EcoR I and HinD 
III sites of plasmid pGEM9 (Promega Corp.) upon which the plasmid 
was re-named pGEM9.TK.
In order to clone the TK gene from plasmid pGEM9.TK into the 
polylinker of plasmid pSP7.2 IV, the remaining unique restriction 
sites in the polylinker of pSP7.2 IV had to be used. To permit the 
accurate introduction of the TK gene, each of the chosen enzymes 
had to cleave only one site in the plasmid pSP7.2 IV (without 
excising the whole insert). The Xho I and Not I polylinker sites were 
found to be intact and suitable for this purpose.
The TK gene was re-cloned from the EcoR I and HinD III sites of 
plasmid pGEM9.TK into the same restriction sites in plasmid vector 
pB luescrip tKS+ to generate the plasmid pKS.TK. The pBluescript 
vector was chosen because the polylinker EcoR I and HindlW sites are 
flanked by Not I and Xho I sites respectively. The TK gene could 
therefore be re-released by a double restriction with Not I and Xho I 
and cloned into the corresponding sites in pSP7.2 IV. This cloning 
step was successfully performed and resulted in the completion of 
the construction of the first of the two mouse PPT-A gene targeting 
vectors. The resultant plasmid was named pSP7.2 V (version 5), a 
map of which is shown in Figure 5.7 (below). For use in cultured ES 
cell transfection experiments, the targeting vector was linearized 
by the endonuclease Not I.
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5.2 CONSTRUCTION OF PPT-A GENE TARGETING VECTOR No. 2
In addition to the plasmid pSP7.2 V (Section 5.1.5), a second mouse 
PPT-A gene targeting vector was designed and constructed. This 
vector displayed a strong sim ilarity to the first because it was 
derived from the same source plasmids. The plasmids pSP7.2 II, 
pSK.Neo and pKS.TK (Sections 5.1.2, 5.1.3.5 and 5.1.5 respectively) 
again supplied the PPT-A genomic DNA fragment, the neo gene and 
the thymidine kinase (TK) counter-selection gene respectively. 
Vector No. 1 was designed to allow thd introduction of the neo gene 
at a precise (upstream) location within an exon as a means of 
disrupting, and ultim ately preventing, the expresssion of the 
(downstream) neuropeptide neurokin-1, in a transgenic mouse. In 
doing this, the neo gene was inserted  (Section 5.1) but no part of the 
genomic PPT-A DNA was deleted. Targeting vector numberl involved 
12 cloning steps in the making and was therefore relatively difficult 
to assemble. However, as a consequence of pursu ing this vector 
design strategy, the foundation was put in place to allow the future 
construction of various other PPT-A gene targeting vectors (based 
on plasmids pSP7.2 and pSP900). Those future vectors could be used 
to generate more subtle targeted mutations, (see discussion 
chapter). The second PPT-A gene targeting vector, for example, was 
just such a variant vector based on the first vector. The second 
vector was more crude in design and involved the deletion of the 
third and fourth exons of the mouse PPT-A gene. The construction is 
detailed below. In contrast to the first vector, in which no genomic 
PPT-A DNA was deleted, the second vector was designed so that 
exons 3 and 4 were deleted and the neo gene inserted in their place. 
The net DNA insert was 900 bp (the 1.8 kb insertion minus the 900 
bp deletion). Since exon 3 is responsible, when translated, for the 
production of the tachykinin neuropeptide neurokinin-1, successful 
homologous recombination using a vector which lacks exon 3 would 
introduce into the mouse germ line a form of the PPT-A gene which 
would be incapable of synthesizing NK-1. ,
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5.2.1 In se rtio n  o f the  N eom ycin  R es is tance  Gene: 
pPPT.Neo I and pPPT.Neo II
5 jig of plasmid pSK.Neo (Dr. D. Donald, pers. comm.) was digested 
with EcoR I to release the intact neo  gene from its plasmid vector 
(see Section 5.1.3.5). The 1.8 kb neo gene was band isolated from a 
1% agrose gel by phenol/chloroform extraction and was then ethanol 
precipitated. The isolated DNA was resuspended in 20 jil of dH 20.
The overhanging EcoR I cohesive termini of the recovered DNA 
fragments were then blunt-ended by incubation with dNTPs and 
Klenow enzyme. The polymerase enzyme was removed by extraction 
with phenol/chloroform.
Using a spectro-photometer, the DNA 
concentration was found to be 50 ng.jul.
5 jug of plasmid pSP7.2 II was linearized with the endonuclease Mlu I. 
Complete digestion was confirmed by electrophoresis of a sample on 
an agarose gel. The Mlu I enzyme was removed by phenol and 
chloroform extraction. The DNA fragments were precipitated, 
resuspended and blunt-ended as for the neo gene (paragraph above). 
The pSP7.2 II fragment was treated with SAP.
Once blunt-ended, both the 1.8 kb EcoR I-EcoR  I neo gene DNA 
fragment and the linearized 9.3 kb Mlu \-M lu  I pSP7.2 II DNA 
fragment were compatible and were ligated under 'conventional' 
ligation conditions (Section 2.21.1). An aliquot of the ligation 
reaction was transformed into E. coli nova blue competent cells. 20 
bacterial clones were picked and cultured overnight. DNA was 
prepared from each culture and analysed by restriction mapping. No 
single restriction endonuclease could be used to analyse the clones 
because successful ligation of the two blunt-ended DNA fragments 
did not cause a recognition sequence to be re-consituted. Therefore 
the single Nco I site known to be included in the sequence of the 
subcloned neomycin gene was utilised. This site was located in the 
new subclone (pPPT.Neo, below) relative to the restriction sites 
which were known to lie within the insert of the recipient plasmid 
DNA, pSP7.2 II. Using this approach, several positive recombinant 
clones were identified and shown to contain the neo resistance gene.
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This gene was cloned in both orientations. A clone containing the 
neomycin gene insert in the same orientation as the PPT-A gene into 
which it was cloned was identified and named pPPT.Neo I (version 1). 
A clone with the insert in the opposite orientation to the PPT-A 
gene into which it was cloned was named pPPT.Neo II. It was 
pPPT.Neo I, however, which was further modified by the introduction 
of the TK gene.
5 .2 .2  In s e rtio n  o f the  T h y m id in e  K in ase  Gene: 
pPPT.Neo.TK
The same thymidine kinase (TK) gene which was used in PPT-A gene 
targeting vector No. 2 and was released from the plasmid pKS.TK by 
restriction with the endonucleases Not I and Xho I was cloned into 
the corresponding polylinker sites of plasmid pPPT.Neo I (Section
5.2.1) in the same way as described in section 5.1.5. The resultant 
plasmid clone constituted the completed second mouse PPT-A gene 
targeting vector and was named pPPT.Neo.TK. When linearized with 
Not I, this plasmid was ready for use in tissue cultured ES cell 
transfection experiments. The completed PPT-A gene targeting 
vector number 2 (plasmid pPPT.Neo.TK) is shown in figure 5.7 below.
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Figure 5.7: Maps of both PPT-A Targeting Vectors (oSP7.2 V and pPPT.Neo.TK)
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and pPPT.Neo.TK respectively). For details, see sections 5.1.4 and 5.2.2, 
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GENE TARGETING CONSTRUCT FOR 
THE MOUSE NK-1 RECEPTOR GENE
5.3 CONSTRUCTION OF THE MOUSE NK-1R GENE TARGETING 
VECTOR
The mouse NK-1R gene was known to comprise 5 exons (Sundelin e t  
al, 1992 and Section 4.9). Exon (1), exon (2) and exons (3, 4 and 5) 
were subcloned from the bacteriophage clones ^SPR8, ?iSPR15 and 
XSPR12 into the three plasmids pSPR8.5, pSPR6.8 and pSPR5.1 
respectively. With respect to gene targeting vector design, the 
higher the degree of conservation of the genomic DNA in the 
targeting vector, the more effective the vector should theoretically 
be at promoting specific, targeted homologous DNA recombination 
events (see Section 5.1). Since exonic sequence is typically the 
most highly conserved, the higher the exonic content of the genomic 
DNA included in the vector, the more effective the vector should be, 
as indicated by the targeting efficiency. Since NK-1 R exons 1, 2 and 
3 were shown to be interspersed by introns of approximately 15 and 
23 kb respectively (Sundelin et al, 1992), the smallest of the 
plasmid subclones, pSPR5.1, which contained a small 'cluster' of 
exons, namely exons 3, 4 and 5 (Section 4.9.3), was selected as the 
basis for the design of the first SPR gene targeting vector. In other 
words, subclone pSPR5.1 contained DNA of suitable 'quality' for use 
in a targeting vector. However, as discussed in section 5.1, the 
quantity of genomic DNA used in such a vector is also an important 
criterion to be considered; the length of the two genomic DNA 
fragments (which flank the neomycin resistance gene in the 
completed vector) when summed, should ideally be at least 6 kb in 
length. The 5.1 kb genomic DNA insert of subclone pSPR5.1 was 
considered to be too short for this purpose. A larger plasmid 
subclone with an insert which overlapped either exon 3, 4 or 5 of the 
mouse NK-1 R gene was therefore sought.
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5.3.1 A Larger. Overlapping NK-1R Subclone: pSPR8
On examination of the restriction map of plasmid pSPR5.1 (Section 
4.9.3), two restriction sites of interest were noted; the HinD III site 
located between NK-1R exons 3 and 4, and the EcoR I site positioned 
between exons 4 and 5. The plasmid pSPR5.1 had been generated 
previously by subcloning a 5.1 kb BamH \-BamH  I fragment of the 
bacteriophage ?iSPR12 (Section 4.9.3). Using bacteriophage ?tSPR12 
DNA as template, a number of double restriction reactions were 
performed where, in each case, one of the endonucleases used was 
either HinD III or EcoR I. The reactibns were electrophoresed
capillary
blotted membrane (Section 2.28).
Because the HinD III site was located upstream of NK-1R exons 4 and 
5, the blotted HinD III double restrictions were hybridised with the 
exon 5-specific oligodeoxynucleotide CS13 (Sections 4.8.2 and
2.29.2). This approach was used to locate restriction sites 
downstream of exon 5, the last NK-1R exon. The newly identified 
sites, when added to the known restriction sites in plasmid pSPR5.1, 
generated a more detailed restriction map of bacteriophage clone 
?iSPR12. (N.B., the new sites were located relative to the HinD I I I  
site which was known to lie within subclone pSPR5.1). In the same 
way, the EcoR  I site located in intron 4, between NK-1R exons 4 and 
5, was used in concert with the exon 3-specific hybridisation probe, 
oligodeoxynucleotide CS11 (Section 4.8.2), to identify restriction 
sites upstream of exon 3, in intron 2. Like the probed HinD III double 
restrictions, these hybridisations proved useful in the identification 
of ^SPR12 DNA fragments which both overlapped with subclone 
pSPR5.1 and were of a large enough size (greater than 6 kb) to be of 
use in the construction of a NK-1 R gene targeting vector.
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Figure 5.8a: Hybridisations of NK-1 R Clone SPR12 DNA with Exon 3 Probe CS11
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Figure 5.8a: A series of double digestions of NK-1R bacteriophage clone 7SPR12 
DNA resolved by electrophoresis, capillary blotted and hybridised with an NK-1 R exon 
3-specific oligodeoxynucleotide (CS11). 1 jig of phage DNA was digested in each lane. 
Lane 1; with EcoR I, lane 2; EcoR \INco\, lane 3; EcoR IIMIu I, lane 4; EcoR IIBgl II,
lane 5; EcoR IIPst I, lane 6; EcoR \/Kpn\, lane 7; EcoR \/Xho I, lane 8; EcoR \IXba I,
lane 9; EcoR I/A  i/a I, lane 10; Eco R I/ BstE II. H a s
lo/\e 0  ( aoV K e re V
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Figure 5.8b: Further NK-1 R Clone SPR12 Hybridisations with Exon 3 Probe CS11
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Figure 5.8b: A series of double digestions of NK-1R bacteriophage clone XSPR12 
DNA resolved by electrophoresis, capillary blotted and hybridised with an NK-1R exon 
3-specific oligodeoxynucleotide (CS11). 1 jig of phage DNA was digested in each lane. 
Lane 11; EcoR l/C/a I, lane 12; EcoR l/EcoR V, lane 13; EcoR \IHinD III, lane 14; EcoR 
I /Not\, lane 15; EcoR I/Sst I, lane 16; EcoR \/Sal I, lane 17; EcoR IISma I, lane 18; 
EcoR l/Ssp I, lane 19; EcoR I/Stu I, lane 20; EcoR \/HinD\\\. NB; the 8 Kb EcoR I/Sst 
I band in lane 15 which was subcloned to generate plasmid pSPR8 which was the basis 
for the NK-1 R gene targeting vector described in this text. Scale is in centimetres. 1  )Cb 
k jd d tf was uspd ia  la as O (txsf V i's i^d ise J  Key's)
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10 jig of ?lSPR12 DNA was double restricted with endonucleases EcoR 
I and Sst I in REact buffer 2 (B.R.L. Ltd.). The digestions were
DNA fragment was band-isolated. The DNA was recovered from the
pBluescriptKS+ was cut with the same endonucleases and recovered 
from an agarose gel slice in the same way. The linearized 3 kb 
plasmid vector and the 8 kb ?^SPR12 EcoR I-Sst I DNA fragments 
were ligated (see Section 2.21.1) and transformed into competent £  
co li cells (TG1 strain). The (white colony) transformants were 
analysed by endonuclease restriction. A clone containing the correct 
8 kb insert was identified and named subclone pSPR8.
A restriction map for pSPR8 was compiled by single and double 
endonuclease digestion which allowed orientahsn of the insert 
restriction sites relative to the known pBluescriptKS+ polylinker 
sites. The agarose gels generated as a by-product of the mapping 
procedure, bearing digested plasmid pSPR8 DNA fragments were 
capillary blotted (Section 2.14), stored and at a later date positively 
hybridised with the oligodeoxynucleotide probe CS11. The 
restriction map and the relative locations of NK-1R exons 3 and 4 
are shown below.
resolved on a gel and the 8 kb
agarose
resuspended.
(see Qiagen Ltd. standard protocol) and 
5 p.g of the plasmid vector
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Figure 5.9 : Map of Targeting Vector pSPR.Neo.TK & Subclones pSPR8 and pSPR5.1
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Figure 5.9: Restriction map of (a) the completed NK-1R gene targeting vector 
pSPR.Neo.TK (section 5.3), the NK-1R plasmid subclones pSPR8 (section 4.9.1) and 
pSPR5.1 (section 4.9.3). S; Sst I, Bs; BstE II, H; H/r?D III, Bg; Bgl II, P; Pst I, X; Xho I, 
E; EcoR I, K; Kpn I, Pll; Pvu II, A; Ava II, B; BamH I.
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5.3.2 In se rtio n  o f the  N eom ycin  R es is tance  Gene: 
pSPR.Neo
Based on the subclone pSPR8, the NK-1R gene targeting vector was 
designed to delete NK-1R exons 3 and 4 from the genomic DNA insert 
of plasmid pSPR8. The vector was constructed by cloning the neo 
gene and the thymidine kinase genes directly into plasmid pSPR8. To 
clone the neo gene, the BamH I restriction site located upstream of 
exon 3 and the Bgl II restriction site located downstream of exon 4 
were utilised. Firstly, plasmid pSPR8 was cleaved with Bgl II. The 
protruding Bgl II cohesive ends were' blunt-ended by incubation of 
the DNA fragments with dNTPs in the presence of Klenow enzyme. 
Residual Klenow enzyme was removed by extraction with 
phenol/chloroform. The linearized, blunt-ended pSPR8 DNA fragment 
was secondly restricted with BamH I and was electrophoresed on a 
0.6% agarose gel. Of the two DNA fragments generated by this 
second restriction, the larger, 8.9 kb fragment was recovered from 
the agarose by phenol/chloroform extraction. The fragment which 
was not recovered, namely the 1.5 kb Bgl II-BamH  I of pSPR8, 
constituted the section of genomic DNA which was deleted from the 
NK-1R gene within the gene targeting vector. This deleted genomic 
DNA fragment encompassd NK-1 R exon 3 sequence.
The neo gene was cloned into pSPR8 in a way similar to the deletion 
of exon 3 as described above. Plasmid pSKNeo (Section 5.1.3.5) was 
restricted with HinD III and blunt-ended and purified in the same as 
described in the above paragraph. The DNA was then digested a 
second time with BamH I and recovered from an agarose gel as 
before. The double digestion released the neo  gene as a 1.8 kb 
fragment with one blunt end and one BamH I cohesive terminal. The 
fragment could therefore be subcloned directly into the prepared 
pS P R 8/£g/ W-BamH I fragment. The fragments were ligated under 
conventional conditions and transformed into E. coli nova blue cells. 
Bacterial clones were selected, cultured and analysed by restriction 
analysis. A 10.7 kb recombinant plasmid clone containing the neo 
gene at the correct location and which was linearised by BamH I was 
identified and named pSPRNeo.
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5.3.3 Insertion of the Thymidine Kinase Gene: 
Subclone pSPRNeo.TK
The Kpn I site in the polylinker of plasmid pSPRNeo, which was one 
of only two remaining unique sites, was selected as the thymidine 
kinase (TK) gene insertion site. (The other unique site was used to 
linearise the final construct). The TK gene had previously been 
cloned into the vector pBluescriptKS+ to generate pKS.TK (Section
5.1.5). In order to clone the thymidine kinase gene from pKS.TK into 
the single Kpn I site of plasmid pSPRNeo, pKS.TK had to be modified 
so that a Kpn I site was located either side of the TK gene. One such 
flanking Kpn I site already existed in the polylinker of pKS.TK. The 
other Kpn I site was introduced at the opposite end of the TK gene in 
plasmid pKS.TK using a short double stranded DNA linker. The linker 
was ge ne ra ted  by s y n th e s iz in g  tw o co m p le m e n ta ry  
oligodeoxynucleotides designed so that when they were annealed to 
each other, a Kpn I restriction site was generated and which was 
flanked by cohesive EcoR I termini as shown below.
Figure 5.10 : Components. Design and Sequence of the EcoR I- EcoR I Linker
( a ) 5 '  AATTCATGGTACCTAG 3 '
I I I I I I I I I I I I
3 '  GTACCATGGATCTTAA 5 '
(b )  ( ! )  ( 2 ) ( 3 )
5 '  AA TTC  ATGG TACCTA G 3 1
(E co R  I  e n d )  | I I I I I I I I I I I (E coR  I  e n d )
G TACCATGGAT C TTA A  5'
Figure 5 .10 : Sequence of the two oligodeoxynucleotides which were annealed, 
phosphorylated and cloned into the EcoR I site of plasmid pKS.TK to generate plasmid 
pKS.TK.Kpn which was in turn digested with the endonuclease Kpn I to release all 2.9 
kb of the thymidine kinase counter selection gene. Part (a) shows the 
oligodeoxynucleotides annealed to each other, whereas part (b) shows the linker 
diagramatically sub-divided to demonstrate the 3 component sections; (1) a EcoR I 
cohesive terminal, (2) a Kpn I recognition sequence (which is underlined), and (3) 
another EcoR I cohesive terminal.
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The two oligodeoxynucleotides were annealed, phosphorylated and 
prepared for ligation as previously described (Section 5.1.2). 
Plasmid pKS.TK was linearized with EcoR I and dephosphorylated 
with SAP in preparation for ligation. The ligation of the short DNA 
linker into the linearised 5.9 kb pKS.TK plasmid was conducted under 
conventional ligation conditions and with a 20 molar excess of 
linker relative to pKS.TK. A 2 jjJ sample of ligation mix was 
transformed into competent nova blue strain E. coli cells. Twenty 
transformants were picked, cultured and analysed by digestion with 
Kpn I. Unsuccessful clones were identified as single restriction 
fragments of 5.9 kb indicating the existence of only one Kpn I site. 
Successful clones were also identified by digestion with Kpn I where 
two DNA fragments were generated of 2.9 kb and 3 kb, corresponding 
to the TK gene and the pBluescript vector respectively. One such 
recombinant plasmid was identified and named pKS.TK.Kpn.
Plasmid pKS.TK.Kpn was restricted with Kpn I to release the TK gene 
as a single 2.9 Kb DNA fragment. The fragment was subcloned 
directly into the Kpn I site of plasmid pSPR.Neo (Section 5.3.2). The
2.9 Kb TK gene fragment was purified from an agarose gel by 
phenol/chloroform  extraction and ethanol precip itation. The 
recipient DNA fragment for this ligation, namely the Kpn I - 
linearized pSPRNeo plasmid, was prepared for ligation by the same 
method but in addition was dephosphorylated with shrimp alkaline 
phosphatase (Section 2.22.2) The ligation
was conducted under standard conditions and a 2 jllI sample was 
transformed into nova blue cells as described above. Successful 
transform ants were selected and cu ltu red under an tib io tic  
(ampicillin) selection in L-broth medium. Recombinant clones were 
identified and shown by restriction enzyme analysis to contain the 
subcloned thymidine kinase counter selection gene. A recombinant 
pSPRNeo plasmid clone which contained the TK gene was identified. 
The TK gene insert was shown by restriction enzyme digestion to be 
in the same 5-3 ' orientation as the NK-1R gene into which it was 
cloned. The recombinant plasmid was named pSPRNeo.TK. This 
plasmid constituted the first completed mouse NK-1R gene targeting 
vector. Only the Cla I restriction site in the polylinker of the 
orig ina l plasmid vector (pB luescriptKS+) remained unique in
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targeting vector pSPRNeo.TK. Prior to transfection into tissue
cultured mouse ES cells, the targeting vector DNA was therefore 
linearized by digestion with the endonuclease Cla I. This resulted in 
the generation of a single 14.9 kb DNA fragment. A linear map of the 
completed NK-1R targeting vector pSPR.Neo.TK is shown in Figure 
5.9).
5.4 FLOW DIAGRAMS DETAILING THE CONSTRUCTION OF THE 
PPT-A AND NK-1 R GENE TARGETING VECTORS
This section comprises three flow diagrams which schematically 
explain the construction of the gene targeting vectors which are 
described in the above text. Figure 5.11 shows the the series of 
complex cloning steps required to assemble PPT-A vector number 1 
(Section 5.1). The final vector was named plasmid pSP7.2 V. Figure 
5.12 demonstrates the construction of PPT-A vector number 2 
(Section 5.2), plasmid pPPT.Neo.TK. Figure 5.13 details how the 
targeting vector for the NK-1R gene was assembled (Section 5.3). 
The final plasmid vector was named pSPR.Neo.TK.
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Figure 5.11 : Assembly of the PPT-A Gene Targeting Vector Number 1 :nSP7.? V
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F ig u re  5.11: Schematic representation of the construction of the PPT-A gene 
targeting vector number 1, plasmid pSP7.2 V. Numbers refer to exons. N; Neo I, S; 
Sst I, B; BstE II, M; Mlu I, P; Pst I.
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Figure 5.12 : Assembly of the PPT-A Gene Targeting Vector Number 2:pPPT.Neo.TK
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Figure  5.12: Schematic representation of the construction of the PPT-A gene 
targeting vector number 2, plasmid pPPT.Neo.TK. Numbers refer to exons. N; Neo I, 
S; Sst I, B; BstE II, M; Mlu I, P; Pst I and "(M)" refers to former Mlu I recognition 
site destroyed by blunt-end cloning.
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Figure 5.13 : Assembly of the NK-1 R Gene Targeting Vector:pSPR.Neo.TK
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Figure 5.13: Schematic representation of the construction of the NK-1R gene 
targeting vector, plasmid pSPR.Neo.TK. Numbers refer to exons. S; Sst I, Bs; BstE 
II,H; HinD III, B; BamH I, Bg; Bgl II, X; Xho  I, E; EcoR I, K; Kpn I and "(Bg)" refers to 
former Bgl II recognition site destroyed by blunt-end cloning.
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DISCUSSION
SUMMARY 
AND 
DISCUSSION
In order to investiga te  the proposed involvem ent of the 
preprotachykinin-A precursor and NK-1R receptor genes in neuronal 
dysfunction, it is important to firstly understand, at the molecular 
level, the normal function and regulation of those genes. When this 
research project was designed, genomic or cDNA clones of neither 
the murine PPT-A and NK-1R genes had been isolated. In the interim, 
clones of both genes have been identified (Kako et al, 1992 and 
Sundelin et al, 1992, respectively). However, a full investigation 
into the organisation and the regulation of those genes remains 
outstanding. Sim ilarly, an understanding of the alterations in 
phenotype, if any, which occur when those genes are rendered non­
functional (by way of molecular gene targeting for example) also 
remains unclear. This study, by cloning those genes in the first 
instance, has made an initial investigation into the function of the 
PPT-A and NK-1R genes. This provides the bedrock for future, more 
comprehensive gene characterisation and gene targeting ('knock-out') 
analyses.
This chapter serves to firstly recapitulate, by way of a summary, 
the results obtained during the research project and to then relate 
those findings to the previously published research findings which 
are detailed in the Introduction. The technical shortcomings of the 
research presented here are discussed. Furthermore, future 
experiments which may help to further elucidate the function of the
Chapter & Discussion
tachykinin neuropeptide neurokinin-1 will also be discussed. It is 
worth bearing in mind that in the results chapters presented earlier 
in this text, the rationale behind the experiments undertaken is 
detailed, and there is some discussion and explanation as to why a 
particular experimental approach was adopted.
6 .1 SUMMARY OF RESEARCH FINDINGS
Firstly, to clone the murine PPT-A gene from a genomic 
bacteriophage library, a 423 bp probe was generated by the 
polymerase chain reaction (PCR) using mouse genomic DNA as 
template. This fragment was subcloned and sequenced. Optimal 
hybridisation conditions were then determined by Southern analysis. 
The probe was used to isolate 10 lambda bacteriophage clones from 
a genomic library, two of which (APPT7 and >.PPT9) contained all 
seven PPT-A exons. Similarly, 186 positively hybridising clones of 
the NK-1R (receptor) gene were isolated from another bacteriophage 
library using an 865 bp rat NK-1R cDNA-derived probe. For the NK- 
1R screen, the same hybridisation conditions as for the PPT-A probe 
were successfully pre-tested by dot blot analysis and used.
Secondly, the PPT-A bacteriophage clones were analysed by 
endonuclease restriction mapping, PCR analysis and by hybridisation 
to exon-specific oligodeoxynucleotides. The seven exons of the 
murine PPT-A gene were then subcloned into plasmids named pSP9, 
pSP7 and pSP10.6. The subclones were restriction mapped and the 
exons were positioned relative to each other on those restriction 
maps. By using the oligodeoxynucleotide probes as sequencing 
primers, mouse PPT-A exon sequence was obtained and compared 
with other species to determine the extent of homology. High dgrees 
of homology (>95%) between the mouse and rat and bovine sequence 
at the 5' flanking, the start, the middle and the 3' end of the PPT-A 
gene were noted. A similar approach was used for the NK-1R 
bacteriophage clones. They were analysed by hybridisation, were 
subcloned, restriction mapped, and the distribution of the exons
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within those subclones was determined (and found to be very similar 
to that of the rat PPT-A gene). Sequence analysis of the NK-1R gene 
is lacking. Other evidence presented here indicates that the murine 
NK-1 R clones are authentic.
Thirdly, gene targeting vectors for use in homologous recombination 
experiments in mouse embryonic stem cells were then constructed 
for both genes (two for the PPT-A gene and one for the NK-1R gene). 
Multiple cloning and subcloning steps were required to complete the 
vectors. Several restriction sites were specifically deleted or 
introduced (by ligation of short DNA linker sequences). Principally, a 
n e o  resistance gene carrying its own promoter and poly(A) 
termination sequence was introduced into the vector (for example 
exon 3 of PPT-A vector number 1, plasmid pSP7.2 V). In PPT-A 
vector number 2 (plasmid pPPT.Neo.TK), the neo resistance gene was 
introduced in place of a deleted 2.4 kb genomic sequence comprising 
NK-1R exons 3 and 4. For the NK-1R vector (plasmid pSPR.Neo.TK), 
exons 3 and 4 of that gene were deleted and replaced by the neo 
resistance gene. In all three vectors, a thymidine kinase (TK) 
counter-selection gene from herpes simplex virus 1 (HSV1) was also 
inserted so as to flank the genomic DNA contained in the targeting 
vector.
Finally, published mouse PPT-A and NK-1R DNA sequence (Voorn e t  
al, 1994, and Mick et al, 1994, respectively) was used in the design 
of 45-mer oligodeoxynucleotides for use in in situ h yb rid isa tio n s . 
20 \vm sagittal sections were prepared from two 10 day neonatal 
mouse brains. The brains were hybridised independently with one of 
the gene-specific oligodeoxynucleotide probes. The purpose of such 
experiments was to ascertain the distribution of mRNA transcripts 
encoded by the mouse PPT-A and NK-1R genes in the brains of 
normal, w ild-type, mice. Furthermore, the results which were 
obtained in this way are of value with respect to future comparisons 
of in situ hybridisation results and demonstrate that there are 
specific but distinctly different expression patterns for both genes 
in the brain of the 10 day old (wild-type) mouse.
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6 .2  GENE CLONING DISCUSSION
Chapter 3 details the strategy adopted, and the ground work 
required, in order to isolate bacteriophage clones for the murine 
PPT-A and NK-1 R genes.
For the PPT-A gene, the PCR-based approach was used to generate a 
library probe because no PPT-A clone DNA (genomic or cDNA) from 
any other species (and suitable for use as a probe) was available at 
that time. Such DNA, if available, would have been used as a 
heterologous probe for library hybridisations. Due to the design of 
the PCR primers, where the PCR product spanned (the neurokinin-1 
encoding) third exon, in theory, any bacteriophage clones isolated 
using this probe would contain not only PPT-A sequence but 
specifically exon 3 of that gene. (Having analysed the bacteriophage 
isolated from both the Cambridge and Glaxo libraries, this has
proved to be the case; see Section 3.3.3 and 3.3.4). This particular 
area of the gene, which was identified at an early stage, was 
considered to be of special interest because of its potential use in 
the design of future PPT-A gene targeting vectors. In that respect, 
it was considered an ideal insertion site for a neo resistance marker 
gene. Insertion of a neo cassette into the exon which encodes NK-1 
offers the greatest probability of disrupting the PPT-A gene 
transcription in any subsequently targeted gene. Such an insertion 
should thereby alter the translation products and halt the synthesis 
of the normal form of the NK-1 peptide. Disruption of NK-1 
synthesis is, after all, one of the long-term objectives of this
targeting project. The inclusion (by design) of this site in the 
original probe sequence proved useful and this site was used at a 
later stage in the construction of one of the PPT-A gene targeting 
vectors. (This particular exon and its use in further targeting 
vectors is discussed in greater depth in section 7.4). If a suitable 
probe DNA had been readily available at the outset of this project, 
the generation of a PPT-A probe by PCR would not have been 
necessary and the time taken to isolate PPT-A clones would probably 
have been reduced. The PCR analysed did serve a positive purpose in
that rat and mouse PCR products of same length were generated from
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the respective genomic DNAs and this supports the authentic cloning 
of murine PPT-A gene as presented in this text. The PPT-A probe 
was sequenced prior to use to ensure its authenticity.
In the case of the NK-1R receptor gene, the rat NK-1R cDNA was 
available at the start of the project and a 965 bp fragment of this 
was used as the NK-1R library hybridisation probe. Subsequently, no 
PCR or subcloning step was required. The NK-1R probe sequence, like 
that of the PPT-A probe, was checked by sequence analysis before 
use. The use of a cDNA-derived probe to isolate clones of the murine 
NK-1R gene (which was believed to span more than 30 kb as it does 
in rat) was thought likely to result in the identification of clones 
which between them would contain all of the expected five NK-1R 
exons. This was the case simply because the rat cDNA probe 
sequence contained regions of high DNA sequence homology to each 
of the five mouse exons. Of the 186 positive clones identified at the 
primary stage, twenty were selected randomly for further analysis 
and were found to contain exons 1, 3, 4 and 5. Those exons were 
subcloned and the location of those exons relative to each other was 
detemined using exon specific oligodeoxynucleotides. Unfortunately, 
none of those 20 selected bacteriophage clones contained any exon 2 
sequence (as concluded from a blank hybrid isation to an 
oligodeoxynucleotide containing published mouse exon 2 sequence 
and derived from Sundelin et al, 1993, data not shown here). It was 
therefore necessary to isolate this exon. To do this, the bank of 186 
primary clones was re-screened with the exon 2 specific  
oligodeoxynucleotide probe (rather than screening a whole library 
again). This appears to have resulted in the successful isolation of 
exon 2 sequence. This exon, which is flanked by 15 and 23 kb introns 
in rat, was shown to be included in an approximately 11 kb BamH 
UBamH I fragment of the isolated clone >.SPR14. In order to confirm 
that the isolated sequence from A,SPR14 is indeed NK-1R exon 2, 
sequence analysis is necessary. Regrettably, no DNA from ^SPR14 
was either subcloned or sequenced. Therefore, the authenticity of 
the exon 2 DNA has not been unequivocally confirmed. Having used a 
100% homologous probe (derived from published mouse sequence), 
which was found to hybrid ise spec ifica lly  under stringent
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conditions, it is, however, very likely that this bacteriophage clone 
contains authentic mouse NK-1 R exon 2 sequence.
One possible future cloning experiment for both the PPT-A and NK- 
1R genes would be the isolation of cDNA clones from another library. 
Such clones would be useful in the future gene characterisation work 
as detailed in Section 7.3.
A. 3 GENE CHARACTERISATION DISCUSSION
£.3.1 Future PPT-A Gene Characterisation Experiments
£ .3.1.1 Sequence Analysis of the Murine PPT-A Gene
The oligodeoxynucleotides previously used as PCR primers and 
hybridisation probes were also used as sequencing primers in 
addition to standard sequencing primers such as T3 and T7 
(Stratagene). This preliminary sequence analysis demonstrated very 
high sequence homologies between the mouse and the rat PPT-A 
sequences at both the 5' and 3' ends of the gene and also in central 
regions in the vicinity of exons 3 and 4 (Section 4.6). The sequence 
obtained for the murine PPT-A gene gas been presented as 
alignments with known, published database sequences. The exact 
location of the exons within those alignments remains to be detailed 
(by further computational analysis). This finding was deemed 
sufficient to confirm the cloned gene as the murine PPT-A precursor 
gene. However, the seven PPT-A exons were not sequenced fully or 
on both strands although oligodeoxynucleotides were shown to 
hybridise to each of the seven murine PPT-A exons in both subclones 
and bacteriophage clones (see Section 4.5). The relative positioning 
of those exons on a linear map (see Figure 4.6 after Section 4.4) 
showed the mouse exons to be dispersed in a similar way as in the 
rat PPT-A gene (Carter et al, 1990). Also, the introns appear to be 
of similar size in both the rat and mouse genes. This acted as 
further evidence supporting the authenticity of the cloned murine
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PPT-A gene. The precise length of the PPT-A exons has not been 
determined by this study and remains outstanding. The seventh exon 
of the rat PPT-A gene is 2 kb in length and the mouse equvalent is 
likely to be similar. Ninety percent of that rat exon is untranslated. 
It would be of value to fully sequence the murine exon 7 and to 
determine the extent of the equivalent untranslated region which is 
likely to exist there. This could be used in the generation of a full 
genomic map of the murine PPT-A gene.
Similarly, the intron/exon boundaries of the murine PPT-A gene have 
not been accurately defined. At the same time as the identification 
of the PPT-A clones detailed here, the cDNA sequence was published 
by Kako et al, (1993). The published information could be of use in 
the identification of the murine PPT-A intron/exon boundaries. This 
information could be used to study the regulation of expression of 
the gene and to identify the mRNA splicing variants which are 
encoded, for example by using the enzyme S1 nuclease which 
specifically degrades unpaired single-stranded DNA sequences. S1 
nuclease protection experiments could be undertaken to study the 
transcription patterns of the murine genes. For the PPT-A precursor 
gene, comparison with the known rat transcription pattern would be 
possible (for rat, see Figure 1.2). Furthermore, Northern blotting 
analysis could be used to study transcription. It is highly likely that 
several transcripts will be encoded by the mouse gene as for the rat 
PPT-A gene (Helke et al, 1990, see Section 1.3.4 and Figure 1.2). 
Those are likely to be translated into several neuropeptides. The 
sequence generated in that way would, at least, allow clarification 
of the physical organisation of the gene and may contribute to an 
understanding of its molecular activity.
fc.3.1.2 PPT-A Promoter and Expression Studies
The rat PPT-A gene was isolated from a genomic library by Carter e t  
al (1990) and from this, one major and two minor transcription 
in itia tion  sites were identified  upstream of the rat gene. 
Comparison of the rat and the bovine PPT-A sequences has 
demonstrated that there are highly conserved regions throughout the 
entire coding region and within the 5' flanking region. The mouse to
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rat homologies for this region are also very high (see Section 4.6). 
This knowledge could help facilitate the further characterisation of 
the murine gene because clones ?iPPT7, ?iPPT8  and APPT9 are known 
to contain genomic sequence 5' of the first exon. This could permit 
the identifcation of promoter (or enhancer) elements within those 
clones. In the human NK-1R gene, exons 1 to 5 are 977, 196, 151,
197 and approximately 3300 bp in size respectively and the exons
are interspersed by introns of >22 kb, >26 kb, >7 kb and 
approximately 2.2 kb (Shigemoto et al, 1990). The human NK-1 R, 
has a TATA box located 24-27 bp upstream of the putative
transcription initiation site. (The TATA box is involved in the 
polymerase nucleotide selection which initiates transcription at a 
specific site). Furthermore, several promoter, enhancer and 
regulatory DNA elements have been identified in the 5'-flanking 
region, including a cyclic AMP responsive element (TGATGTCT) and 
an AP-1 sequence. In many species, the PPT-A precursor gene 
dem onstra tes a restric ted  expression pattern both during 
development and in the adult. The transcriptional regulation of the 
murine gene needs to be elucidated as does a more accurate
understanding of its tissue-specific expression. Neurokinin-1, 
neurokinin A, neuropeptide K, and neuropeptide y are each encoded 
from the PPT-A gene by tissue-spec ific , a lte rna tive  post- 
transcriptional processing (alternative RNA splicing) and post- 
translational pathways (Carter et al, 1990). Alternative splicing of 
the primary PPT-A RNA transcripts generates three mRNAs which, in 
turn, generate several distinct precursor proteins. McDonald et al 
(1989) presented results which dem onstrated tha t m ultip le 
tachykinins are produced and secreted as a consequence of post- 
translational processing of the three preprotachykinin-A precursor 
proteins, a-, p-, and 7 - prepro-tachykinin. This form of processing 
in mouse needs to be clarified. The role of tachykinins such as 
neurokinin-1 in neurogenesis and in triggering the differentiation of 
mature neurons is also worth analysis. Further in situ hybridisation 
studies (see Section 7.5), which would compliment those presented 
in this text (see Chapter 6 ), may allow researchers do this by 
focussing on particu la r developm ental stages during which 
processes such as neurogenesis are most or least active. The 
findings referred to in section 1.3.8 .3 regarding the developmentally
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transient expression of the NK-1R receptor in neuronal cells of the 
developing floor plate (Heath et al, 1995) indicate that research of 
th is nature is already underway and contribu ting to the 
understanding the transient expression of neuronal gene products. 
This in turn w ill permit further understanding of the role of 
neuropeptides in the signalling systems of the mammalian nervous 
system. Using the PPT-A (and NK-1R) clones described here, the 
factors which mediate the regulation of neuropeptide expression in 
various tissues and at various developmental stages may be 
investigated.
The promoter for the rat PPT-A precursor gene has been cloned (see 
Mulderry et al, 1993, Section 1.3.5). The equivalent murine promoter 
has not. The murine promoter may well be located within the 
bacteriophage clones isolated during this research which are known 
to contain sequence 5' of PPT-A exon 1. The clones could therefore 
be sequenced in order to pinpoint regulatory motifs and regulatory 
factor binding sites within that promoter (using DNAase footprinting 
techniques and band-shift studies for example to do so). Mulderry e t  
al (1993) used deletion analysis to study the rat PPT-A promoter 
and the regulation of expression. Sequences which are important to 
the regulation of this gene in rat dorsal root ganglia (DRG) neurons 
are located between 47 and 865 nucleotides upsteam of the start of 
the gene. There is also evidence of regulatory elements residing in 
the 5' untranslated regions of genes. For example, an iron responsive 
element is located in the 5' leader sequence of the ferritin gene 
(Goosen et al, 1990). Reporter assays could also be used to study a 
promoter. Furthermore, those promoter elements could be mutated 
so as to locate the critical sequences. Zajac-Kaye et al (1988) used 
the human oncogene c-myc as a model and utilised exonuclease 
enzymes in order to identify numerous potential binding sites for 
regulatory proteins which were mapped either upstream or within 
the human c-myc oncogene. A similar approach could be adopted in 
future studies of the PPT-A (or NK-1R) genes. Of the ten positively- 
hybridising PPT-A bacteriophage clones identified, >.PPT9 contained 
all seven PPT-A exons and was used in the gene characterisation 
experiments described in Chapter 4. The other nine clones, which 
contain sequence both 5' and 3' of that clone, have not been fully
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analysed (although the extent of overlap is shown in Figure 3.18). 
This flanking sequence could be examined for regulatory elements. 
Expression of a specifically mutated PPT-A (or NK-1R) gene 
promoter in tissue cultured neural-derived cells is another possible 
way to study promoter control and gene expresion. The rat PPT-A 
gene utilises alternative RNA splicing events to regulate expression. 
This is also likely to occur in the murine PPT-A gene. An analysis of 
this would also be o f interest. There are other machanism of 
regulating gene expression that could be explored. For example, 
there may be several promoters for a given gene which could result 
in the the generation of several distinct mRNA isoforms. (As an 
example of this, the Drosophila melanogaster alcohol dehydrogenase 
gene, as reported by Benyajati et al, (1983), differs in its 5' end 
during different developmental stages). In addition to promoter 
studies, a similar approach to studying the regulation of the PPT-A 
gene (or the NK-1R gene) could be applied to the identification and 
activity of enhancer elements or repressor elements, if indeed there 
are any (see Quinn, 1987).
£.3.2 Future Murine NK-1R Gene Characterisation 
Experiments
The subcloned NK-1R exons 1, 3, 4, and 5, although subcloned, have 
not been fully sequenced on both strands and the exact length of the 
exons has not been determ ined. Sim ilarly, the intron/exon 
boundaries have not yet been determ ined and this remains 
outstanding. Exon 2 also remains to be subcloned as well as fully 
sequenced. Completion of this would contribute to the further 
characterisation of this gene and by obtaining the sequence upstream 
of exon 1 where the NK-1R promoter and the transcriptional start 
site could possibly be identified. It would also be of use to look at 
the 166 NK-1R bacteriophage clones which were isolated from the 
Toronto library (Section 3.6), but were not studied further (186 in 
total, 20 already analysed). By defining the extent of overlap 
between them, it may be possible to determine whether the whole 
murine NK-1R gene, which is over 30 kb in rats, has been cloned. The 
first full genomic map of the NK-1R gene (which is not given in the
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original murine NK-1R gene cloning publication from Sundelin et al, 
1993), could be generated from this data.
The polymerase chain reaction technique could also be used as a 
further means of supporting the authenticity of the cloned murine 
NK-1R gene (in the absence of conclusive sequencing data). The 
isolated NK-1R bacteriophage (and the subsequently generated 
plasmid subclones) could be used as PCR templates to do this. 
Several oligodeoxynucleotides already exist that contain mouse NK- 
1R genomic exonic sequence (from Sundelin et al, 1993) and which 
appear to hybridise to the NK-1R exons of the isolated bacteriophage 
clones and could be used as PCR primers. Unfortunately, of the 
existing oligodeoxynucleotides specific to each of the five murine 
NK-1R exons, all are in the 5'-3' orientation. An anti-sense primer 
would therefore neeed to be designed and synthesised for use as the 
second primer in diagnostic PCRs.
There is currently very little known about the DNA sequences and 
trans-acting factors which control the expression of NK-1R in 
different tissues and during development. Identification, sequence 
analysis and mutational analysis of the promoter (for example using 
the exonuclease-based approach described in Section 7.3.2.2 for the 
PPT-A gene) would be equally useful in identifying potential 
regulatory elements of the NK-1R gene. Add itiona lly , an 
investigation of the trancriptional control and the activity of this 
gene would be of interest. This activity is very likely to vary during 
development as it is known to do from one tissue to another.
Furthermore, there are a whole host of gene characterisation 
experiments that could  be performed using the clones for the murine 
PPT-A and NK-1R genes bur which is too exhaustive to include here. 
The means to achieve a fully and comprehensively characterise those 
genes is however, presented here.
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C. 4 GENE TARGETING VECTOR DISCUSSION
Chapter 5 details the design and construction of gene targeting 
vectors for the murine PPT-A and NK-1R genes. The gene targeting 
vectors described are designed to have a major impact on gene 
activity. Taking the PPT-A targeting vectors as an example, the 
insertion of the neomycin resistance gene (with its own termination 
sequence) into the PPT-A gene should grossly disrupt the activity 
and term inate transcrip tion prem aturely in any subsequently 
generated transgenic mouse. Therefore the synthesis of all of the 
several neuropeptides encoded by that gene should be halted by this. 
A resultant transgenic mouse may therefore display phenotypes and 
behaviours which will correlate with the gross disruption of PPT-A 
as a whole but not with the specific deletion of a single 
neuropeptide gene product. A cause and effect relationship between 
the altered phenotype and the deletion of a particular gene product 
would not be established using this approach. A more subtle 
mutation would be required in order to disrupt the expression of a 
single neuropeptide specifically. The gene targeting vectors 
described in this text provide the capacity to permit the assembly of 
future gene targeting vectors that could successfully introduce 
specific, less gross, neuropeptide specific mutations.
On some occasions, a targeted mutation will be lethal to the host 
cell and in such instances, the host organism may not reach the point 
of developmental maturity. The function of a neuropeptide such as 
NK-1 in the adult organism cannot be studied in such instances. The 
adult stage is the point at which the mutant phenotype would 
typically be analysed (for example in mammalian model systems 
where normal function would be under investigation as opposed the 
fluctuations in gene activity that may occur during development). In 
order to study the function of transgenic PPT-A and NK-1R genes in 
the nervous system of a mature, adult mouse, a conditional gene 
targeting approach to introducing specific mutations may be 
required (as mentioned at the start of Section 7.4). This would 
permit the development of a "latently" transgenic animal to reach 
maturity before triggering the mutation of interest. The Cre-/oxP 
system is one such way of generating such conditional gene 'knock
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ou ts '. The Cre-/oxP approach can be used to precisely halt the 
expression of a particular gene in a particular cell type (or at a 
particular developmental timepoint) as demonstrated by Gu et al, 
(1994). This report details the deletion of the promoter and exon 1 
of DNA polymerase p gene, but only in murine T-cells. This technique 
utilises the Cre-/oxP recombination system which is intrinsic to the 
bacteriophage P1. The Cre recombinase induces site specific 
recombination by aligning two lo x P sites which are in the same 
(repeat) orientation. The enzyme then excises the intervening DNA 
and leaves a single lo x P site. Therefore, if the expression of the 
recombinase enzyme can be harnessed, the timepoint at which the 
targeted mutation is induced can be controlled. The Cre-/oxP system 
offers this capacity but requires two transgenic strains (of mice for 
example). One strain carries the target gene (such as PPT-A or NK- 
1R) flanked by a pair of loxP sites in the same 5'-3' orientation. The 
other mouse strain will carry a c re  recom binase expressing 
transgene under the specific temporal and spatial control of a 
promoter (for example a promoter expressed solely in differentiated 
adult neurons). The complete deletion of the target gene, and 
therefore its expression in neuronal tissue, would be possible by 
adopting a mouse breeding program that crossed the cre expressing 
transgenic line with a transgenic line bearing the target gene 
flanked by lo x P sites. A potential problem associated with this 
approach would be the identification of a suitable promoter for use 
in the construction of the cre  transgene. If however, the c re  
transgene were targeted to the endogenous PPT-A (or NK-1R) gene 
locus, the cre  gene would fall under the transcriptional control of 
the PPT-A (or NK-1R) promoter. Unfortunately, this approach would 
knockout PPT-A (or NK-1R) gene expression in a ll tissues. This 
approach would therefore not be of use if haploid insufficiency were 
responsible for preventing germline transmission of a mutation. The 
chromosomal insertion site of the cre  transgene may contribute 
unpredictable expression patterns especially if the transgene is 
transien tly  expressed th roughout  ^ developm ent. Under such 
circumstances, the cre recombinase enzyme may have insufficient 
time to excise all DNA fragments flanked by lo xP sites. This could 
explain why only an estimated 40% of T-cells were homozygous for 
the targeted deletion of the DNA polymerase-p gene as reported by
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Gu et al (1994). Therefore, with respect to c re  transgene
expression, the choice of promoter is critical to the likelihood of a 
conditional mutation strategy working successfully for any given 
gene. This is equally relevent for the murine PPT-A and NK-1R 
genes, and as discussed previously (Section 7.3.1.2), identification 
of the promoters and regulatory elements for those genes would be 
of value in the design of future conditional targeting vectors.
There are other techniques currently used to generate tissue
specific mutations. The yeast FLP enzyme can manipulate genes in a 
similar way to the Cre-/oxP system, by inducing the deletion of DNA 
fragments flanked by frt sequences, (Fiering et al, 1993). This
system was used recently to induce site-specific recombination in
transgenic mice, (Dymecki et al, 1996). Another more subtle means 
of introducing a specific germ line mutation involves the insertion 
of a neomycin resistance gene lacking its intrinsic promoter and 
transcription term ination sequence. This approach is detailed 
further in Section 7.4.1.
The existing plasmid subclones for the murine genes (pSP10.6 and 
pSPR5 for example) could be used to generate further gene targeting 
vectors for the PPT-A and NK-1R genes respectively, using the 
subtle targeting approaches detailed above. Similarly, the existing 
gene targeting vectors (pSP7.2 V and pSPR.Neo.TK) could be modified 
in order to focus the targeted mutations on specific neuropeptides 
translated by a precursor gene or on specific regions of a translated 
receptor peptide. The 186 isolated NK-1R bacteriophage clones and 
the other 9 PPT-A bacteriophage clones could be further analysed in 
order to locate DNA fragments for use in future targeting vectors.
Unfortunately, mice with transgenically altered PPT-A or NK-1R 
genes were not generated during this research project due to time 
restraints. Flaving cloned, characterised and generated targeting 
vectors for both murine genes, the transfections, the tissue culture 
of positive ES cell clones, the analysis of those clones (by Southern 
analysis) and, ultimately, the generation of knock-out mice lies 
ahead. (Indeed, some experience of tissue culture techniques has 
been gained). must be Therefore the generation of targeted ES cell
C h ap ter C_ Discussion Vho £_____
lines using the vectors described must be one immediate future aim 
in order to produce chimaeric mice and germline transmission of 
that mutation. The research presented in this text does, however, 
lay very strong foundations for successfully doing this in the near 
future. The vectors are indeed ready for transfection. Access to the 
targeting technology which can mutate a gene in a temporal and 
spatial manner also offers numerous possib ilities for future 
investigation. A host of further experiments and comparative 
analyses will be possible when such transgenic animals are 
generated and a clearer picture of the role of neurokinin-1 in the 
mammalian nervous system should be obtained.
&.4.1 PPT-A Gene Targeting Vector and Future Vectors
As briefly mentioned in Section 7.2, sequence from the third PPT-A 
exon was included in the sequence of the PCR-derived PPT-A library 
probe (used in Section 3.3). As this exon encodes the NK-1 peptide in 
the rat, bovine and human PPT-A genes (section 1.4), it is very likely 
to also do so in the mouse (although this remains to be confirmed 
experimentally). This specific location was also of interest because 
it could be used as the insertion site for an alternative kind of 
marker gene in further targeting vectors. For example, a neomycin 
resistance gene lacking an intrinsic promoter and transcription 
termination sequence could be inserted. This approach has been used 
successfully by Vaulont et al, (1995) where the adenosine deaminase 
(ADA) gene was disrupted in ES cells using a promoter-trap gene 
trageting approach. A dicistronic targeting construct containing a 
promoter-less IRES (internal ribosomal entry site) B geo  cassette 
was inserted into the ADA gene. This permits direct, cap- 
independent translation of the B geo  reporter gene which encodes a 
protein with B-galactosidase and neomycin activities. This type of 
marker gene permits the target gene to function normally except 
that it disrupts the synthesis of the specific translation product 
encoded by the disrupted exon. (This approach is of particular 
relevence to neurokinin-1 which is one of several peptides encoded 
by the PPT-A gene). Further translation products encoded 
downstream of that marker gene insertion site would be unaffected 
by this type of mutation. This approach could be used to specifically
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disrupt the production of one  translation product encoded by the 
murine PPT-A gene, without affecting the normal translation and 
functional activity of the other peptides encoded by the gene. This 
type of subtle mutational modification of normal gene activity is a 
powerful tool in understanding the roles of the individual peptides. 
It is very likely that neurokinin A, neuropeptide K and neuropeptide 
gamma are encoded by murine PPT-A (as in the rat and bovine genes) 
and that they could be targeted individually, using this approach, in 
order to investigate the role of each peptide in the mammalian 
nervous system.
£.4.2 NK-1R Gene Targeting Vector and Future Vectors
The murine NK-1R targeting vector (pSPR.Neo.TK, Section 5.2) 
contains mouse genomic DNA sequence. . 8 kb of genomic sequence 
which includes exons 3, 4 and 5 was taken as the starting DNA. 1.5 
kb of that sequence, the BamY\ I/Bgl II sequence encoding exons 3 and 
4, was then deleted. The remaining 6.5 kb was cloned into the 
targeting vector pSPR.Neo.TK. In that vector the 6.5 kb was split 
into two shorter sequences by the insertion of a neomycin resistance 
gene (see Section 5.2.1). In rat, exon 3 encodes the fifth 
transmembrane domain and the third intracellular region of this G- 
protein coupled receptor. Also in the rat, exon 4 encodes the sixth 
transmembrane domain, the third in tracellu lar region and the 
seventh transmembrane domain of the receptor. It is very likely that 
the corresponding mouse exons encode similar portions of the NK-1R 
receptor. In a successfully targeted transgenic mouse , because of 
the very high expected mouse to rat DNA sequence identity (and 
receptor amino acid sequence identity), those segments of the mouse 
receptor encoded by exons 3 and 4 would most likely be lacking. This 
targeting vector is crude by design, in that a relatively large 
segment of the receptor peptide sequence will (theoretically) be 
deleted in a resultant transgenic receptor. If successfully 
expressed, this deletion is extremely likely to render the receptor 
non-functional. This may even be a lethal mutation which would 
prevent development of the transgenic animal to the point of 
maturity (in which case the Cre-/oxP approach detailed above may be 
appropriate). Only by performing the gene targeting experiment
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itself will this predicted alteration in the transgenic receptor be 
either confirmed or rejected.
A more subtle approach to targeting a gene encoding a membrane 
receptor (as opposed to one encoding signal peptides) would be to 
perform single deoxynucleotide mutagenesis experiments using PCR 
oligodeoxynucleotide primers with known nucleotide changes 
included. A single nucleotide change could be used to alter a single 
codon and the single amino acid encoded at that corresponding point 
in a transgenic peptide. This, when analysed with the help of 
classical pharmacology (ligands, antagonists etc), in addition to 
molecular biology and biochemistry, would permit the identificiation 
of important areas of the three dimensional receptors' amino acid 
sequence. The specific segments of the receptor which are critical 
to receptor ligand binding could be identified in this way. Similarly, 
segments of the receptor important to three dimensional folding of 
the peptide may be identified. This form of mutational analysis is 
very precise and also presents numerous future targeting 
possibilities and the means to functionally analyse the murine NK- 
1R receptor.
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£.5 GENERAL DISCUSSION POINTS AND FUTURE RESREARCH
There are numerous further experimental approaches which are 
available to the researcher wishing to explore the role of the murine 
neuropeptide neurokinin-1 and to comprehend the activities of the 
genes that encode that peptide and its corresponding receptor. (This 
could similarly be extended to the other tachykinins and the other 
peptides encoded by the PPT-A gene). Several of those approaches 
are detailed in the sections above.
The modern day molecular biologist has an increasing number of 
research tools. In addition to the future experiments which are 
proposed in the above sections, it may be of value to clone the cDNAs
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for the NK-1R gene. cDNAs encoding the preprotachykinin-A and 
preprotachykinin-B protein precursors respectively, were isolated 
from a mouse brain cDNA library by Kako et al (1993), but the NK-1R 
(receptor) gene cDNAs have not been cloned. The genomic DNAs 
which have been cloned and are presented in this text could be used 
to facilitate this if they are used as homologous probes for cDNA 
library screens. Cloned cDNAs could then be transcribed in vitro 
using modern expression vectors and the resultant receptor studied 
at the biochemical, pharmacological and molecular levels. Similarly, 
such a receptor could be expressed in Xenopus  oocytes. Many facets 
of gene expression .could be studied using tissue cultured cell lines, 
for example, mapping promoter elements and other regulatory 
elements such as enhancers and repressors (see Section 7.3.1.2). 
This is typically conducted by determining the effects of induced 
deletions within such regulatory elements. Examination of the 
tissue specific expresssion of the PPT-A and NK-1R genes is also 
possible. For example, tissue-specific elements have been found in 
the rat insulin gene by Edlund et al, (1985), where tissue specific 
expression is mediated by elements in the 5' flanking region. 
Considering the range of tissues in which neurokinin-1 (as well as 
the other tachykinins) are expressed, research of this nature would 
be valuable in understanding NK-1 expression patterns. It may well 
be that elements that control PPT-A and NK-1R gene expression are 
also located in the 5' flanking region (also see Section 7.3.1.2). The 
immediate 5' flanking regions (upto 5 kb) of both genes are known to 
be contained in the plasmid clones detailed in Section 4.3 (Figure 
4.6) for the PPT-A gene, and Section 4.8 (Figure 4.13) for the NK-1R 
gene.
A combination of classical pharmacological research (using agonists 
and antagonists for example) and modern molecular biology could be 
utilised to gain a fuller picture of neuropeptides, their functions and 
inherent properties. A clearer understanding of NK-1 synthesis and 
its role in nociception (see Section 1.2.2.1) could be attained in this 
way. Similarly, it would be of value to determine the specificity of 
the murine NK-1R receptor for its ligands (as detailed for rat in 
section 1.5.2) using classical pharmacology. To date, three 
tachykinin receptors have been identified; the neurokinin-1 (NK-1),
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NK-2 and NK-3 receptors (described in Section 1.5). The three rat 
receptor gene cDNAs were cloned from mammalian tissue in 1987 
(Masu et al, 1987, Nakanishi et al, 1987). These receptors are 
pharmacologically distinct (Watson et al, 1987), but when the three 
possible ligands are added at a high enough concentration, each of 
the endogenous mammalian tachykinin neuropeptides can elicit a 
response from each of the three receptors. This is most likely to be 
a consequence of the common carboxy terminal amino acid sequence 
characteristic of the tachykinins. As for the rat NK-1 receptor, the 
murine NK-1 receptor is likely to be activated by more than one such 
ligand. Will this activation at high ligand concentrations also occur 
with the eqivalent mouse receptors?. The cloning of the murine NK- 
1R gene is detailed in ths text, however, the molecular cloning of the 
murine NK-2R and NK-3R receptors could also be performed where 
DNA fragments of the NK-1R genomic clones described here could be 
used as heterologous library hybridisation probes at low stringency 
in order to isolate genomic or cDNA clones.
Neuropeptides are also believed to influence a range of other more 
complex, long-term behavioural changes such as learning, arousal, 
memory, emotional state and schizophrenia (Gilles et al, 1979; 
McKelvy et al, 1986). This area also merits further, more precise 
examination. On a more physical level, the ligand binding sites of 
the NK-1R receptor protein could be further examined, using X-ray 
crysta llography for example, to clarify its te rtia ry  structure. 
Furthermore^ immunocytochemical and Western blotting methods 
could be used to detect and size the peptides encoded by the PPT-A 
and NK-1R genes and permit the quantification of those peptides in 
tissues. Phosphorylation, glycosylation proteolysis, and methylation 
studies of those peptides could also be included.
Chromosomal localisation of the PPT-A and NK-1R genes can also be 
undertaken using the latest fluorescent labelling technology. 
Cyanine based dyes can be used to label selected DNA probes (for 
example by nick translation) which can then be used to hybridise In  
situ to chromosomal metaphase spreads for example. The human NK- 
1R gene is located on chromosome 2 (Shigemoto et al, 1990). On 
which chromosome is the murine NK-1 R (and PPT-A) gene located?.
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The neuropeptides which mediate long-range communication between 
neurons are traditionally referred to as 'hormones', whereas those 
which mediate short-range communication and occur in membrane- 
bound vesicles are termed 'transmitters' (Burbach et al, 1992). The 
distribution of NK-1 both in and outwith the central nervous has 
been documented (see Section 1.4.2 and 1.6.1). The focus of the 
research presented here has been on NK-1 within the CNS. Therefore, 
there is obviously scope to research NK-1 and its activities in other 
non-neuronal tissues in the future.
As stated in Section 1.3.1, a common amino acid sequence (H -A rg - 
Pro-Lys-Pro-G ln-G ln-Phe-Phe-G ly-Leu-M et-NH2 ) has been identified
and is characteristic of the tachykinin fam ily of neuropeptides 
(where X is either a hydrophobic or aromatic amino acid residue 
[Erspamer et al, 1981]). Single base pair mutational analysis of the 
DNA sequence encoding those terminal amino acids (using the 
targeting technologies detailed in Sections 1.7.4.3 and 7.4) may also 
help to further our understanding of neurokinin-1.
The rat PPT-A gene has been shown to be regulated by a number of 
stimuli including growth factors (Kessler et al, 1981), conditioned 
media (Nawa et al, 1990), cocaine (Hurd et al, 1992), inflammation 
(Noguchi et al, 1992), and factors present in innervated target tissue 
(Barakat-Walter et al, 1991). Expression of the PPT-A gene and the 
level of tachykinin biosynthesis appears to be under homeostatic 
control in rat. The same approaches as those utilised by Kessler e t 
a l (1981) for example, could also be used to study the equivalent 
murine peptide. Tachykinin expression in the anterior pituitary 
gland has been shown to be under hormonal control in rats (Jonassen 
etal, 1987). Although likely, is this also the case in mouse?.
As documented in Section 1.3.8, mammalian tachykinins have been 
associated with sensory and motor function as well as immunologic, 
in flam m atory, card iovascu lar, resp ira tory and gastro in testina l 
function. Additionally, they may act as trophic and mitogenic 
factors and have a role in asthma (Ichinose et al, 1992). 
Furthermore, tachykinin peptides may have some involvement with
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neurogenic inflammation (as indicated by Guard et al, 1991) and may 
subsequently be involved in the processes of arthritis. In addition, 
the locus coeruleus region of the mamalian brain plays an integral 
role in the control of sleep and alertness (Kolb et al, 1989). 
Tachykinins, including neurokinin-1, have been shown to be potent 
activators of locus coeruleus neurons and may therefore have some 
role to play in the regulation of sleep A host of
different experimental approaches could be used to clarify those 
proposed roles of the tachykinins
C learly, there is evidence to suggest that the tachykin in 
neuropeptide neurokinin-1 has some association, correlation or 
involvement in several, normal mammalian neuronal and non­
neuronal ce llu lar processes. However, the precise role of 
neurokinin-1 and its corresponding receptor in those processes 
remains unclear. Furthermore, its role in abnormal processes 
remains to be seen. The research presented in this text provides a 
very strong foundation to further investigate this neuropeptide and 
its multi-faceted nature.
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